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ABSTRACT 
 
Hepatitis C virus NS5A is a multi-functional viral protein essential for viral replication and 
assembly, although the exact role the protein plays in the viral lifecycle remains unclear. A vast array of 
functions have been attributed to NS5A in recent years, despite the lack of enzymatic activity. NS5A has 
been found to interact with over 130 host proteins including many which are central to cellular signaling 
pathways.  NS5A is composed of three domains separated by regions of low complexity. All three domains 
perform important functions in the viral lifecycle. Domains I and II are essential for viral replication 
whereas domain III is required for viral assembly. However, the role that NS5A and its individual domains 
may play in modulating viral translation remains controversial. Previous studies have utilized translation 
reporter systems that do not accurately reflect the role of the viral 3´-UTR in modulating viral translation. 
We and others have shown that NS5A binds to the poly-U/UC region of the 3´-UTR. In addition to serving 
as the initiation site for negative strand synthesis the 3´-UTR functions to significantly enhance viral 
translation. The mechanism of translation enhancement remains unclear but may involve long range RNA-
RNA interaction with the IRES, the binding of cellular proteins which stimulate translation and/or the 
recycling of ribosomes.  Therefore, the protein-RNA interaction between NS5A and the poly-U/UC region 
has the potential to modulate viral translation. Therefore we set out to determine the role of NS5A and 
its individual domains in modulating viral translation and the role of the NS5A-poly-U/UC region 
interaction in this modulation.  
Utilizing monocistronic RNA reporters which contain the viral 5´- and 3´-UTRs and an internal 
Renilla luciferase reporter gene, we determined that NS5A specifically down-regulates viral translation in 
a dose-dependent manner through a mechanism dependent upon the presence of the poly-U/UC region 
in the viral 3´-UTR. Furthermore, we have re-tested the effect using full-length HCV genomic RNA 
reporters. These results suggest that NS5A is able to interfere with the stimulation of viral translation 
exerted by the 3´-UTR. This down-regulatory function of NS5A may function in mediating a switch from 
translation to replication, a step required in the lifecycle of a positive sensed RNA virus. Having established 
a role for NS5A in modulating viral translation, we then aimed to determine which region of NS5A was 
responsible for this effect. We found that each of NS5A domains was capable of this modulatory effect on 
viral translation independently. Although surprising, this finding is not entirely unexpected as each domain 
has been shown to retain the ability to bind to the poly-U/UC region.    
Within NS5A domain I we identified a 61 aa. region sufficient for translation down-regulation. 
Furthermore, we have identified a number of positively charged residues within this region involved in 
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the modulation of viral translation, in particular arginine 112 (R112). This residue has previously been 
found to be at the domain I dimer contact interface and to form an intermolecular hydrogen bond with 
glutamic acid 148 (E148). We found that mutations R112A and E148A individually negate the ability of 
domain I to modulate viral translation and these mutations impede the formation of domain I dimers.  
Additionally, the R112A mutation appears to affect the ability of domain I to interact with the poly-U/UC 
region of the viral 3´-UTR alluding to the possible mechanism of translation modulation. Finally this 
mutation was lethal in an HCV subgenomic replication, confirming the link between NS5A dimerization, 
RNA binding and viral replication. These results collectively point to a crucial role for the NS5A arginine 
112 residue in the modulation of HCV lifecycle by NS5A. 
Within NS5A domain II, we identified a 47 aa. region sufficient for translation modulation. Through 
the mutation of positively charged amino acids within this region, we found that lysine 312 (K312) was 
essential for this effect. The ability of this domain to modulate viral translation was completely lost when 
K312 was mutated within a full domain II protein fragment. The mechanism behind this modulation 
remains unclear but the 47 aa. region identified has been previously found to contain a region proposed 
to make contact with poly-U RNA and the K312 residue was suspected to interact directly with such RNA. 
Furthermore, this region interacts with the host protein cyclophilin A, an interaction that enhances the 
RNA binding ability of domain II. These findings strongly suggest that domain II modulates viral translation 
by binding within the poly-U/UC region. 
While investigating the modulation of viral translation by NS5A domain III we determined that the 
C-terminal 31 aa. are sufficient for the effect of this domain on viral translation.  Through alanine scanning 
mutagenesis we identified glutamic acid 446 (E446) as playing a key role in the modulatory function of 
this region. Within a domain III protein fragment mutation of this E446 residue abolishes the modulatory 
function of this domain towards HCV translation. The mechanism behind this modulation and the role of 
E446 in this effect remains to be determined.  
These findings suggest that in addition to being essential for viral replication and assembly, NS5A 
has an important role in modulating viral translation through a mechanism requiring the poly-U/UC region 
of the viral 3´-UTR. Furthermore, each domain of NS5A appears to contribute to this effect. These results 
support the description of NS5A as a multi-functional protein and the further characterization of its 
functions may aid in the development of novel antivirals targeting the numerous functions of this 
complex, and at times puzzling, viral protein.  
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1.0 LITERATURE REVIEW 
1.1 Hepatitis C Virus 
1.1.1 Identification and Molecular Characteristics 
 
Hepatitis C virus (HCV) was first identified in 1989 as the cause of transfusion associated Non-A, 
Non-B hepatitis (NANBH) (1, 2). This discovery was the result of significant advances in the field of virology 
as HCV was the first virus identified using exclusively modern molecular cloning techniques (3). 
Identification of HCV was accomplished by utilizing a bacterial cDNA clone library derived from 
chimpanzees infected with NANBH patient blood (3). This  clone library was then screened with antibodies 
isolated from the serum of NANBH patients (3). One of the clones identified through this screening process 
was subsequently found to originate from a large extrachromosomal RNA molecule found only in NANBH 
infected patients therefore identifying the HCV viral genome (3).   
HCV is an enveloped, positive sense RNA virus classified as member of the Flaviviridae family within 
the Hepacivirus genus (4) . Other members of Flaviviridae include yellow fever virus, dengue and West 
Nile virus (5). The only other members of the Hepacivirus genus are GB virus B, of which only a single 
isolate obtained from a laboratory-housed new world primate exists, and novel Hepacivirus recently 
identified in various animals including dog, horses, rodents, bats and non-human primates (4, 6, 7). HCV 
exhibits a very limited host species tropism (6). Humans are the only naturally infected hosts, although 
chimpanzees can be infected experimentally (6). The evolutionary origin of HCV remains unclear as no 
closely related virus capable of crossing the species barrier has been isolated (6).  
HCV is characterized by a high degree of genetic heterogeneity, it is currently classified into 7 
distinct genotypes (7). The genotypes differ by approximately 30-35% at the nucleotide level and are 
further subdivided into at least 67 subtypes that differ in their nucleotide sequence by 20-25% (8, 9). 
Furthermore, within an infected patient the virus exists as  quasi-species, a mixture of distinct but closely 
related viral genomes differing in sequence by up to 10% (10). This substantial genetic diversity is the 
result of the high level of viral replication during infection combined with the absence of proof-reading 
capability by the viral NS5B polymerase which results in the accumulation of mutations within the viral 
genome (10). 
 The HCV virion is pleomorphic, ranging between 40-80 nm in diameter, and enveloped by a cellular 
derived lipid bi-layer acquired during viral particle secretion (11). Two viral glycoproteins, E1 and E2, which 
mediate viral entry are displayed on the surface of the virion (11).  Within this envelope is the viral 
nucleocapsid which contains a single copy of the viral genome (11). Furthermore, virus particles exist as 
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complex heterogeneous lipoviroparticles within the infected host due to association with both low-
density and very-low density lipoproteins that contain various apolipoproteins, particularly ApoE (11, 12). 
The precise composition and structure of these lipoviroparticles remains unclear as does the role this 
association plays in the viral lifecycle. Association with lipoproteins may protect the virus from neutralizing 
antibodies as well play a role in viral entry (13). Association with ApoE is required for infectivity in cell 
culture and high lipid content correlates with high infectivity (13).  
The 9.6 kb viral genome contains a single large open reading frame (ORF) which is flanked by two 
highly conserved untranslated regions (UTRs) referred to as the 5´- and 3´-UTRs which play key roles in 
viral translation and replication (Figure 1.1) (14). Translation of this single ORF is mediated by an internal 
ribosomal entry site (IRES) within the 5´-UTR and results in the production of the viral polyprotein of 
approximately 3000 amino acids (15). The viral polyprotein is cleaved co- and post translationally by 
cellular and viral proteases to produce at least 10 viral proteins (16). This includes three structural 
proteins; Core, E1, E2, and seven non-structural proteins; p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. 
Additional proteins such as the F protein may be produced by alternate reading frames within the core 
coding region but expression of such proteins has yet to be demonstrated in vivo (17).  
The core protein forms the viral nucleocapsid though its interaction with, and packaging of, the viral 
genome (18). In addition to its structural role, core is thought to interact with numerous cellular proteins 
and modulate cellular gene expression, cellular signalling networks and lipid metabolism (19). The E1 and 
E2 proteins, which form a non-covalent heterodimer, are the viral glycoproteins present within the viral 
envelope (20). They and are required for viral assembly and entry (20). The P7 protein is a viroporin that 
forms an ion channel in artificial lipid membranes and is essential for viral assembly and release (20, 21). 
However, the exact role of p7 in the viral lifecycle is unclear but (20, 21). NS2 is a cysteine protease which 
cleaves the viral polyprotein the NS2/NS3 junction, a process which is strongly enhanced by the N-terminal 
region of NS3 (20). NS2 also appears to be involved in viral assembly independently of its protease activity 
(20). NS3 is a multifunctional viral protein with a serine protease domain located within its N-terminal 
region (22). In association with co-factor NS4A, which ensures proper folding of NS3 and membrane 
association, the NS3/4A complex mediates cleavage of the NS3 to NS5B region of the viral polyprotein 
(22). The NS3/4A protease is also involved in controlling the innate immune response by cleaving the 
cellular adaptor protein IPS-1 in the RIG-I ssRNA recognition pathway (23-25) The C-terminal domain of 
NS3 possesses NTpase/helicase functions that are essential for viral replication and assembly, though the 
specific function in the viral lifecycle is still uncertain (22). NS4B is proposed to be involved in both the  
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Figure 1.1 - The HCV genome and viral proteins. Diagram of the HCV genome and viral proteins. The 
positive-sense HCV genome is approximately 9.6 kb and flanked by two highly structured UTRs. 
Translation of the viral genome is mediated by the IRES within the 5´UTR and results in the production of 
the viral polyprotein. Cleavage of the polyprotein is accomplished through use of both cellular and the 
viral NS2 and NS3/4A proteases at the indicated cleavage sites. The NS3-NS5B proteins are sufficient for 
viral replication.  
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formation of an ER-associated membranous web and in the organization of the viral replication complex 
at this membranous structure (20). NS5A is a phosphoprotein that plays essential, but unclear, roles in 
viral replication and assembly (26). NS5A is also speculated to act as a signalling hub due to its interaction 
with a wide array of cellular proteins, suggestive of a key role in modulating the cellular environment in 
favour of viral survival and pathogenesis (27). NS5B is the RNA-dependent RNA polymerase which 
catalyzes the synthesis of new viral RNA genome via a negative strand intermediate (20). 
 
 
1.1.2 Epidemiology 
 
According to the World Health Organization, there are an estimated 130-150 million people 
globally infected with HCV which represents a worldwide prevalence of 2% (28). This prevalence varies 
considerably between different regions of the world.  HCV prevalence is highest in Africa and the Middle 
East with rates as high as 15% in Egypt (29, 30). Conversely, in developed regions such as North America, 
Northern and Western Europe HCV prevalence is less than 2% (29, 31). Countries with the highest number 
of HCV infections; China (29.8 million), India (18.2 million), Egypt (11.8 million), Pakistan (9.4 million) and 
Indonesia (9.4 million) contain approximately half of worldwide HCV infections (29, 31). The incidence of 
HCV infection is difficult to estimate due to the challenges in identifying new infections, as acute infections 
are generally asymptomatic. However, up to 4 million people may become newly infected with HCV 
annually (31, 32).  Of the seven viral genotypes, genotype 1 is the most common worldwide accounting 
for an estimated 46% of infections (9, 30). Genotype 3 is the second most common at 22% and is followed 
by Genotype 2 (13%), Genotype 4 (13%), Genotype 6 (2%) and finally Genotype 5 (1%) (30). Genotype 7 
has currently only been isolated in a single case (9). The global distribution of HCV genotypes is highly 
varied and also characterized by regional differences affected by such factors as modes of transmission 
and immigration (31). Genotypes 1, 2 and 3 are fairly widespread globally while genotypes 4, 5 and 6 are 
relatively centralized in specific regions of the world (31). Genotype 1 is the most widespread and is most 
prevalent genotype in the Americas, Australia, Northern and Western Europe and Japan (30). Genotype 2 
is more prevalent east Asia and west Africa (9). Genotype 3 is predominant in Asia, primarily within the 
Indian subcontinent (30, 33). Genotypes 4 is found in Africa and the Middle East, genotype 5 is limited to 
South Africa while genotype 6 is found in regions of Asia (29).  
HCV is a blood-borne virus and transmission occurs primarily through parenteral routes (33, 34). 
However, the main routes of viral transmission differ throughout the world. In developed countries, HCV 
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infection is primarily spread through the sharing of contaminated needles and supplies among 
intravenous drug users (34, 35). In Canada, for example, up to 80% of newly acquired HCV infections are 
associated with injection drug use (36, 37). In developing countries, HCV is primarily spread through 
unsafe therapeutic injections (34, 35, 38). It is estimated that up to 39% of injections in the developing 
world are performed with reused medical equipment resulting in up to 2 million new HCV infections per 
year (35, 38). An example comes from the reuse of contaminated syringes during national schistosomiasis 
treatment campaigns in Egypt between 1960 and 1987 that resulted in widespread HCV transmission (39). 
As a result, Egypt currently has the highest prevalence of HCV in the world at 15% (39, 40). Similar mass 
treatment or vaccination campaigns are suspected to be responsible for HCV epidemics in a number of 
central African countries including Cameroon, Gabon and the Democratic Republic of Congo (34). The 
introduction of widespread HCV screening in the blood supply during the early 1990’s virtually eliminated 
transfusion associated HCV in developed countries (34, 41). However, transmission of the virus though 
blood transfusion remains a route of infection in countries that either fail to screen for infectious diseases 
or lack the rigid quality control found in the blood supply system in developed countries (34, 38, 41).   
Other, less frequent routes of infection include household exposure, such as the sharing of razor 
blades, occupational exposure, tattooing, and intranasal drug use (34, 35). Although the efficiency of 
sexual transmission remains controversial, as transmission between monogamous heterosexual partners 
is exceedingly low, it is associated with high-risk sexual activity and men who have sex with men (35, 42, 
43). HCV can also be transmitted vertically from mother to child during pregnancy at rates of 
approximately 5% in HCV mono-infected women and up to 11% in HCV/HIV co-infected women and 
represents the leading cause of pediatric HCV in industrialized countries (44, 45). 
 
 
1.1.3 Clinical presentation 
 
HCV primarily infects hepatocytes, the most abundant and main functional cells of the liver (46, 
47). Hepatocytes perform multiple metabolic, endocrine and secretory functions (46, 47). Of those 
individuals infected with HCV, an estimated 75% develop a chronic infection (29). The reasons why up to 
25% of acutely infected individuals can resolve the infection remain unclear but factors include ethnicity, 
gender and other host genetic variations (29, 32). Acute HCV infection is asymptomatic in the majority of 
those infected and thus typically goes undiagnosed (32). While rare, acute infection may present with 
jaundice and even fulminant hepatic failure (35). Those who do develop symptoms of acute infection are 
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more likely to clear the virus than in asymptomatic cases (35). In the majority of patients who develop a 
chronic HCV infection, decades of clinically silent infection can result in severe liver diseases, such as 
steatosis, cirrhosis, hepatocellular carcinoma and end-stage liver disease (32). Accordingly, HCV is the 
leading cause of both hepatocellular carcinoma (HCC) and end-stage liver disease in developed countries 
(32).  The chronic inflammation and associated unresolved wound-healing process associated with chronic 
HCV infection can lead to progressive liver fibrosis which can advance to cirrhosis (48). This cirrhosis can 
progress to decompensated liver disease and culminate in end-stage liver diseases (48). At this stage the 
only treatment option is a liver transplant, however there is universal reoccurrence of HCV infection in 
the liver graft and disease progression is typically accelerated (48, 49). HCV associated cirrhosis is also a 
significant risk factor in the development of hepatocellular carcinoma (48). Factors found to exacerbate 
the progression of HCV associated liver diseases include patient age at time of infection (>40), alcohol 
consumption and co-infection with human immunodeficiency virus (HIV) (35, 50). 
HCV is also associated with a number of extrahepatic manifestations including autoimmune 
disorders such as cryoglobulinemia and thyroid disease in addition to glomerulonephritis, 
lymphoproliferative disorders, type 2 diabetes and neuropsychiatric conditions (35, 48, 51). The 
mechanism underlying many of these conditions remains ulcer but such conditions contribute to the 
lower-health quality of life of those infected with HCV (35).   
 
 
1.1.4 Treatment 
1.1.4.1 Sustained virological response: The goal of HCV treatment  
 
 Tremendous progress has been achieved in the treatment of chronic HCV infection in recent 
years. Many direct acting antivirals (DAAs) targeting various aspects of the viral lifecycle have been 
approved for clinical use in the last 3 years alone. These new treatment options have resulted in 
dramatically increased treatment efficacy. The goal and measurement of successful treatment of chronic 
HCV infection is a sustained virological response (SVR) (52). SVR is defined as undetectable serum HCV 
RNA 24 weeks after the end of treatment (53). Serum HCV RNA levels are determined by use of a sensitive 
polymerase chain reaction (PCR) assay with a detection limit of least than 50 IU/mL (53). Assays with lower 
detection limits of between 10-15 IU/mL have recently been developed and put into clinical use (53). This 
SVR benchmark has been proven to be indicative of a cure, as numerous follow-up studies have found 
SVR to be durable (52, 54). A large cohort study that followed patients for approximately 4 years after 
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achieving SVR found that over 99% of these patients maintained undetectable levels of serum HCV RNA 
throughout this period (54). Similar results have been obtained in longer term studies of up to 23 years 
post SVR (55, 56). Findings from studies such as these suggest the probability of HCV reoccurrence after 
SVR is achieved is exceedingly low. Furthermore, for the small percentage of patients in follow-up studies 
who were found to be HCV RNA positive after achieving SVR it is unclear whether this represents a relapse 
or a reinfection (53, 54). Through the use of highly sensitive molecular techniques, very low levels of HCV 
RNA have been occasionally detected in circulating peripheral blood mononuclear cells, such as 
lymphocytes and macrophages, in addition to tissues within of the liver of patients who have achieved 
SVR (53, 57-60). However, it remains unclear if these findings represent infectious viral RNA or have any 
clinical relevance. 
In addition to the clearance of viral RNA to levels below detection, SVR is also associated with the 
abrogation of disease progression and histological improvements within the liver (53, 61). Liver fibrosis 
and inflammatory activity have been observed to regress in the majority of patients achieving SVR and 
complete resolution of these impairments is also possible (53). Furthermore, even a regression in liver 
cirrhosis has been observed, contrary to the previous thought that this damage was irreversible (53, 61). 
As such, the risk of developing hepatocellular carcinoma is significantly reduced in patients that have 
achieved SVR (53). Therefore, SVR leads to significant reduction in liver-related complications and 
mortality associated with HCV (53).  
 
 
1.1.4.2 History of HCV Treatment 
 
The standard of care for all HCV genotypes between 2001 and 2011 consisted of pegylated 
interferon-α (Peg-IFN) and the nucleoside analogue Ribavirin (RBV) (62). IFNα was first used as a 
treatment for NANBH in 1986, 3 years before HCV was even identified as the causative agent, due to its 
use against hepatitis B (63). IFNα does not act directly on the virus itself but rather activates a general 
antiviral state within the cell through induction of IFN-stimulated genes (64). However, this early 
treatment regime was poorly effective, with SVR achieved in only 6% to 16% of patients undergoing  24 
and 48 week treatments, respectively, and the rate of relapse was high (63). In 1998 RBV was added to 
this treatment regimen in combination with IFNα (63). This dual therapy resulted in increased rates of 
SVR; approximately 34% and 42% upon completion of 24 or 48 week courses of treatment, respectively, 
in addition to a reduction in relapse rates (63, 64). The precise molecular mechanism behind RBV antiviral 
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activity against HCV is unclear (64). Multiple mechanisms have been proposed (64). The next improvement 
to this dual therapy occurred in 2001 when the half-life of IFNα was enhanced though the molecular 
modification of pegylation, a process which involves the covalent conjugation of IFN with polyethylene 
glycol (63, 65).  Although leading to increased rates of SVR, it was found that HCV genotype significantly 
affected the antiviral response to this dual PEG-IFN/RBV treatment (4). While SVR could be achieved in up 
to 80% of patients infected with genotype 2/3 virus after 24 weeks of treatment, those infected with 
genotype 1/4 virus at best achieved SVR 50% of the time after a 48 week course of treatment (4). This 
dual therapy is also associated with a wide array of adverse side-effects (4). These include flu-like 
symptoms, haemolytic anaemia, autoimmune syndromes and various neuropsychiatric side effects such 
as severe fatigue, apathy and depression with an increased risk of suicide (66). These adverse side effects 
combined with the low efficacy, particularly in genotype 1 patients, contribute to poor adherence and 
treatment avoidance. Despite these significant issues this PEG-IFN/RBV combination therapy remained 
the standard of care for non-genotype 1 infected individuals until only recently (52, 67).  
As the understanding of HCV has expanded substantially over the past 26 years, an increasing 
amount of research has gone into developing DAAs that directly target essential viral proteins.  
Development of DAAs was initially focused on genotype 1 virus due to both the poor response of genotype 
1 to PEG-IFNα/RBV therapy and its predominance in developed countries compared to other viral 
genotypes (63).  The first two DAAs were approved in 2011 for clinical use against this genotype (63). 
These two drugs, Telaprevir (Vertex) and Boceprevir (Merk) directly impede the viral lifecycle by inhibiting 
the activity of the viral NS3/4A serine protease (52). Addition of one of these protease inhibitors to PEG-
IFN/RBV therapy results in SVR rates of up to 75% in treatment naïve genotype 1 infected individuals (4). 
The continued requirement for PEG-IFN/RBV in combination with protease inhibitors was due in part to 
the rapid selection for resistance mutations during studies of monotherapy (62). Furthermore, these 
protease inhibitors add additional side effects such as anemia, nausea and rash to an already harsh 
treatment (68).  A third protease inhibitor, Simeprevir (Janssen), was approved for use in 2013 and further 
increased SVR up to 80% for genotype 1 patients (62). Despite the impressive advances in treatment 
efficacy these first generation protease inhibitors have already been replaced by more recent and more 
effective DAAs. 
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1.1.4.3 Current Standard of Care 
 
In October of 2014, Harvoni (Gilead), the first PEG-IFN/RBV free treatment was approved for use 
in treatment of HCV genotype 1 infections (69).  Harvoni is a once-a-day single tablet combination therapy 
that consists of two DAAs; Ledipasvir (LDV) and Sofosbuvir (SOF) (69).  LDV is a potent inhibitor of the 
essential viral protein NS5A although the precise mechanism of action is unclear (70, 71). However, LDV 
has been found to inhibit both viral assembly and replication (72).  SOF is a nucleotide analog inhibitor of 
the viral polymerase NS5B (73). The drug acts as a mimic of the uridine nucleotide and leads to RNA chain 
termination after its incorporation into the viral RNA during replication by NS5B (73). Treatment duration 
of Harvoni is typically 12 weeks but may be extended up to 24 weeks in treatment experienced patients 
who display cirrhosis or shorted to 8 weeks in treatment naïve patients without cirrhosis and low baseline 
HCV RNA levels (70, 74, 75). This combination treatment has been found to be highly effective, with SVR 
rates consistently above 90% and as high as 100% (1b subtype) in clinical trials of genotype 1 infected 
individuals (70, 74, 75).  Additionally, this therapy is well tolerated with few side effects reported, 
headache and fatigue being most common (70, 74, 75).  The convenience of a daily single pill, compared 
with weekly injection of IFN, twice daily RBV and three times daily protease inhibitor, and lack of the 
severe side effects associated with IFN will undoubtedly significantly improve patient adherence and 
treatment uptake. However, the cost of this state of the art treatment remains a significant barrier to 
widespread use, as a single pill is estimated to cost over $1100, which puts the price of treatment at an 
estimated $63,000 to $189,000 for 8 and 24 week courses, respectively. These prohibitive costs will 
significantly slow the global use of this treatment as the majority of HCV infected individuals reside in 
resource limited countries (38).  
Due to the pan-genotypic activity of SOF this drug can also be used in the treatment of non-
genotype 1 infections (73). Unfortunately, the use of LDV is restricted to genotype 1 virus due to genotypic 
differences (73). Treatment with SOF/RBV for 12 or 24 weeks is currently recommended for those infected 
with genotype 2 or genotype 3, respectively (76-80). With this treatment regime over 90% of genotype 2 
or 85% of genotype 3 infected patients have been shown to achieve SVR in clinical trials (76-78, 80). For 
the remaining viral genotypes (4, 5 and 6) it was found that the addition of peg-IFNα was beneficial so the 
recommended therapy is 12 weeks of triple IFNα / RBV / SOF (79).  As with the Harvoni treatment for 
genotype 1, SOF costs are in a similar range, over $1000 per pill, so again this represents a significant 
barrier to widespread access (81).    
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Despite the drastically improved efficacy of newly approved therapeutics, treatment of patients 
who have failed to respond to previous treatments, and those with varying levels of cirrhosis, remain 
particularly challenging (82). Due to unknown factors, patients with cirrhosis often display a reduced 
ability to clear the infection upon treatment (82). Investigations into new treatment combinations, 
dosages and treatment duration continue with hopes of improved efficacy in these hard to treat 
populations (82). 
 
 
1.1.4.4 HCV antivirals in clinical trials 
 
An impressive number of new DAAs are currently in phase II/III clinical trials (68, 82). These include 
new NS3/NS4 protease inhibitors, NS5A inhibitors and both nucleoside analogue and non-nucleoside 
inhibitors of the viral polymerase NS5B (68, 82). Some of these new antivirals offer increased potency, 
higher barriers to resistance and pan-genotypic activity (82). In addition to the numerous DAAs currently 
in development and clinical trials, a number of drugs targeting essential host factors are being investigated 
(83). Advantages of such therapies include pan-genotypic activity and a high-barrier to resistance (83). 
These treatments include Cyclophilin A inhibitors, miR-122 antagonists and viral entry inhibitors (4, 83). 
Cyclophilin A is a host factor and its interaction with the viral NS5A protein is required for viral replication 
(84). One inhibitor, Alisporivir (Novartis), is currently in phase III clinical trials (83). miR-122 is a micro-RNA 
that binds within the 5´-UTR of the viral genome, an interaction that is essential for efficient viral 
replication (85). Miravirsen (Roche), currently in Phase II trials has been shown to prevent this interaction 
between the micro-RNA and viral genome and inhibit viral replication (83, 85). There are also a number 
of small molecule inhibitors of viral entry under investigation (4). One compound, ITX 5061 (iTherx), 
currently in phase II clinical trials is an antagonist of a receptor involved in HCV entry, scavenger receptor 
BI, and has demonstrated an ability to prevent viral entry into the cell (83).  
 It is expected that by combining a number of these next generation antivirals that SVR rates will 
continue to get closer to 100% (82). As treatments continue to improve, a focus must be placed on 
eliminating barriers to treatment access as to ensure those who need treatment can access the best 
available options. This remains a challenge given the world-wide prevalence of HCV, the socio-economic 
issues involved and the extremely high cost of newly developed therapies. 
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1.1.4.5 Prevention / HCV vaccine 
 
 As there is no vaccine available for HCV current prevention efforts are aimed at preventing new 
infections and preventing disease in those already infected. One of the most successful prevention 
mechanisms is screening of the blood supply for the presence of HCV. Although such measures have been 
in place in developed countries since shortly after the discovery of the virus, this screening is lagging in 
developing countries (35, 38). Many of these regions either lack proper quality controls and/or focus 
primarily on HIV screening or, as is the case in 39 countries, do not perform routine testing for transfusion 
transmissible diseases (35, 38).  Education and observance of infection control practices is key in 
preventing new infections, as unsafe medical procedures are the main route of HCV infection in 
developing countries (34, 38).  In the developed world, much of the efforts at preventing new infections 
are targeted to intravenous drug users, as this is the population most at risk in these regions of the world 
(34, 35). Efforts include needle exchange programs in addition to educating and counselling both non-
infected and HCV infected IDUs in an effort to eliminate transmission prone practices (35). Treatment 
uptake in IDU populations has been observed to be incredibly low, with estimates ranging between 1-6% 
(37). As such a lot of effort has been directed towards removing barriers to treatment that exist within 
these marginalized populations (37, 86). Additionally, medical organizations such as the Centers for 
Disease Control in the United States are now recommending that all individuals born between 1945 and 
1965 be screened for HCV infection regardless of potential risk factors (87, 88). This population is 
estimated to include at least two-thirds of adults infected with HCV in the United States, many of who are 
unaware of their infection status (35). Once an infection has been identified, treatment can be initiated 
before the progression to severe liver disease such as cirrhosis and HCC. Such wide scale Identification 
and treatment will also help limit the spread of new infections. 
In order to eradicate HCV infections an effective vaccine against HCV is required. The cost barriers 
associated with HCV treatment and potential for re-infection clearly demonstrate the continued need for 
a vaccine (89). Unfortunately the development of an HCV vaccine has proven elusive due to reasons such 
as the remarkable genetic diversity of the virus and the lack of a clear understanding of what constitutes 
a protective immune response to HCV (10, 89). Contributing to the difficulty in vaccine development is 
the lack of a small animal model in which to assess candidate vaccine safety and efficacy (10).  The 
Identification of immune correlates in the approximately 25% of acute HCV infections that are 
spontaneously resolved is key to the development of an effective vaccine as this is the response vaccines 
should aim to reproduce (90). Furthermore, the fact that up to 80% of those who become re-infected 
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after this spontaneous clearance are able to clear the second infection suggests that the establishment of 
protective immune memory is possible (90, 91). Studies have suggested that a broad and multifunctional 
virus specific CD4+ and CD8+ T-cell response is associated with viral clearance (90, 92, 93). The role that 
an HCV specific antibody response may play in viral clearance is less clear, although recent findings suggest 
it may play a more predominant in viral clearance than previously thought (94-96). Therefore a successful 
HCV vaccine will likely have to stimulate both cellular and humoral immune responses in order to be 
protective (90, 94). A number of vaccine candidates are at various stages of development including phase 
II clinical trials (89, 90). One such candidate with promising results utilizes a prime-boost strategy with a 
replication defective simian adenovirus vector and a modified vaccinia Ankara vector encoding the NS3-
NS5B HCV proteins (97). Results from the recently completed phase I clinical trial indicate that this 
vaccination strategy induced high levels of polyfunctional effector and memory T-cells, both CD4+ and 
CD8+, specific for multiple viral antigens (97). These results are in line what is known about a protective 
response in vivo and lead to high expectations for the current efficacy trial underway in a population of 
intravenous drug users. 
 
1.1.5 Hepatitis C Virus Lifecycle 
1.1.5.1 Viral entry 
 
HCV particles circulating in the blood stream enter the liver after crossing though the fenestrated 
endothelium of the liver sinusoids (14). Once in the liver, the virus has direct access to the basolateral 
surface of hepatocytes within the space of Disse (14). The entry of virus particles is still not fully 
understood and appears to be a more complex process than observed for other viruses (11, 98). This 
involves sequential interactions with multiple cellular receptors (11). The implicated cellular receptors 
include; low-density lipoprotein receptor (LDLR), heparin sulfate proteoglycans (HSPGs), CD81, scavenger 
receptor B-1 (SRB1), tight junction proteins claudin-1 (CLDN1) and occludin (OCLN) and cholesterol 
absorption receptor Niemann-Pick C1-like 1 (NPC1L1) (99-105). Humanized mouse models show that 
transgenic mice, which stably express human CD81 and OCLN, are susceptible to HCV infection at a level 
similar to primary human hepatocytes (106, 107). These findings demonstrate a role for these receptors 
in governing the species tropism of HCV (106, 107).  
Initial attachment of the virus particles to the hepatocyte surface appears to be mediated by low 
affinity interaction between the viral particle and glycosaminoglycans of HSPG, the LDLR and SRB1 (11, 
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14, 98). The receptors utilized in this initial step are proposed to be dependent upon the lipid make-up of 
the virus particles (14, 98). Initial contact is thought to occur independently of the viral glycoproteins and 
rely on the interaction between viral associated lipoproteins, most notably ApoE, and the cellular 
receptors (11, 98). However, the glycoprotein E1 may play a role through is interaction with 
apolipoproteins (108) 
Following this initial attachment the virus particle then interacts with CD81 through the viral E2 
glycoprotein (11). However, the region of E2 that interacts with CD81 is initially masked by its 
hypervariable region 1 region (11, 14). In addition to its role in initial attachment SRB1 is thought to be 
responsible for exposing the CD81 binding region of E2 (11, 14). This is proposed to occur through either 
modification of virion lipid composition by SRB1 lipid transfer activity and/or direct interaction with the 
hypervariable region of E2 (14, 109, 110). Once associated with CD81, the CD81-HCV complex undergoes 
lateral movement and interacts with the tight junction protein CLDN1 (111-114). The mechanism behind 
this migration remains unclear but several cellular signalling pathways have been implicated. This includes 
protein kinase A and two receptor tyrosine kinases; epidermal growth factor receptor and ephrin receptor 
A2 and downstream RAS and RHO GTPases (114-116). Activation of these pathways is thought to 
modulate cell surface trafficking of CD81 and possibly CLDN1 in order to promote the formation of the 
HCV-CD81-CLDN1 co-receptor complex at the basolateral surface (114-116). The formation of this 
complex then induces internalization of the virus-receptor complex by clathrin-mediated endocytosis 
(Figure 1.2) (115). The role that OCLN, another tight junction protein, plays in viral entry is unclear but it 
is essential for this process and thought to function at a late stage of entry after CD81 and CLDN1 
interaction (99, 117).  
After internalization, the acidic environment within the early endosome promotes fusion between 
the HCV envelope and endosomal membrane mediated by the viral glycoproteins (98, 118). The 
interaction with CD81 is thought to promote conformational changes in the E1 and E2 viral glycoproteins, 
priming them for pH-dependent membrane fusion (118). The CD81 and OCLN cellular factors that are 
endocytosed along with the virus particle are also thought to contribute to this membrane fusion (98).  
After this fusion event the viral nucleocapsid is released into the cytosol where it undergoes an uncoating 
process to release the viral genome (11, 14). The viral genome can then undergo translation to produce 
the viral proteins (11, 14). While the HCV E2 glycoprotein plays an essential role in mediating viral 
interaction with CD81 the role of E1 in entry less defined. However, E1 is proposed to be involved in 
modulating E2 structure affecting the accessibility of binding domains (119, 120). This was found to 
modulate binding of E2 to the cellular receptors SRB1, CD81 and permit an interaction between E1E2 with  
  
14 
 
 
 
 
Figure 1.2 - The Hepatitis C virus lifecycle. The virus enters the cells via clathrin-mediated endocytosis 
after interacting with numerous cellular receptors including SRB1, CD-81 and CLDN1. pH-dependent 
fusion between the HCV envelope and endosome then releases the viral nucleocapsid. This is followed by 
capsid uncoating which releases the viral genome into the cytosol. The viral genome is then translated in 
association with the ER to produce the viral polyprotein. After cleavage of the viral polyprotein by both 
cellular and viral proteases the viral proteins induce the formation of the ER-associated membranous web. 
Viral replication is proposed to occur within DMVs in the membranous web. Viral RNA is thought to be 
transported to the surface of core/NS5A coated lipid droplets (black circles) and then to the assembling 
virion, which buds into the ER. The virion then acquires it envelope and associates with lipoproteins during 
transport through the secretory pathway and Golgi. The infectious HCV virion is then released from the 
cell.   
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CLDN1 (119). E1 also participates in mediating fusion between the viral envelope and endosomal 
membrane along with E2 (119, 121, 122). The role of the NPC1L1 cholesterol absorption receptor in viral 
entry is also unclear (14, 100). This cellular factor was found to be necessary for HCV infection but the 
mechanism remains to be determined (100).   
While the above described route of viral entry is required to establish an infection there is 
accumulating evidence to suggest a mechanism of cell-to-cell spread of HCV between adjacent 
hepatocytes plays a role in propagation of the virus within the infected liver (123-126). Such a mechanism 
may promote viral persistence though evasion of neutralizing antibodies (124). While this route of entry 
is dependent upon the viral glycoproteins and may utilize many of the same host factors required for cell 
free transmission, the mechanism has yet to be defined (14). An additional mechanism involving virion 
independent transfer of HCV RNA between hepatocytes mediated by exosomes has also been described 
(127, 128). However, the physiological relevance of these alternative mechanisms of viral entry remains 
to be determined. 
 
 
1.1.5.2 Translation 
1.1.5.2.1 Permission to use 
 
 This section contains an amended version of our previously published article: Hoffman B, Liu Q. 
2011. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int. 
31:1449-1467. As per Liver International policy no formal permission is required for reuse or modification 
by the author. Details available at http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291478-
3231/homepage/Permissions.html 
 
1.1.5.2.2 HCV IRES and proposed mechanisms of HCV protein translation 
 
As the HCV RNA genome does not possess a 5´-cap, the initiation of HCV protein translation occurs 
through a cap-independent mechanism mediated by an IRES (129, 130). The HCV 5´-UTR is a highly 
structured region that contains four distinct domains (I, II, III and IV) and is highly conserved among 
different viral strains (Figure 1.3) (131, 132). The IRES occupies the majority of the 5´-UTR spanning 
between nucleotides 40-372, encompassing domains II-IV (133). Domains II and III contain the structural  
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Figure 1.3 - Secondary RNA structure of the HCV 5´-UTR. The 5´UTR is composed of four domains labelled 
I-IV and numerous subdomains labelled a-f. The HCV IRES is composed of domains II-IV and the start codon 
is found within domain IV. The IRES functions to directly recruit the 40S ribosomal subunit during 
translation initiation. The stem-loop within domain I is required for viral replication.  
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elements crucial for the initiation of translation whereas domain IV contains the initiation codon and part 
of the core-coding sequence (131, 133-136). Domain II forms a long irregular stem-loop and is composed 
of two subdomains, IIa and IIb (137-139). Domain III, the largest and most complex of the IRES domains, 
contains six branching stem-loops that make up the domain III subdomains a-f (133, 137). Subdomains 
IIIabc make up a four-way junction at the apical portion of domain III while subdomain IIId is part of a 
three-way junction in the middle of domain III (133, 140). A four-way junction is present in the basal 
portion of domain III composed of sub-domain IIIe and a proposed pseudoknot formed by interactions 
between nucleotides present in domain IIIf and those in domain IV, upstream of the initiation AUG codon 
(133, 140, 141). The function of the HCV IRES is dependent upon both its conserved secondary structure 
as well as partly on the primary sequence as demonstrated by mutational analysis (142).  
Translation initiation begins with the direct recruitment of the 40S ribosomal subunit to the HCV 
IRES in the absence of any host translation initiation factors, a single-step process that requires the basal 
portion of domain III (136, 137, 143-145). The 40S complex binds to the IRES in such a way that the 
ribosomal P-site is in the immediate vicinity of the initiation AUG codon, bypassing the need for scanning 
(136, 137, 144). 40S ribosomal subunit binding involves multiple sites of interaction with the IRES, this 
includes interactions between the IRES and ribosomal proteins and RNA (146-148). High affinity binding 
requires the junction formed between domains IIIabc as well as the junction formed by domains IIIe/f 
(137, 142). This binding additionally requires IRES domain IIId (137, 142). Furthermore, the proposed 
pseudoknot structure is also thought to be involved in the 40S-IRES interaction (141, 149). The interaction 
between the pseudoknot structure and the 40S ribosomal subunit is believed to contribute to the 
positioning of the AUG codon in the mRNA binding cleft of the 40S ribosome (141, 149). Disruptions of 
this pseudoknot structure show that it is required for efficient IRES-mediated translation initiation (141, 
149). The 40S ribosomal subunit also interacts with domains II and IV, however these interactions do not 
add to the affinity between the IRES and the 40S subunit (142, 150). Domain II, particularly subdomain IIb, 
partially occupies the exit channel and extends towards the P-site in the ribosomal subunit and this 
interaction induces a conformational change in the 40S subunit that is thought to result in the opening of 
the mRNA entry channel of the ribosome to allow stable accommodation of the HCV RNA (133, 142, 150). 
Additionally, insertion of start codons upstream or downstream of the authentic start codon position is 
not recognized by the ribosome. This indicates that the IRES structure and the resultant multiple 
interactions between IRES domains and the 40S ribosomal subunit are involved in the correct placement 
of the 40S ribosome (142, 151-153).  
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Following the recruitment of the 40S ribosomal subunit, the eIF2-GTP-Met-tRNAi ternary complex 
and eIF3 translation initiation factor are recruited by domain IIIb and join the 40S-IRES complex, resulting 
in the formation of the 48S complex (137, 142). The ternary complex forms codon:anticodon base pairing 
interaction with the AUG start codon in the ribosomal P-Site (144). eIF3 interacts with the junction formed 
by domains IIIabc as well as loops in domains IIIa and IIIb (144). eIF3 is thought to stabilize the ternary 
complex thereby enhancing translation efficiency and initiation complex formation. This stabilization may 
be crucial for formation of the functional 80S ribosome complex (136, 142). Although this is the order of 
assembly suggested by assembly studies, it is possible that in vivo the 40S ribosomal subunit may already 
be associated with eIF3 and the ternary complex prior to IRES binding, nonetheless, these associations are 
not required for the recruitment of the 40S to the IRES (149). After the binding of the ternary complex 
and eIF3, GTP hydrolysis mediated by eIF5 and facilitated by HCV IRES domain II leads to the release of 
eIF2-GDP (137, 154). Further GTP hydrolysis by eIF5B is then required to release eIF3 during the joining of 
the 60S ribosomal subunit to form the 80S complex (154). During this process, eIF5B and domain II of the 
IRES are also thought to adjust the position of the initiator tRNA to facilitate 80S formation (155). This 
translationally competent 80S ribosome can then proceed with elongation, with efficiency of the first 
translocation event modulated by IRES domain II, and continue along the genome resulting in synthesis 
of the viral polyprotein (156) .  
This mechanism of HCV IRES-mediated translation initiation allows HCV to translate its genome 
while utilizing only the limited set of host translation initiation factors described above. This is in contrast 
to cellular mRNA cap-mediated translation which requires at least nine initiation factors involved in such 
functions as ribosome recruitment and scanning for the start codon (142, 157). A wide array of additional 
cellular factors are also utilized to enhance the efficiency of this process (158). Notably the HCV IRES 
directly recruits the 40S ribosomal subunit independent of the eIF4F cap-binding complex required for 
cellular mRNA translation (142, 157). This direct recruitment is important as the formation of the cap-
binding complex is a rate-limiting step of cellular cap-dependent translation initiation and, therefore, the 
virus does not have to compete with cellular mRNAs for the limited pool of eIF4F complexes (159, 160). 
Furthermore, formation of the eIF4F complex is antagonized during times of unfavourable physiological 
conditions such as low nutrient availability (160).  
In contrast to the proposed mechanism described above, other studies suggest that the HCV IRES 
and HCV-like IRES (e.g., CSFV) are capable of initiating translation using an eIF2 independent mechanism 
during periods of cellular stress (161, 162). During times of cellular stress, such as during viral infection, 
the α-subunit of eIF2 undergoes phosphorylation, a modification which transforms eIF2 into an inhibitor 
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of eIF2B as opposed to a substrate (162, 163). eIF2B normally functions as a guanosine nucleotide 
exchange factor which promotes GDP/GTP exchange on eIF2 enabling the formation of the eIF2-GTP-Met-
tRNAi ternary complex (164). The resulting inhibition of eIF2-GDP to eIF2-GTP exchange results in the 
global down-regulation of protein synthesis as eIF2 can no longer deliver the initiator tRNA to the 
ribosome (163). However, initiation of HCV translation has been found to be functional in the presence of 
reduced levels of the eIF2-GTP-Met-tRNAi ternary complex that effectively block cellular cap-dependent 
translation (165). Under conditions of induced eIF2α phosphorylation, HCV can initiate translation using 
only eIF3 and eIF5B/eIF2 and requires no GTP hydrolysis (161, 162). In one proposed model, eIF5B 
functions in a similar fashion as its bacterial homolog, IF2, in promoting initiator tRNA binding to the 
ribosomal P-site (161). Alternatively, eIF2A, which is thought to only play a minor role in cellular 
translation, may be involved in delivering Met-tRNAi through interactions with domain IIId of the HCV IRES 
(166, 167). The biological significance of these proposed alternative translation initiation mechanisms are 
not fully understood. However, the ability to accomplish protein translation during times of cellular stress, 
when cellular protein synthesis is down-regulated, would provide HCV with a selective advantage during 
such conditions.  
 
 
1.1.5.2.3 Alternative reading frame products 
 
The possibility of an alternative reading frame (ARF) within the HCV genome was first suggested 
by studies which found the HCV core-coding sequence to be far more conserved than necessary to 
preserve the amino acid sequence (168, 169). Subsequent studies proved this in fact to be true as an ARF 
that overlaps the core-coding sequence at +1 nucleotide was proposed to encode ARF proteins (ARFPs) 
(170, 171). Although never directly observed in a natural infection, antibody and T-cell responses directed 
towards potential ARFPs in HCV patients provide indirect evidence that ARFPs are expressed in vivo (170-
175). Low expression levels may account for the lack of recovery of ARFPs from infected patients. The first 
proposed form of ARFP was the 16 kDa ARFP/F (F protein/core+1, core=21 kDa) that was found in HCV-1 
replicating cells (176). This protein contains approximately 10 amino acid residues of the core protein 
attached to approximately 150 amino acids encoded in the ARF (176). Translation of the ARFP/F protein 
is thought to be initiated at the AUG of the main HCV ORF and translation occurs in this reading frame 
until an adenine-rich sequence is encountered at codons 8-11 which acts as a “slippery sequence” and 
stimulates a programmed +1 ribosomal frame-shift into the ARF (176, 177). Translation then proceeds in 
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the ARF until the first in-frame stop codon is reached (176). However, this adenine-rich sequence was 
found to be very rare among HCV variants and as such this mechanism alone cannot fully account for the 
observed ARFP-directed immune responses in HCV patients (176).  
Another proposed ARFP product that was generated in E. coli from an HCV core encoding 
fragment referred to as the ARFP/DF is produced as a result of a double frame-shift (176, 178). ARFP/DF 
is a chimeric protein that contains 42 amino acids of core, 101 amino acids of ARFP and ends with another 
30 amino acids of core (176, 178). The first frame-shift event is proposed to occur at a conserved RNA 
structure within the core-coding sequence referred to as stem-loop VI (176). The second frame-shift that 
shifts the ribosome back into the original ORF occurs when the ribosome encounters a stop codon located 
just upstream of another conserved RNA structure, the terminal stem-loop element (176). Other 
mechanisms reported to mediate ARFP expression in addition to ribosomal frame-shifting include internal 
initiation and transcriptional slippage (169). In the case of transcriptional slippage, in which nucleotides 
are added or deleted during RNA transcription at run of adenines or thymines, the cluster of adenines 
between codons 8-11 in HCV-1 was found to be prone to transcriptional slippage by both T7 and viral 
NS5B polymerases (177). Therefore the addition or deletion of an adenine in this region could lead to a 
frame-shift and result in production of ARFPs (177). However as mentioned above, this adenine rich 
sequence is very rare among HCV variants and in HCV strains containing the adenine-rich sequence, no 
heterogeneity has been reported. As such, although it is possible that transcriptional slippage may 
contribute to ARFP expression in the quasispecies variants within infected patients, this is likely not the 
lone or major mechanism for production of ARFPs (177). Consistent with this notion, an ARFP has been 
proposed to be initiated at internal methionine codons at positions 85/87 through an internal initiation 
mechanism (171). The internal initiation results in the production of a protein called ARFP/S (core +1/S) 
(171). In the absence of codons 85/87, codon 26 in the ARF has also been found to function as an internal 
translation initiation site (171). Only recently have ARFPs been shown to be expressed in the infectious 
cell culture system (169). Expression of a family of core isoforms ranging in size from 8 to 14 kDa has been 
observed (169). The 8 kDa isoform was subsequently determined to likely be the result of internal 
initiation at or near codon 91 (169). These investigations collectively suggest that there may be multiple 
mechanisms resulting in ARFP expression and these mechanisms may differ among HCV variants. 
However, the biological relevance of these mechanisms is not well understood as it is unclear if and how 
ARFP expression occurs in vivo.  
The functions that ARFPs may play in the viral lifecycle remain unclear. Mutational studies suggest 
that these proteins play no critical role in the viral lifecycle as abolishing ARFP production had no 
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measurable effect on HCV replication in cell culture or in the uPA-SCID mouse model (179). Also 
MacMullan et al. found that the ARFPs F and DF were not essential for virus replication in a chimpanzee 
infected with an HCV clone containing four stop codons within the alternate reading frame (180). 
However, ARFPs have been associated with a variety of functions including suppression of cell cycle 
regulator p21 expression, disruption of transcription factor c-Myc activity, disruption of iron metabolism 
and enhanced hepatocyte proliferation (17, 181-183). ARFPs have also been implicated in the induction 
of various cytokines and chemokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte 
chemoattractant protein-1 (MCP-1) (184). This is intriguing as it has been shown that large amounts of IL-
6, IL-8 and MCP-1 are produced in HCV patients with advanced liver disease and that a higher prevalence 
of ARFP antibodies has been found in HCV patients that develop hepatocellular carcinoma suggesting that 
ARFP levels are higher in patients with advanced liver disease and HCC (171, 172). These findings point to 
a role in viral persistence and pathogenesis and/or modulation of host processes as possible functions of 
ARFPs.  
 
1.1.5.2.4 Cis-modulation of HCV protein translation 
1.1.5.2.4.1 Core coding sequence 
 
As mentioned previously, domain IV of the HCV 5´-UTR is a component of the IRES and extends 
into the core-coding region. In addition to containing this 3´-terminal portion of the IRES, the core-coding 
region also contains a number of conserved RNA secondary structures that are postulated to be involved 
in HCV translation modulation (179, 185). Four highly conserved stem-loop (SL) structures have been 
predicted to be present in the core-coding region: from 5´- to 3´, SL47/SLV, SL87/SLVI, SL248, and SL443 
(179, 185-187). It has been observed that disruption of the structural integrity of SL47 and SL87 but not 
SL248 or SL433 impairs translation and viral replication in cell culture and in the urokinase-type 
plasminogen activator-severe combined immunodeficiency (uPA-SCID) mouse model (179). It has been 
suggested that SL47 and SL87 enhance HCV translation through the binding of trans-activating factors or 
possibly through long-range RNA-RNA interactions with other parts of the HCV viral genome (179). On the 
other hand, a number of studies have identified a suppressive effect of a portion of the core-coding 
sequence on translation through a long-range RNA-RNA interaction between the 5´-UTR and nucleotides 
within the core-coding region (188-190). Kim et al. found that nucleotides 428-442 of the core-coding 
sequence, which is located at the 5´-end of SL87, can interact with nucleotides 24-38 in domain I of the 
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5´-UTR (188). Mutations that disrupted the stability of this interaction significantly enhanced HCV IRES-
mediated translation while compensatory mutations that restored the RNA-RNA interaction lead to 
inhibition of translation in a bicistronic reporter system (188). It is worth noting that the bicistronic 
reporter system used included non-HCV sequences that may alter the secondary structure of RNA 
elements of the 5´-UTR of HCV. Perhaps the best evidence supporting a role of structured elements in the 
core-coding region modulating HCV lifecycle comes from the study by McMullen et al. mentioned in the 
previous section (180). In this study, the HCV clone that was modified through silent mutations to add 
four stop codons in the ARF resulted in low levels of viremia and minimal liver damage (180). However, it 
was determined that this effect was not the result of impaired ARFP expression but rather the disruption 
of RNA secondary structure. (180). The last two stop codons disrupted base-pairing within the predicted 
secondary structure of SL87 (SLVI) in the core-coding sequence, indicating the importance of maintaining 
this structured element in HCV lifecycle (180). These findings suggest that the core-coding sequence may 
be involved in modulation of HCV translation via long-range RNA-RNA interactions or perhaps though 
interactions with host or viral proteins. 
 
 
1.1.5.2.4.2 NS5B coding sequence 
 
In addition to the core-coding sequence, the 3´-end of the NS5B coding sequence is also predicted 
to form conserved RNA structures (185, 186, 191). One of these structures, a stem-loop referred to as 
5BSL3.2 (SL9266) has been observed to be essential for viral replication as mutations disrupting its 
structure blocked RNA replication (191, 192). This stem-loop was found to interact with SL2 of the X-tail 
region of the viral 3´-UTR, forming a functional kissing-loop tertiary structure (192). This kissing-loop 
interaction is required for HCV replication (193, 194). In addition to the kissing-loop interaction with the 
3´-UTR, the 5BSL3.2 structure is proposed to interact with a non-structured conserved sequence about 
200 nucleotides upstream within the NS5B coding sequence (195). Disruption of this interaction was 
found to inhibit viral replication in the Con-1 replicon system (195). However, it is not known whether this 
interaction occurs simultaneously with the interaction between 5BSL3.2 and the X-tail region or at 
different time points during the viral lifecycle (195). Since these two interactions involve distinct regions 
of 5BSL3.2, it is possible that the upstream interaction functions to stabilize the kissing-loop interaction 
(195). In addition to the above interactions that are proposed to play a role in viral replication, 5BSL3.2 
has also been proposed to participate in a long-range interaction with the IRES found in the 5´-UTR (196). 
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The apical loop of domain IIId of the IRES and the internal loop of 5BSL3.2 were found to be essential for 
this interaction (196).  The interactions between the UTRs and this structured region of the NS5B coding 
sequence has also been implicated in modulating the structure of both the IRES and 3´-UTR (197, 198). 
Although the biological significance of such a long-range interaction remains to be clearly determined, it 
is possible that this end-to-end communication between the IRES and NS5B coding sequence could play a 
role in the circularization of the viral genome and/or the switch between different stages of the viral 
lifecycle (196). Furthermore, cellular or viral proteins that interact with these regions of the viral genome 
could be involved in mediating this RNA-RNA interaction and its potential effects on the viral lifecycle 
(196).   
 
 
1.1.5.2.4.3 The 3´-UTR 
 
In cap-dependent translation, translation is stimulated by poly(A)-binding protein (PABP) bound 
to the 3´-poly A region of mRNA transcripts interacting with eIF4G of the eIF4F cap-binding complex (199, 
200). This interaction has been suggested to promote the circularization of the transcript (199, 200). The 
interaction between PABP and eIF4G has been shown to increase the affinity of the eIF4F complex for the 
5´-cap potentially resulting in increased 40S recruitment. The circularization of the transcript may also 
enhance translation by promoting ribosome recycling (199, 200). In a conceptually similar fashion, the 
HCV 3´-UTR has been shown to have stimulatory effects on HCV translation (200-205). The 3´-UTR of HCV 
is composed of three distinct regions: the variable region, the poly-U/UC tract and the X-tail, a region with 
highly conserved secondary structure (Figure 1.4) (201). The X-tail forms three stem loop structures, 
named SL1, SL2, and SL3 (205).  
Although clearly essential for replication as it serves as the initiation site for negative strand 
synthesis, the exact role of the 3´-UTR in HCV translation remains unclear (200, 201, 205). For many years 
the role of the 3´-UTR in the modulation of HCV translation was a contentious issue with published reports 
suggesting that the region down-regulates, enhances or has no effect on translation (200-204, 206-211). 
However, as observed in a study by Song et al., these discrepancies may have been partly due to the 
reporter design (201). Only when monocistronic RNA reporters with precise 3´-ends or complete RNA 
genomes are utilized is efficient translation enhancement observed (201). The use of bicistronic reporters 
and the transfection of DNA reporters either encoded on circular or linearized plasmids or PCR fragments 
may not accurately reflect the role of the 3´-UTR (201). In the same study, the authors found that the  
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Figure 1.3 - Secondary RNA structure of the 3´-UTR. The 3´-UTR is composed of four regions; the variable 
region, poly-U/UC region and the x-tail region, which contains 3 highly conserved stem-loops. The 3´-UTR 
is essential for viral replication as it serves as the initiation site of negative strand synthesis. The 3´-UTR 
also functions to significantly enhance viral translation. A wide array of cellular proteins has been found 
to bind to the 3´-UTR and modulate viral translation and replication.    
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variable region, the poly-U/UC tract and SL1 (the 3´ most terminal stem loop) of the X-region contribute 
significantly to the translation enhancement provided by the 3´-UTR while SL2 and SL3 play only minor 
roles (201).  
The mechanism of 3´-UTR enhancement of translation remains to be clearly defined. Possible 
mechanisms include cellular or viral factors binding to the 3´-UTR that may promote circularization of the 
viral genome as well as potential long-range RNA-RNA interactions between regions of the 3´-UTR and 
IRES or other regions (200, 201). The poly-U/UC region is proposed to act as a molecular interaction 
platform for recruitment of host and viral proteins including the viral NS3, NS5A and NS5B proteins (212-
215). Host proteins interacting with this region such as HuR and Lsm1-7 will be described in upcoming 
sections (216, 217). Furthermore, interactions between the IRES and the 3´-UTR have been found to alter 
the structure of essential IRES subdomains IIIb and III and domain IV (197). Conversely the 5´-UTR has 
been observed to be involved in modulating the structure of the 3´end of the viral genome, particularly 
the 3´Xtail (198). These results suggest a complex network of long-range RNA-RNA interactions that may 
modulate different steps of the viral lifecycle (197, 198). The 3´-UTR is also proposed to function in the 
recycling of the ribosome back to the IRES following translation termination, facilitating efficient initiation 
of subsequent rounds of translation (200, 218). 
 In a study aimed at determining the specificity of the enhancement of translation by the 3´-UTR, 
Bung et al. utilized chimeric monocistronic reporters with 5´- and 3´-UTRs from different viruses (205). 
They found the HCV 3´-UTR is capable of stimulating not only HCV IRES-mediated translation but also 
translation mediated by the structurally similar porcine teschovirus IRES to a comparable extent (205). 
Porcine teschovirus does not possess a structured 3´-UTR similar to HCV but rather is polyadenylated at 
its 3´-end (205). Additionally, the HCV 3´-UTR was found to stimulate both the translation of the ECMV 
IRES which is structurally and functionally different than the HCV IRES as well as the translation of a capped 
cellular mRNA (205). However, this results in only a moderate stimulation of translation and is only 
observed in certain cell culture systems suggesting the importance of both UTRs in modulating this effect 
(218). These results suggest that the mechanism of stimulation by the HCV 3´-UTR may not be solely based 
on the recognition or interaction of specific RNA structure or sequences present within the HCV genome 
such as IRES by the 3´-UTR (205). Adding to this view is the fact that in the same study, the substitution of 
the HCV 3´-UTR with a poly (A) tract also lead to the stimulation of HCV IRES translation, albeit to a lower 
extent (205). These results therefore suggest that the stimulation of protein translation by HCV 3´-UTR 
may occur through multiple mechanisms such as RNA-RNA interactions with HCV IRES structure and 
recruitment of cellular factors bound to the 3´-UTR that interact with components of the translational 
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machinery present on the IRES in a fashion similar to the PABP-eIF4G interaction found on cellular mRNAs 
(205). The latter might be a more generalized mechanism which may explain why HCV 3´-UTR can enhance 
protein translation directed by a non-HCV IRES. Another potential role of HCV 3´-UTR in HCV lifecycle is 
that this region may be important for the switch between viral protein translation and RNA replication as 
this site is essential for both replication and translation (201). This switch could involve the sequential 
interactions of cellular and/or viral factors with the 3´-UTR or RNA-RNA interactions.    
 
 
1.1.5.2.5 Trans-modulation of HCV protein translation 
1.1.5.2.5.1 Cellular factors/ ITAFS 
 
In addition to the limited number of canonical translation initiation factors (eIF2, eIF3 and eIF5/B) 
required for HCV translation, a number of non-canonical cellular factors have been shown to interact with 
the HCV IRES and/or 3´-UTR and potentially modulate translation (Table 1.1). These IRES-trans-acting 
factors (ITAFs) have been proposed to function through multiple mechanisms such as enhancing the 
recruitment of translational machinery, as well as other trans-acting factors, or act to stabilize the IRES 
structure to facilitate efficient translation. This section will give an overview of some of the ITAFs listed in 
Table 1.  
The La autoantigen has been shown to interact near the initiator AUG codon and a GCAC motif 
within stem-loop IV appears to be important in this interaction (219-221). This interaction was determined 
to be facilitated by the RNA recognition motif (RRM) 2 RNA binding domain present with La autoantigen 
(221). The interaction between the viral RNA and La autoantigen appears to enhance IRES-mediated 
translation as mutations in this GCAC motif that alter the primary sequence while maintaining the overall 
secondary RNA structure affect the binding of La autoantigen and result in a significant impairment of 
IRES-mediated translation (220-222). Additionally the seclusion of La autoantigen results in inhibition of 
HCV IRES- mediated translation (223). In terms of the mechanism, it was observed that such mutations to 
this GCAC motif in addition to affecting the binding of La autoantigen also appeared to impair the binding 
of the S5 ribosomal protein, which is a component of the 40S ribosomal subunit known to interact with 
the HCV IRES, suggesting a role for La autoantigen in enhancing 40S ribosome recruitment (221). 
Furthermore, a synthetic peptide derived from the RRM2 domain of La autoantigen, which mediates its 
interaction with the GCAC motif within the IRES, competes with La protein for IRES binding and interferes 
with the assembly of the 48S ribosomal complex, resulting in inhibition of translation (222). These 
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Table 1.1 Cellular trans-modulators of HCV translation 
 
Cellular 
factors 
Effect on 
HCV 
translation 
Proposed mechanisms Cellular functions References 
Gemin5 - 
Binds to IRES and forms 
complex with eIF3a, b, c. 
Addition of purified 
Gemin5 resulted in down-
regulation of HCV IRES 
activity, while shRNA 
knockdown of Germin5 
resulted in increase of HCV 
IRES activity. 
snRNA binding protein of SMN 
complex, which is involved in 
biogenesis of snRNPs ,a 
component of mRNA slicing 
machinery. Also involved in 
down-regulation of cellular 
translation in which a complex 
containing eIF4E is formed. 
(224)  
hnRNP D 
(AUF1) + 
Interacts with SLII of HCV 
IRES.  Knockdown inhibits 
translation but increases 
replication suggesting a 
role in balancing viral 
translation and replication. 
Involved in mRNA decay, 
telomere maintenance and 
translation initiation.  
(225)  
hnRNP L + 
Binds to 3´ end of HCV IRES 
and 5´- terminal region of 
5´-UTR. hnRNP L specific 
RNA aptamers inhibited 
IRES function in dose 
dependent manner. Also 
found to promote efficient 
replication 
Role in mRNA processing 
including alternative splicing, 
mRNA export and mRNA 
stability. (226-228)  
Hu 
antigen R 
(HuR) 
+ 
Binds to poly-U/UC region 
of 3´-UTR. Over-expression 
enhances HCV IRES activity 
while knockdown down-
regulates HCV IRES activity. 
Selectively binds and stabilizes 
AU rich element containing 
mRNAs. 
(217, 229, 
230)  
IGF2BP1 
(IMP-2) + 
Binds to 5´- and 3´ UTRs 
(poly-U/UC). siRNA 
knockdown down-regulates 
HCV IRES activity. May 
stimulate translation by 
promoting RNA 
circularization and/or 
recruitment of eIF3.  
Binds to and regulates the 
translation of certain mRNA 
such as insulin-like growth 
factor 2 and beta-actin.  (227, 231)  
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La auto-
antigen 
+ 
Binds near the initiation 
AUG codon of IRES. 
Facilitates formation of 
initiation complex and 
stimulates internal 
initiation of translation. 
Multifunctional protein with 
roles in RNA biogenesis. Binds 
to the 3´termni of many newly 
synthesized RNAs, particularly 
those made by RNA pol III, 
protecting the 3´ ends from 
exonucleases. Autoantigen in 
systemic autoimmune 
diseases. 
(219, 221-
223, 232-235)  
LSm1-7 + 
LSm1-7 ring binds to 5´-
UTR dependent on SLIII. 
Also binds to poly-U/UC 
tract of 3´-UTR. Silencing of 
LSm1 selectively down-
regulates HCV translation.   
Component of P-bodies. 
Involved in mRNA turnover. 
Binds to short oligo (A) tracts 
at 3´ end of deadenylated 
mRNA and inhibits 3´ 
degradation while promoting 
decapping and 5´ to 
3´degradation. 
(216)  
miR-122  + 
Binding to S1 and S2 sites 
in 5´-UTR upstream of the 
IRES enhances translation. 
Thought to enhance the 
association of 40S 
ribosomal subunit and HCV 
RNA. 
Well-conserved, highly 
abundant, liver specific 
microRNA. Binding to 3´-UTR 
of cellular mRNA encoding 
cationic amino acid 
transporter CAT-1 results in 
down-regulation of CAT-1 
protein levels. 
(236-240) 
miR-
199a* ? (-) 
Target sequence in domain 
II of the HCV IRES. Over-
expression results in down-
regulation of viral 
replication. 
Implicated in the post-
transcriptional regulation of 
gene expression for various 
genes such as Ceruloplasmin 
(CP). 
(241, 242)  
mIR-196 - 
Potential target sequence 
present in HCV NS5A 
coding region. Over-
expression results in down-
regulation of HCV protein 
expression and replication. 
Implicated in the post-
transcriptional regulation of 
gene expression for various 
genes such as Bach1. (242-244)  
Nucleolin ? (+) 
No data using HCV 
reporter. Identified by 
mass spectrometry as a 
component of HCV IRES 
bound 40S ribosomal 
subunit. Bound by yeast 
inhibitor RNA (IRNA). 
Stimulates poliovirus IRES.  
Implicated in a variety of 
processes including rRNA 
maturation, and ribosome 
assembly. (245-247)  
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NSAP1 
(SYNCRIP, 
hnRNP Q)  
+ 
Binds to adenosine rich 
region downstream of AUG 
start codon in core coding 
sequence. Facilitates 40S 
ribosome binding and 
enhances 80S ribosome 
formation 
A member of hnRNP family of 
proteins implicated in mRNA 
processing mechanisms. 
Component of the 
spliceosome. 
(248, 249)  
PTB ? 
Interacts with both 5´- and 
3´ UTRs of HCV RNA. Role 
in HCV protein translation 
is unclear with 
contradictory reports 
suggesting stimulation, 
inhibition, or no effects on 
HCV protein translation.  
Implicated in the regulation of 
pre-mRNA splicing. 
(250-256)  
PSMA7 + 
Knockdown by siRNA or 
ribozymes results in 
significant inhibition of HCV 
translation. 
Human 20S proteasome α-
subunit type 7 is a component 
of 20S core structure of 
proteasome. 
(230, 257)  
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observations combined with the observation that La autoantigen binding appears to alter IRES 
conformation strongly suggest a mechanism through which La autoantigen binding induces a 
conformation change that enhances the recruitment of the 40S ribosomal subunit to the IRES and/or is 
involved in ensuring the proper positioning of the 40S subunit on the IRES (221, 222).  Furthermore, the 
La autoantigen is purposed to contribute to the host tropism of HCV as expression of human La 
autoantigen significantly enhanced both viral translation and replication in mouse cell lines (232).  
Other host proteins shown to modulate HCV IRES-mediated translation are heterogeneous 
ribonucleoprotein D (hnRNP D) and hnRNP L (225, 226, 228). hnRNPs are a diverse family of RNA-binding 
proteins that are involved in wide range of functions related to cellular nucleic acid metabolism, such as 
the splicing and packaging of nascent transcripts as well as translational regulation (258). In regards to 
HCV translation, hnRNP D was found to bind to the stem-loop II region within the IRES (225). Over-
expression of this cellular protein enhances viral translation while siRNA knockdown of hnRNP D inhibits 
viral translation suggesting that hnRNP D is a viral translation enhancer (225). It was also observed that 
an increase in HCV RNA replication occurs when hnRNP D expression is knocked down (225). This leads to 
an interesting possibility that hnRNP D acts to balance translation and replication and may be even 
involved in the switch from translation to replication (225). In regards to hnRNP L, Hahm et al. found that 
it binds to the HCV RNA genome within the 3´ border region of the HCV IRES which includes part of the 
core-coding sequence (228). This study also showed that hnRNP L binding increased translational efficacy 
of translation driven by the HCV IRES (228). In agreement with this model, a dose-dependent inhibition of 
HCV IRES function occurs when hnRNP L is depleted using RNA-aptamers (226). These results suggest an 
important role of hnRNP L in the modulation of HCV IRES-mediated translation. hnRNP L has also recently 
been shown to interact within the 5´- terminal region of the 5´-UTR and promote efficient replication 
(227). Another member of the hnRNP family, NSAP1 (also referred to as hnRNP Q and SYNCRIP) has also 
been shown to interact with and modulate the HCV IRES (248). NSAP1 binds within an adenosine rich 
region in the N-terminal region of the core-coding region (248). Same as with hnRNP D and L, over-
expression of NSAP1 enhances HCV IRES-dependent translation whereas small interfering RNA (siRNA) 
knockdown or mutation of its binding site results in inhibition of HCV IRES-mediated translation (248). In 
terms of a mechanism NASP1 has been found to also interact with the 40S ribosomal subunit and is 
proposed to aid in correctly positioning the viral RNA thereby enhancing 80S complex formation (249).  
Another cellular protein proposed to be involved in the modulation of HCV IRES-mediated 
translation is polypyrimidine tract-binding protein (PTB), another hnRNP protein family member. 
Contradictory results have been published and as a result the role for PTB in HCV translation remains 
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unclear (256). PTB has been found to interact with both the 5´- and 3´-UTRs, a finding that lead to the 
speculation that PTB may be involved in 5´-3´ crosstalk resulting in the circularization of the viral genome 
(252, 259). However, subsequent studies by various groups have had different results, reporting that PTB 
stimulates, inhibits or has no effect on HCV translation (250, 251, 253-256). 
Interestingly, a number of cellular proteins implicated in modulating viral translation are capable 
of interacting with each other (15). For example, hnRNP D interacts with hnRNP L, IGF2BP1 and NSAP1 
whereas the La protein can interact with LSm1-7 (260-263). This suggests that cellular ITAFs may act as a 
larger complex bridging different regions of the IRES and/or regions of the 3´-UTR to enhance translation 
initiation (15). However, this concept and the significance of these interactions on viral translation 
remains to be investigated. 
Recent research has led to the suggestion that the autophagy pathway may be involved in HCV 
translation (264). Autophagy is an evolutionary conserved process that functions to maintain cellular 
homeostasis by removing damaged organelles and protein aggregates from the cytoplasm through the 
formation of autophagosomes which facilitate delivery to the lysosome for degradation (265). In some 
viral infections, autophagy performs an antiviral function by targeting viral proteins and/or viral particles 
for lysosomal degradation and as such viruses have developed mechanisms to evade the autophagic 
response (265). In other cases, however, viruses appear to have evolved to utilize the autophagic 
machinery in their viral lifecycle (265). Poliovirus is thought to induce the formation of autophagosome 
and utilize this structure as scaffold for viral replication and for use in non-lytic viral release (265, 266). In 
the case of HCV knockdown of key autophagic proteins (Beclin-1, Atg4B, Atg5, and Atg12) results in the 
suppression of productive HCV infection (264). By analyzing the effect of this knockdown on the various 
stages in the viral lifecycle it was determined that the autophagy machinery is required for the translation 
or delivery of incoming RNA to the translation machinery but is not required once translation/replication 
is established (264). The mechanism of this involvement remains to be clarified but it has been speculated 
that HCV may utilize autophagosome membrane as a site of initial translation prior to viral induced cellular 
modifications (264). However, where in the viral lifecycle autophagy acts remains controversial.   
While the above discussed cellular modulators of HCV translation are expressed in a wide range 
of tissues, a recently identified modulator of HCV translation, miR-122, is a well conserved, highly 
abundant liver-specific micro-RNA (miRNA) (267). miRNAs are 21-23nt long non-coding RNAs that play a 
key role in post-transcriptional regulation of gene expression (268, 269). miRNAs modulate gene 
expression by binding to complementary sequences typically found within the 3´-UTR of cellular mRNA 
transcripts (269). As part of an RNA-induced silencing complex containing Argonaute and other proteins, 
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miRNAs act to determine target specificity (269). The binding of the RNA-induced silencing complex to 
complementary sequences within the 3´-UTR of cellular transcripts mediates translational repression by 
a number of different mechanisms including cleavage of the transcripts and steric interference of initiation 
complex formation (268, 269). miR-122 functions to down-regulate the expression levels of cationic amino 
acid transporters and has been implicated in modulation of genes involved in lipid and cholesterol 
metabolism within the liver (237). The HCV RNA genome contains three potential miR-122 binding sites 
(237). Two sites (S1 and S2) are located between stem loops I and II of the 5´-UTR (237). The third potential 
site (S3) is located within the 3´-UTR (237). The function of miR-122 in the HCV lifecycle was first identified 
by Jopling et al. who observed that sequestration of miR-122 resulted in reduced accumulation of HCV 
RNA in cell culture, suggesting a role in viral replication (267). Additional studies have determined that 
miR-122 binding to sites S1 and S2 in the 5´-UTR positively affects HCV RNA levels and virus yields with 
the S1 site having the dominant effect (237, 239). The ability of miR-122 binding to the S1 and S2 sites to 
modulate viral RNA levels and infectious yields was shown to be position-dependent (239). When the S1 
binding site was placed in the 3´-UTR of a reporter construct it was observed to mediate down-regulation 
of reporter gene expression (239). 
 In many of the first studies on miR-122, viral translation did not appear to be modulated by miR-
122 binding. However, more recent studies have found that miR-122 binding to both S1 and S2 sites in 
the viral 5´-UTR has a positive effect on IRES-mediated translation (237, 240, 270, 271). Mutations in either 
S1 or S2 result in a 50% reduction in HCV IRES-mediated translation and this reduction is partially restored 
by provision of complementary miR-122 mutants (237). This stimulation was proposed to be the result of 
enhanced association between the 40S ribosomal subunit and the HCV IRES (270). Another study 
suggested that the stimulation of HCV translation by miR-122 occurs through a conformation change of 
the IRES (236). It was found that the binding of miR-122 to the 5´-UTR shifts the conformation of the IRES 
from a closed to an open conformation by preventing the formation of the inhibitory long-range annealing 
motif between nucleotides 438-442 within the core-coding region and nucleotides 24-38 within domain I 
of the 5´-UTR (236). However, a role for this mIR-122 induced conformational change in IRES modulation 
remains controversial (236, 237, 240). Additionally, it has been observed using IRES mutants that the 
stimulation of translation by miR-122 binding cannot alone account for the effect on RNA levels observed 
in other studies (237). Recent data suggests that miR-122 may play a major role in stabilization of the viral 
genome by protecting the 5´-end of HCV RNA from degradation by cellular exoribonucleases XRN1 and 
XRN2 (272-275). mIR-122 binding may also serve to block recognition of the 5´-end of the viral genome 
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by cellular RNA sensors and prevent induction of an innate immune responses (238, 272). As such it 
appears that miR-122 may have multiple positive effects on HCV lifecycle (237, 276).  
Recently, two other miRNAs, miR-199a* and miR-196, have been identified to potentially 
modulate the HCV lifecycle (241, 243). miR-199a* has a target sequence present in IRES domain II and 
over-expression of miR-199a* results in suppression of HCV replication (241). The effect of miR-199a* on 
HCV protein translation has yet to be determined but with a target sequence found within the IRES it is 
likely miR-199a* has an effect on protein translation. The other miRNA, miR-196, has been observed to 
down-regulate HCV translation and replication when over-expressed and a potential binding site for miR-
196 has been found within the NS5A-coding sequence (243). These findings suggest that miRNAs may play 
a larger role in the HCV lifecycle beyond the effects of miR-122.  
 
1.1.5.2.5.2 Viral factors 
 
The majority of the research into the modulation of HCV IRES-mediated translation by trans-acting 
factors has been focused on determining the effects of non-canonical cellular factors. In the meantime, 
there have been numerous studies on the potential roles of the viral proteins in this process (277). It is 
important to point out that most of the results generated thus far remain controversial, likely due to the 
variety of reporter systems used (277). The viral NS5A protein, which is essential for the viral replication 
and particle assembly, has been implicated in the modulation of viral translation (207, 277-282). NS5A is 
capable of binding to the poly-U/UC region within the HCV 3´-UTR as well as to regions within the IRES in 
the 5´-UTR, leading to speculation about a role in genome circularization and/or in the switch between 
translation and replication (214, 279, 283). However, the role NS5A plays in translation remains unclear, 
as contradictory studies have been published suggesting that NS5A stimulates, inhibits or has no effect on 
viral translation (207, 277, 280-282). One possible reason for this discrepancy is the use of reporters that 
lack the 3´-UTR where NS5A binds, as well as the use of plasmid encoded reporters that may not accurately 
reflect the role of the 3´-UTR in HCV translation (201).   
In addition to the core-coding sequence, the core protein has also been implicated in the 
modulation of HCV IRES translation. However, as with NS5A, the results are unclear as core has also been 
shown to stimulate, inhibit or have no effect on HCV IRES-mediated translation (190, 277, 284-287), 
although the consensus opinion seems to be leaning more towards an inhibitory function. In this regard, 
the core protein has been observed to bind to regions within the 5´-UTR/IRES and inhibit viral translation 
(285-289). The mechanism of the proposed inhibition is unclear, however a potential interaction between 
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core and a GGG triplet within domain IIId of the IRES could lead to a disruption of the interaction between 
the 40S ribosomal subunit and the IRES (285).   
The NS3 protease has also been implicated in the modulation of viral translation. In addition to 
cleaving the viral polyprotein, a single study has observed NS3 binding within the IRES, predominantly in 
stem-loop IV (234). This interaction was found to compete with La autoantigen for binding to this region 
of the IRES, downregulating viral translation (234). Furthermore, overexpression of NS3 in a viral replicon 
system was found to decrease viral translation but significantly enhance viral replication, suggesting  a 
role in the switch between these stages in the viral lifecycle (234).  
Other HCV proteins such as NS2, NS4A, NS4B, and NS5B have also been proposed to be involved 
in modulating HCV IRES-mediated translation (277, 290, 291). However, as with both NS5A and core, there 
is no definitive answer as to the role these proteins play in viral translation. The discrepancies in these 
studies again emphasize the crucial importance of the use of appropriate translation reporter systems. 
Other potential factors include the cell lines and concentrations of viral proteins used in each study.  
Despite a fair amount of research into how cellular ITAFs and individual viral proteins modulate 
viral IRES-mediated translation, it remains unclear how all of these factors coordinate to modulate this 
process. Further research into the interplay between IRES modulating factors will be required in order to 
obtain a clear overall model of how HCV IRES translation is controlled. 
 
 
1.1.5.2.6 Targeting HCV protein translation as a therapeutic approach 
 
HCV translation represents a target in the development of novel antiviral therapeutics as this 
process is mediated by a distinct mechanism that relies on highly conserved sequences and secondary 
structures in addition to utilizing different modulating factors than typical eukaryotic cap-dependent 
translation (292, 293). It is speculated that by targeting such highly conserved regions and functions, the 
risk of the emergence of resistant viral variants over the course of treatment may be decreased. Another 
way to minimize the development of viral resistance is through the combination of treatments with 
multiple targets, such as combining treatments that target viral protease with viral translation inhibitors 
(294, 295).  
A number of different approaches have been investigated to target viral translation as a 
therapeutic approach. The direct targeting of the IRES as well as therapeutics targeting host cellular 
factors involved in viral translation are two strategies under investigation. These approaches are used in 
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an attempt to block the translation of the viral RNA and/or to accelerate breakdown of the viral RNA (296). 
However, it is important to note that the strategies presented in this section, with the exception of mir-
122 targeting, represent proof of principle experiments performed in cell culture. Therefore, the major 
challenges of drug delivery, final formulation and the optimizing of pharmacokinetics have not been 
addressed in these studies. In terms of targeting the HCV IRES, many researchers have utilized 
oligonucleotide based components such as antisense oligonucleotides, RNA interference (RNAi), 
ribozymes/DNAzymes, as well as DNA/RNA aptamers (293, 296-302). Common targets for such 
oligonucleotide based strategies which significantly inhibit viral translation in vitro include IRES domain III 
and IV (293).   
In addition to strategies using oligonucleotides, a number of small molecule inhibitors that target 
the IRES have also been studied (296, 299).  Two classes of small molecules, benzimidazoles and 
diaminopiperidines, have been found to interact with the IRES subdomain IIa and inhibit viral translation 
(292, 303, 304). These molecules are thought to function by interfering with conformational changes of 
the secondary RNA structure within this essential IRES region (292, 304, 305). Benzimidazoles restrict the 
IRES subdomain IIa to an extended state which may interfere with 40S ribosome binding while 
diaminopiperidines confine this domain in a bent conformation possibly preventing ribosome release 
(292, 304, 306) 
An alternative therapeutic strategy to targeting the RNA genome of HCV is to target essential non-
canonical translation initiation factors involved in the initiation of HCV translation. One potential 
advantage of this strategy is the thought that it is less likely that the virus can develop resistance to such 
indirect treatment. This can be approached using some of the above mentioned strategies such as 
therapeutic RNAi to block the expression of the host factors. One host factor that has been targeted in 
such a fashion is mIR-122 as previously discussed. However, extreme caution must be used when targeting 
host factors as to not cause cellular toxicity by interfering with potentially essential cellular functions of 
such factors. Additionally, decoy RNA or small peptides can be utilized to sequester cellular HCV IRES 
trans-acting factors. An approximately 60 nucleotide long RNA isolated from yeast, termed IRNA, has been 
found to specifically inhibit viral translation while having little to no effect on the translation of cellular 
mRNA by sequestering trans-acting factors such as La autoantigen that modulates HCV translation (307, 
308). Furthermore, small RNA molecules corresponding to domain III and subdomains IIIe and IIIf have 
been used to effectively and selectively inhibit HCV IRES-mediated protein translation in a similar fashion 
(309).  
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One final strategy that involves utilizing HCVs requirement for ITAFs is to design synthetic peptides 
corresponding to regions of such ITAFs as inhibitors of translation (222, 255, 310). Peptides composed of 
the RRM2 motif of La autoantigen, which mediates the interaction between the protein and a GCAC motif 
near the initiator AUG codon, have been found to inhibit viral translation (233, 311). These peptides were 
shown to compete with cellular La autoantigen protein for binding to the HCV IRES and selectively inhibit 
viral protein translation by interfering with 48S ribosome complex assembly (233, 311). 
Although many of these therapeutic strategies appear to be promising in cell culture based 
studies, one major problem is efficient and targeted delivery. Recent advances in the use of liposomes, 
nanoparticles, polymers, exosomes and viral/bacteriophage vectors as delivery agents have improved the 
delivery efficacy and specificity of oligonucleotide based treatments (301, 312). In the case of peptide 
based treatments strategies such as Pegylation, hyperglycosylation, polymeric nanospheres and fusion to 
cytoplasmic transduction peptides such as HIV trans-activator of transcription peptide have been found 
to enhance peptide stability and/or delivery (313, 314). As these delivery methods are further improved, 
such potential treatment approaches may be further studied in animal models to test for toxicity and to 
investigate the pharmacokinetics. 
 
 
1.1.5.3 Replication 
1.1.5.3.1 Viral proteins required for replication 
 
Following translation of the viral genome and polyprotein processing, the viral replicase complex 
is formed within a viral induced membranous web. The molecular switch which signals for the transition 
between viral translation and replication is unclear at this point but a number of potential viral and cellular 
proteins involved have been previously discussed. The viral proteins NS3, NS4A, NS4B, NS5A and NS5B are 
the minimal requirements for this complex formation as subgenomic replicons containing these viral 
proteins flanked by the 5´- and 3´ UTRs are sufficient for viral replication (315). For unknown reasons these 
viral proteins are largely required to be expressed in cis as a polyprotein from the RNA that undergoes 
replication (316, 317). Only a limited number of mutations in NS5A and NS4B can be rescued by 
transcomplementation (316, 318, 319). This requirement has complicated the investigation into the role 
that each of these viral proteins in replication (320). 
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1.1.5.3.2 The membranous web 
To facilitate viral replication, HCV induces extensive rearrangements of intracellular membranes 
(321-323). HCV, like all positive stranded RNA viruses, replicates its genome in these distinct membranous 
compartments, the formation of which are induced by the action of viral proteins in concert with cellular 
proteins (323-327). These altered membrane structures provided a scaffold on which viral replication 
complexes assemble (323, 328). This structure is referred to as the membranous web and is composed of 
an accumulation of various vesicle structures, including single membrane vesicles (SMVs), double 
membrane vesicles (DMVs) and multiple membrane vesicles (MMVs) (322, 329-331). The membranous 
web appears to be primarily derived from the ER but also contains markers of early and late endosomes, 
secretary pathway vesicles, mitochondria and lipid droplets (322, 323, 328). It was originally thought that 
NS4B was the viral protein mainly responsible for the induction of the membranous web formation (321, 
332, 333). Expression of NS4B was sufficient to induce massive membrane rearrangements that were 
characteristic of the membranous web observed during viral replication (321). NS4B contains 4 
transmembrane segments and amphipathic helices (AHs) within its N and C-termini (321). Due to this 
membrane localization and its ability to self-oligomerize NS4B is predicted to be a major scaffold protein 
within the membranous web (333, 334). However, it has recently been observed that each viral replicase 
factor is capable of inducing distinct membrane alterations individually (322). While NS4B induces the 
formation of primarily SMVs, NS5A expression leads to the formation of DMVs and MMVs (322, 330). 
NS3/4A expression leads to the accumulation of complex large SMVs distinct from the smaller SMVs 
induced by NS4B (322). Finally, expression of the viral polymerase NS5B induced enlargements of the ER 
(322). These observations suggest that the proper formation and organization of the membranous web 
requires the collaborative action of all the viral replicase components (322).  
The role that the various vesicle structures in the membranous web play in viral replication 
remains controversial. The MMVs that are observed within the membranous web are not thought to be 
directly involved in the replication process as they appear late after infection (322). This suggests that 
they may form as a result of stress response due to the massive membrane alterations induced by viral 
infection (322). Mutations in NS4B that prevent self-oligomerization are detrimental to viral replication 
and disrupt the formation of NS5A induced DMVs (332, 333). This suggests that the DMVs are crucial to 
viral replication and supports the notion that NS4B serves as a scaffold protein to membrane alterations 
primarily induced by NS5A (320). In further support of DMVs serving as the site of viral replication, viral 
replicase components have been observed to colocalize with DMVs within the membranous web in close 
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association with the ER and lipid droplets (322, 329). Furthermore, upon extraction and purification of 
NS4B containing membrane structures from HCV infected cells it was found that DMVs were dominant 
(331). Additionally, these purified DMVs were found to contain NS3 and NS5A and were capable of de 
novo HCV RNA synthesis (331). Host proteins found to be required for replication were also located within 
these DMVs (331). Finally, DMVs were shown to be associated with active viral replication though 
metabolic labelling of nascent viral RNA (331). Replication is thought to occur within the lumen of these 
DMVs, as this process is detergent resistant and protected from protease and nuclease activity (322, 328, 
335, 336).  However, it remains possible that replication occurs on the surface of the DMVs similar to what 
it believed to occur in poliovirus replication (322). In this case, the replication complex may be protected 
by the tight clustering of the replication vesicles (322). 
These DMVs appear to be protrusions of the ER into the cytosol and frequently remain connected 
to the ER (322). Some of these DMVs have also been observed to possess an opening to the cytosol, which 
may function to allow the transport of components required for replication, such as viral proteins, viral 
RNA and nucleotides, from the cytosol to the lumen of the DMV (322). Alternatively, various nuclear pore 
complex proteins may be involved such transport (337). Nuclear pore complexes (NPCs) are normally 
found within the nuclear envelope and regulate the transport of molecules between nucleus and 
cytoplasm (337).  NPC proteins have been found to be required for HCV infection where they are recruited 
to the membranous web and interact with viral proteins (337). Interference of the interaction between 
nuclear transport machinery and viral proteins inhibits viral replication (338). These findings suggest that 
NPCs may contribute to membranous web architecture and facilitate transport of viral and cellular 
proteins from cytosol into viral replication sites within the membranous web (337, 338).    
The biogenesis of these DMVs remains unclear. However, a number of interactions between viral 
and host proteins have been implicated in this process. For example, NS5A and NS5B lead to the activation 
of the host protein phosphatidylinositol 4-kinase IIIα (PI4KIIIα) during viral infection, activation which 
appears to play a key role in membranous web production (330, 339, 340). Active PI4kIIIα results in the 
substantial production and redistribution of phosphatidylinositol 4-phosphate (PI4P) lipid to the 
membranous web (330, 341). Inhibition of PI4KIIIα impedes HCV replication and disrupts membranous 
web structure (330, 339). PI4P may contribute to curvature or integrity of the membranous web vesicles 
in addition to recruiting other cellular factors to the replication site (340, 341). One such factor, four-
phosphate adaptor protein 2 (FAPP2) a glycosphingolipid transport protein required for HCV replication, 
contains a Pleckstrin homology (PH) domain which binds to PI4P and mutation of this PH domain impedes 
viral replication (341). This suggests that PI4P binds to FAPP2, recruiting glycosphingolipids to the 
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developing replication complex (341). Localized membrane accumulation of glycosphingolipids may 
stimulate membrane curvature, potentially representing the first step in membranous web vesicle and 
HCV replication complex formation (341). PI4P also functions to recruit oxysterol-binding protein (OSBP), 
which is required for DMV formation, to the developing membranous web (342). OSBP normally functions 
to exchange PI4P and cholesterol at ER-Golgi contact sites and is speculated to perform a similar function 
on the HCV induced membranous web (340, 342). Additionally, NS5A has been implicated in utilizing the 
host protein ADP-ribosylation factor GTPase-activating protein 1 to remove the PI4P phosphatase Sac1 
from the membranous web (343). Therefore, NS5A both promotes PI4P synthesis at site of replication and 
actively displaces the PI4P phosphatase to maintain high levels of PI4P (330, 341, 343). Another example 
of a host protein implicated in membrane reorganizations during membranous web formation is proline-
serine-threonine phosphatase interacting protein 2 (PSTPIP2), which belongs to the Pombe Cdc15 
homology (PCH) family of proteins involved in generating membrane curvature during vesicle formation 
(344). Both NS4B and NS5A interact with PSTPIP2 and recruit it to the membranous web where it is 
involved in DMV formation dependent upon its membrane-deforming activity (344). From findings such 
as those discussed here it is apparent that the formation of the membranous web is accomplished through 
the action of both viral and co-opted host factors.   
In addition to the rearrangement of cellular membranes, HCV infection also results in the 
accumulation of lipids through the up-regulation of genes involved in lipid metabolism (345-347). HCV 
leads to the increased expression of multiple lipogenic proteins such as acetyl CoA carboxylase and fatty 
acid synthase (345, 347). Inhibition of these enzymes is detrimental to virus replication (347). The increase 
in cellular lipid levels may be required for the membrane proliferations characteristic of the membranous 
web and for the modification of viral proteins (320, 348, 349) 
 
1.1.5.3.3 Viral replication complex and RNA synthesis 
Within this membranous web, the membrane associated viral replication complex containing the 
NS3, NS4A, NS4B, NS5A and NS5B viral proteins replicates the viral genome via a negative strand 
intermediate (320). In addition to acting as a viral protease in association with co-factor NS4A during 
polyprotein processing, the NS3 protein possess NTPase/helicase activity required for replication that may 
be involved in unwinding the viral RNA (350-352). This may function during replication initiation by 
resolving the stem loops found in the 3´-UTR and/or during the elongation phase by separating the 
double-stranded replication intermediates and removing proteins bound to the viral RNA (22, 320, 351). 
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Furthermore, there appears to be significant coordination between the NS3 helicase activity and the viral 
polymerase NS5B(22, 353-355). These proteins have been observed to modulate each other activities (22, 
353-355). NS4A, in addition to acting as a co-factor for NS3 protease activity, mediates membrane 
association of NS3/4A (22, 356).  As discussed NS4B appears to be a main factor in membranous web 
formation but is also speculated to be involved in the assembly of the viral replication complex itself. NS4B 
may serve as an interaction platform within the replication complex. NS4B as it has been observed to 
interact with multiple non-structural viral proteins in addition to the viral RNA (334, 357-359). These 
interactions are critical to viral replication as demonstrated by the inhibition of viral replication upon 
disruption of the interaction between NS4B and NS5A (360). Also heavily involved in the formation of the 
membranous web, NS5A performs essential but still unclear functions in viral replication which may be 
modulated by its phosphorylation status (26, 361, 362).  NS5A has been observed to modulate NS5B 
activity and bind to the viral RNA (363-367). Within the replication complex NS5A and NS5B interact with 
different domains of the host protein hVAP-33, which is typically involved in intracellular vesicle trafficking 
(368-370). The interaction between NS5A and hVAP-33 is dependent upon the phosphorylation status of 
NS5A and disruption of this interaction or silencing of hVAP-33 inhibits viral replication (369, 370). These 
findings suggest hVAP-33 may play an important role in the assembly of the replication complex by 
bringing together NS5A and NS5B (369). NS5A also interacts with a wide array of cellular proteins many 
of which are central to cellular signalling pathways suggesting NS5A may play a key role in inducing a 
cellular environment that favours the virus (26, 27). The role of NS5A in the viral lifecycle will be discussed 
in greater detail in a later section.  
The NS5B protein is the viral RNA-dependent RNA polymerase which catalyzes the synthesis of 
new viral genomes via a negative stand intermediate (320). Synthesis of the negative strand intermediate 
is initiated presumably by NS5B binding to the extreme 3´ end of the 3´-UTR of the viral genome (320). In 
agreement with this model, purified NS5B has been shown to be capable of de novo initiation in vitro (371-
373). However, de novo initiation at the 3´ end of the positive strand appears to occur with low efficiency, 
possibly due to the presence of a stem loop structure, suggesting that other viral and/or host factors are 
involved in regulating this process (320, 374).  After synthesis of the negative strand NS5B can then initiate 
production of new positive viral genomes through de novo initiation at the 3´ end of the negative strand 
(374). This end consists of a stem loop with a single strand overhang which facilitates efficient de novo 
initiation by the NS5B polymerase (374, 375) These nascent viral positive strands can then presumably be 
utilized for either negative strand synthesis, polyprotein translation or be packaged into new viral particles 
(320). Synthesis of the negative stand is detectable 4-6h after introduction of the viral genome in cell 
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culture (320, 375, 376). Asymmetric RNA synthesis occurs and plateaus 24-48h after infection with a 10:1 
ratio of positive to negative stranded viral RNA (320, 375, 376).  Due to the lack of proofreading ability 
RNA synthesis by NS5B is highly error prone with an error rate of approximately 10-3 per nucleotide site 
observed which facilitates the genetic variation of the virus and development of resistance mutations 
(377).  
A wide array of cellular factors has also been implicated in modulating viral replication beyond 
those involved in membranous web formation (26, 378-380). A number of these proteins were described 
in the section on viral translation such as miR-122 and hnRNP D.  Furthermore, over 70 cellular proteins 
have been found to interact with the viral genome within the 3´-UTR and a role in modulating viral 
replication has been ascribed to some of these RNA binding proteins, though the mechanism remains 
largely unclear (381). This includes the RNA helicase DDX5, Nuclear factor proteins such as NF90 and the 
far upstream element binding protein (381-383). Additionally, numerous cellular proteins have been 
found to interact with viral proteins and modulate viral replication such as FK506-binding protein 8 
(FKBP8) and Cyclophilin A and B (CypA/CypB) (384-386). FKBP8 interacts with NS5A and recruits the heat 
shock protein 90 (Hsp90) to the replication complex (386, 387). The mechanism is unclear but Hsp90 is a 
chaperone protein involved in protein folding and stabilization and disruption of this NS5A-FK506-Hsp90 
complex impairs viral replication (386, 387). CypA and CypB are cellular peptidyl isomerases that facilitate 
protein folding and CypB interacts with NS5B and stimulates its polymerase activity whereas an 
interaction between CypA and NS5A is essential for viral replication (84, 384, 385, 388).  
 
1.1.5.3.4 Modulation of viral replication by cis-acting RNA elements 
In addition to acting as the site for replication initiation the 3´-UTR also contains a number of cis-
acting RNA elements which modulate viral replication (212). The variable region, although not absolutely 
required for replication, contributes to efficient replication (389, 390). In the poly-U/UC region a minimal 
26-33 stretch of consecutive uridines is required for replication, although the precise position is variable, 
supporting its proposed role as a platform for molecular interactions described previously (212, 389, 391). 
The threes stem-loop structures within the x-tail region are all essential for replication (389, 390, 392). 
Both the sequence and structure of this x-tail region appear to be critical for viral replication (320, 390, 
392). In addition to the 3´-UTR RNA, structures found within the coding region have also been found to 
modulate viral replication. As discussed in the section on HCV translation both, the core and NS5B coding 
regions contain regions of secondary RNA structure implicated in modulating HCV replication. In regards 
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to positive strand synthesis, the 3´-UTR of the negative RNA strand intermediate contains secondary 
structures which differ significantly from that of the complementary 5´-UTR region of the positive viral 
RNA genome which contains the IRES (393, 394). The negative strand intermediate 3´-UTR contains seven 
stem loop structures (395). However, only the terminal 125 nucleotides, containing two of these 
structures, are required for viral replication (395). 
 
 
1.1.5.4 Virion assembly and release  
 
The assembly and secretion of HCV particles remains poorly defined. However, the process has 
been found to be linked to cellular VLDL synthesis (396, 397). Accordingly, viral particles have been 
observed to circulate within infected patients as low-density lipoviral particles resembling VLDL associated 
with lipoproteins such as ApoB and ApoE resembling VLDL (398-401). Additionally, multiple interactions 
between various viral proteins and viral or cellular protein have been observed to be involved in 
modulating viral assembly (402). However, how these interactions coordinate to assemble and secrete 
the virus particle remains largely unclear. Contributing to the lack of a precise working knowledge of viral 
assembly and release is that Huh7 derived cells, which are utilized for infectious HCV cell culture (HCVcc), 
are defective in the VLDL secretion pathway (403). These cells produce mainly intermediate density 
lipoprotein (404). This results in physical differences between viral particles produced in HCVcc and those 
isolated from infected patients or primary cell culture (405, 406). Viral particles produced in HCVcc have 
a higher density and lower infectivity compared to those produced in vivo (398, 401, 405, 407). Despite 
these shortcomings, a model for viral assembly and release has emerged and is described below.    
After synthesis and prior to assembly, Core is localized to the surface of lipid droplets (LDs), a 
cellular lipid storage organelle derived from the ER and primary source of lipids for incorporation into 
VLDL (408-410).  This interaction results in accumulation of LDs in the perinuclear region, compared to 
their dispersed distribution in uninfected cells (411). This localization of core to the surface of LDs is 
required for viral assembly and may act to sequester core prior to initiation of assembly, potentially 
preventing premature nucleocapsid formation (402, 412-414). Efficient recruitment of core to LDs 
requires at least two host factors involved LD biosynthesis, the triglyceride synthesizing enzyme 
diacylglycerol acyltransferase 1 (DGAT1) and cytosolic phospholipase A2 (PLA2G4A) (415, 416). NS5A plays 
an essential role in assembly through co-localization with core on the surface of LDs and this localization 
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is also dependent upon DGAT1 (417-420). The precise role NS5A plays in assembly is unclear. However, 
NS5A is a member of the replication complex and binds to the viral RNA (410). It may thus play a role in 
the transition from replication to assembly by transporting nascent viral RNA from the ER associated 
replication complex RNA to LDs to interact with core (410). In support of this model, mutations which 
impair NS5A association with LDs also impairs the recruitment of viral RNA to the surface of LDs (413). 
Furthermore, two cellular proteins Rab18, a lipid droplet associated protein and regulator of vesicular 
traffic, and tail-interacting protein 47 (TIP47), which is involved in LD biogenesis, bind to NS5A and 
promote association between LDs and the site of viral replication (421-424). Interestingly, it was observed 
that TIP47 interacts with NS5A in complex with viral RNA and is also involved in regulating viral replication 
(421). NS5A also interacts with the cellular trafficking protein annexin A2 (425, 426). An interaction that 
has been observed to stimulate both viral replication and assembly, possibly though modifications of the 
ER membrane structures involved in these processes (425, 426). An additional interaction between NS5A 
and ApoE is also required during virus assembly though the mechanism is unclear (427-429). The VLDL-
associated molecular chaperone ApoJ interacts with both NS5A and core on LDs, stabilizing this interaction 
and facilitating viral assembly (427-429).   
The viral glycoproteins E1 and E2 are translocated into the ER where they interact to form 
heterodimers during translation (430, 431). Early in viral assembly NS2, is involved in organizing structural 
and non-structural proteins on the ER (432). This function is independent of the protease activity of NS2 
(433). NS2 interacts with p7 and this interaction is required for the further recruitment of the E1/E2 
glycoproteins and the NS3/4A complex by NS2 to the sites of assembly on the cytosolic ER membrane 
(432, 434-437). These non-structural proteins are thought to interact in close proximity to the core/NS5A 
coated LDs (434). The core protein is then recruited from the LD to the ER-complex site of assembly (438-
440). This recruitment is dependent upon the interaction between p7-NS2 and NS3/NS4 (438-440). An 
interaction between core and the cellular protein AP2M1, which is involved in modulating intracellular 
trafficking, is also required for the recruitment of core from LDs (441). A transient and weak interaction is 
also observed between NS5A and the p7-NS2 complex at this stage of viral assembly (434, 436, 437). It 
remains unclear how the RNA enters the site of assembly. It may be recruited along with LD associated 
core or it may be recruited directly from the replication complex. An interaction between core and the 
RNA helicase domain of NS3 is essential for virus assembly, suggesting that NS3/4A may be involved in 
packing the viral RNA during this process (402, 433, 442). Nucleocapsid formation is proposed to occur on 
the surface of the ER at this site concurrent with budding into the ER lumen (402).   
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The results of this process is the production of a virus particle surrounded by a lipid envelope, 
with the viral glycoproteins on the surface, and containing the viral nucleocapsid that encapsidates the 
viral RNA (434).  Intracellular virus particles are of significantly higher density than those secreted from 
the cell, indicating that viral particles go through a maturation process in which they acquire low-density 
properties prior to release (397, 443). This process may begin in the ER lumen through association of the 
viral particles with VLDL precursors, luminal lipid droplets (434).  In support of this model, it was found 
that blocking microsomal triglyceride transfer protein, which has a role in VLDL biogenesis through 
transporting lipids to ER, inhibits viral particle production (396, 397). Unlike VLDL biogenesis, however, 
HCV assembly has been observed to be dependent upon ApoE rather than ApoB in some studies (440, 
444). Virus particles associated with ApoE are then proposed to be exported through the secretory 
pathway and pass through the Golgi complex similarly to VLDL. Within the Golgi, the viral glycoproteins 
E1/E2 undergo modifications and further lipidation of the viral particle may occur similar to VLDL (438, 
440, 445). The mechanism of viral egress through the secretory pathway to the plasma membrane is 
largely unknown, but it appears to be associated with endosomal trafficking (446). Components of the 
endosomal sorting complex required for transport pathway have been implicated in this process as have 
early, late and recycling endosomes (440, 446-449). During viral maturation and egress, the viral p7 
protein functions to protect nascent virions by regulating pH gradients (450).  P7 prevents the acidification 
of compartments of the secretory and endosomal pathways, presumably by functioning as ion channels 
(450). Upon arrival at the cell surface, vesicle-associated membrane protein 1 mediated fusion between 
the HCV containing vesicle and the plasma membrane results in the release of the viral particle into the 
extracellular environment (440).  
 
1.2 HCV Non-Structural Protein 5A 
 
The HCV non-structural 5A protein (NS5A) is multifunctional phosphoprotein and as discussed in 
preceding sections is essential for viral replication and assembly, although the exact role the protein plays 
in the viral lifecycle remains unclear (361, 418, 419, 451-455). NS5A interacts with numerous cellular and 
viral proteins and as such has been implicated in a multitude of functions such as modulation of cellular 
signalling pathways and interferon resistance (27, 456, 457). In fact, NS5A has been found to potentially 
interact with over 130 host proteins including many that are central to cellular signalling pathways (27, 
456, 458). This suggests NS5A plays a key role in modulating the cellular environment to favour viral 
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pathogenesis. Despite being implicated in such a diverse range of functions no enzymatic activity has been 
found for NS5A (459).  NS5A is composed of an N-terminal AH and three domains that are separated by 
two regions of repetitive low complexity sequences (LCS) (Figure 1.5) (456). The AH is necessary and 
sufficient for membrane localization of NS5A, at the site of the viral replication complex, and is essential 
for replication as mutation of this region leads to a diffuse cytoplasmic localization of NS5A and inhibition 
of viral replication (460-462). The AH has also been found to mediate the interaction between NS5A and 
TIP47, which is involved in the interaction between the replication complex and LDs (422). The LCS-I is a 
serine rich region while the LCS-II is proline rich (463). The individual domains of NS5A have been 
implicated in various aspects of the viral lifecycle and will be discussed in detail below.  
 
1.2.1 Phosphorylation  
 
NS5A has been found to be present in two differently phosphorylated forms within infected cells 
(456). A basally phosphorylated form and a hyperphosphorylated form are resolved, based on the 
presence of 56 kDa and 58 kDa bands, upon SDS-PAGE resolution (456). Hyperphosphorylation, but not 
basal phosphorylation, is thought to be mostly dependent upon expression of NS5A in cis with NS3 and 
NS4A/B (464, 465). Phosphorylation has been implicated in the regulation of multiple functions of NS5A. 
It may regulate the transition between viral replication and viral assembly, possibly by modulating the 
conformation of the viral protein or the interaction with cellular or viral proteins (361, 451, 456, 466). 
However, both the exact sites of phosphorylation and the kinases responsible for it remain unclear. It is 
thought that NS5A is basally phosphorylated on residues within the central and C-terminal regions, 
whereas residues responsible for hyperphosphorylation reside mainly within the LCS-I region (370, 466-
468). 
  Residues S222, S225, S229 and S232 within the LCS-I have been implicated in 
hyperphosphorylation and cell culture adaptive mutations that reduce hyperphosphorylation often affect 
residues within this region (20, 361, 467, 469). Adaptations that reduce hyperphosphorylation generally 
increase replication of HCV replicons, although this effect differs between viral genotypes (451, 468, 470, 
471). Suppression of NS5A hyperphosphorylation by kinase inhibitors in non-adapted HCV replicons also 
leads to enhanced replication (472, 473). In support of this model the previously described interaction 
between NS5A and VAP-A, which is essential from viral replication, is blocked by hyperphosphorylation, 
leading to disruption of the replicase complex and inhibition of viral replication (369, 370). Furthermore,  
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Figure 1.5 - NS5A domain organization and proposed functions in the viral lifecycle. Numbering 
corresponds to 1b N HCV NS5A protein. NS5A is composed of an N-terminal amphipathic helix and three 
domains separated by low complexity sequences (LCS). Various functions attributed to the regions of 
NS5A are indicated. See text for details. 
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basally phosphorylated NS5A mainly localizes in high-density fractions along with replicase components 
NS3 and NS5B in addition to ER markers, consistent with a key role of basally phosphorylated NS5A within 
the replication complex (466). In contrast, hyperphosphorylated NS5A is predominantly located within 
low-density fractions where it interacts with lipid droplets, an interaction essential for viral assembly (466, 
474). Our understanding of NS5A phosphorylation is further complicated by the observations that the 
combination of multiple adaptive mutations that reduce hyperphosphorylation, or the treatment of 
adapted viral replicons with kinases inhibitors that further reduce hyperphosphorylation, inhibits HCV 
replication (451, 472, 473). This suggests a complex differential modulation of NS5A activity by 
hyperphosphorylation that has both positive and negative effects on RNA replication. 
Seven serine residues within the LCS-I region have so far been identified as phosphorylation sites 
(361, 463, 466, 469). Consistent with the contrasting effects of hyperphosphorylation on viral replication, 
phosphorylated serine residues within this region have been observed to have differing effect on viral 
replication. Some phosphorylation events enhance replication whereas others are inhibitory (370, 463, 
469). For example, mutation of S225 or S232 to alanine, which prevents phosphorylation, results in a 10-
fold reduction in replication of JHF-1 (genotype 2a) HCV (463). However, mutation of S229 or S235 to 
aspartic acid, which mimics a constitutively phosphorylated state, results in a similar reduction in viral 
replication (463). These mutations were all found to negatively affect the establishment of viral replication 
complexes by disrupting the cellular distribution of NS5A and other replicase components, such as NS3, 
PI4P lipid and the viral dsRNA intermediate (463). The mechanism remains to be defined but could result 
from a reduced motility of NS5A or the disruption of interactions between NS5A and cellular or viral 
proteins (463). Interestingly, mutation of S229 to alanine is also lethal, again demonstrating the 
complexities in the roles of NS5A phosphorylation in regulating the viral lifecycle (361, 455).  
A cluster of serine residues within the C-terminal region of domain III undergo basal 
phosphorylation and play a key role in modulating viral assembly (419, 420, 452). These residues, and the 
phosphorylation of threonine 356 (T356) will be discussed in detail below when describing NS5A domains 
II and III.  
Regulation of NS5A phosphorylation appears to be tightly controlled but the mechanism remains 
elusive. A number of cellular serine/threonine protein kinases have been implicated in this process, such 
as casein kinase I (CKI-α), casein kinase II (CKII), Polo-like kinase I, testis-specific serine kinase, protein 
kinase A (PKA) and mitogen-activated protein kinases (362, 466, 475-477).  CKI-α may be one of the best-
characterized examples. It has been implicated in a hyperphosphorylation event that may regulate the 
recruitment of NS5A to lipid droplets, recruitment which is required for viral assembly (466). Recent 
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observations suggests that hyperphosphorylation may also occur in a sequential manner (361). As 
mutations which mimic phosphorylation within the serine cluster in LCS-I (S222-S238) approach the C-
terminus of this region a progressive increase in the apparent molecular weight of the basally 
phosphorylated species is observed (361). These findings suggest that the phosphorylation of a residue 
within this region would promote the phosphorylation of upstream residues possibly by acting within the 
kinase recognition motif of the neighbouring residue (361). Furthermore, phosphorylation of S146 within 
domain I appeared to negatively impact hyperphosphorylation, perhaps through intra-protein 
interactions, suggesting an additional mechanism that regulates NS5A phosphorylation (26, 361).  Other 
viral proteins also appear to be involved in regulating NS5A phosphorylation. Such regulation is suggested 
by the requirement of NS5A expression in cis with NS3 and NS4A/B for hyperphosphorylation. Adaptive 
mutations that reduce NS5A hyperphosphorylation have also been mapped to NS4B, and mutation of 
residues implicated in mediating the interaction between NS4B and NS5A abolished NS5A 
hyperphosphorylation (360, 473).  
 
1.2.2 NS5A Domain I: Crystallization and dimerization 
 
 NS5A domain I (aa. 33-213) is highly conserved and has been found to function in multiple 
essential roles assigned to NS5A in the viral lifecycle, including genome replication and virion assembly.  
Domain I contributes to the RNA binding activity of NS5A and mediates NS5A dimerization, functions that 
will be discussed in detail below. Domain I also interacts with multiple host proteins including the 
previously described PI4KIIIα and FK506-binding protein 8 which play key roles in membranous web 
biogenesis and viral replication (26, 386, 387, 478). In regards to assembly, the amino acid (aa.) 99-104 
sequence within domain I has been implicated in mediating the recruitment of NS5A to the surface of LDs 
(413). Mutation of this region inhibits not only the recruitment of NS5A but also of the viral RNA to LDs 
(413)  
Due to the essential role of NS5A in viral replication, and therefore its attractiveness as a drug 
target, a number of studies have been performed to determine its structure of NS5A. Such information 
on the structure of NS5A would help guide the design and development of NS5A targeting antivirals. To 
date only domain I of NS5A has been successfully crystallized. In one such study by Tellinghuisen et al. a 
genotype 1b (Con1) domain I fragment made up of residues aa. 25-215 was found to form a homodimer 
composed of two subdomains, the N-terminal subdomain IA where contact between the molecules 
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primarily occurs, and a C-terminal subdomain IB (479). A zinc-binding motif containing the previously 
identified essential Cys-57, Cys-59 and Cys-80 residues was identified within subdomain IA, the location 
of which suggested a structural role of this zinc molecule in maintaining the NS5A fold (479, 480). The 
molecular surface of this domain I dimer was found to have uneven charge distribution with the N-
terminal subdomain IA displaying a primarily basic surface and the C-terminal subdomain IB containing a 
largely acidic surface (479). Additionally, a surface exposed region spanning subdomains IA and IB was 
found to contain a high number of conserved residues the authors propose may represent an interaction 
surface (479). The dimer contact interface was found to be composed of two regions with the larger region 
found primarily in subdomain IA containing several conserved residues in close proximity to the zinc 
binding motif (479).  The second and smaller dimer interface region was found in subdomain IB and 
displays lower sequence conversion (479). Lastly, a large basic groove was formed between the 
subdomain IB regions that was predicted to have sufficient dimensions to bind either single or double 
stranded RNA and as such was identified as a potential site of NS5A/RNA interaction (479). This crystal 
structure identified a number of intriguing structural elements of a domain I dimer but it has, however, 
proven difficult to reproduce, leading to the possibility of the existence of alternative form of NS5A 
domain I dimers (481, 482).  
Accordingly, an alternative domain I dimer crystal structure has been obtained by Love et al. using 
a genotype 1b (Con1) domain I fragment containing aa. 33-202 residues (482). In this structure, the zinc 
binding motif displayed the same organization as the Tellinghuisen dimer (479, 482). Also in a similar 
fashion to the Tellinghuisen et al. dimer, an uneven surface charge distribution was observed with a 
predominantly basic N-terminus and a more acidic C-terminal portion (479, 482). However, the 
association of the domain I monomers differed substantially between the two different crystal structures 
and there was no overlap between the dimer contact interface regions as the contact interface of the 
Love et al. dimer was fully exposed in the Tellinghuisen et al. dimer (479, 482). Conceptually the 
Tellinghuisen et al. dimer can be described as a face to face interaction with the N-termini facing inward 
whereas the Love et al. dimer was organized back to back with the N-termini facing outward (479, 481, 
482). In the Love et al. dimer there was an extensive buried surface area and the dimer contact interface 
was composed of approximately 20 residues from each monomer covering the residues; 92-99, 112-116, 
139-143, 146-149 and 160-161 (482).  This represents the most highly conserved surface region within 
domain I (482).  Within this contact region an intermolecular salt bridge, a combination of a hydrogen 
bond and electrostatic interaction, was formed between the highly conserved Arg-112 and Glu-148 and a 
hydrogen bond was formed between the conserved Ala-92 and Gly-96 (482).  Notably absent in this crystal 
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structure was the positively charged cleft that was proposed to be an RNA binding site in the Tellinghuisen 
et al. dimer (479, 482). One potential implication of the non-overlapping dimerization interfaces of the 
two different domain I dimers is the assembly of domain I proteins via interactions of alternating 
interfaces which would result in a superhelical appearance and sterically accommodate domains II and III 
of NS5A (482).   
To further add to the complexity of our understanding of domain I dimerization, a third study by 
Lambert et al. has obtained crystals of a genotype 1a (H77) domain I aa. 33-202 fragment which reveled 
two novel domain I dimer structures (481). The domain I crystal structures obtained in this study consisted 
of 4 monomers, termed A, B, C and D, with two dimeric interfaces forming an AB dimer and a CD dimer 
(481) . The exposed surfaces of these molecules appeared similar to those found within the Love et al. 
study, whereas the zinc binding motif appeared similar in organization to both the previously identified 
dimers (479, 481, 482). The contact interface within the AB dimer was found to be similar, although 
smaller, to that reported for the Love et al. dimer (481, 482). The residues that composed the contact 
interface were 97-99, 112-115, 149 and 160-161 (481). One notable difference, however, was that the 
orientation of one of the monomers in the AB dimer was reversed, creating a head to tail (N-terminus to 
C-terminus) interaction as opposed to the back to back interaction observed in the Love et al. dimer (479, 
481, 482). Also differing from the Love et al. dimer was the lack of the salt bridge between Arg-112 and 
Glu-148 and the hydrogen bond between Ala-92 and Gly-96 (481, 482).  The second domain I dimer in this 
study, dimer CD, was aligned in a head to head conformation (N-terminus to N-terminus). The contact 
interface of dimer CD was composed of highly conserved residues 74-78 and 83-84 (481). Within this 
region, intermolecular hydrogen bonds were formed between Ile-74 and Arg-78 and between Gly-76 and 
Gly-76 (481). It was also observed that copies of dimer CD interacted together utilizing the same interface 
as the AB dimer, suggesting the possibility of higher order multimers (481). The authors speculated that 
such an extended multimeric network could interact with the membranous web and therefore have 
implications in viral replication (481).  Common to the different domain I crystal structures identified thus 
far, the overall polypeptide fold of each NS5A monomer was similar (479, 481, 482). The finding of such 
distinct domain I dimers is perplexing. However, it is possible that all are physiologically relevant and may 
represent different dimers that have distinct functions within the viral lifecycle. The regulation of the 
conformations may be influenced by such factors as phosphorylation or interaction with viral or cellular 
proteins, or viral RNA (361).   
Results from NS5A inhibitor studies suggest that NS5A dimers are physiologically relevant as they 
may represent the target for high potency NS5A inhibitors. Highly potent NS5A inhibitors such as LDV and 
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Daclatasvir (DCV) (Bristol-Myers Squibb) are symmetrical in nature (483). Based on selection for resistant 
mutations in the N-terminus of NS5A domain I, and models of NS5A structure, the inhibitors are predicted 
to interact at the NS5A dimer interface (483-486). Resistance mutations tend to cluster around the dimeric 
interfaces, most predominantly at Tyr-93 (487). Furthermore, recent studies have demonstrated specific 
high affinity binding by symmetrical inhibitors to NS5A and provided evidence for the interaction of the 
drug compound with NS5A dimers and possibly higher order multimers (484, 487).  Additional evidence 
comes from the finding that NS5A inhibitor candidate compounds lead to disruption of both intra- and 
intermolecular NS5A conformations (488). These compounds were found to alter the conformations of 
domains I and III within a single NS5A molecule, and to increase the distance between the N-termini of 
NS5A molecules found in multimeric conformation (488). However, treatment actually leads to the 
formation of large aggregates of NS5A, rather than disrupting NS5A multimer formation, a finding which 
may help explain the high potency of such NS5A inhibitors (488). The relevance of multiple NS5A dimer 
conformations within infected cells is also suggested by the finding that these NS5A inhibitors cannot be 
observed to interact with purified NS5A in vitro (481, 484). These inhibitors have been observed to 
physically interact with NS5A only in HCV replicon cells (481, 484). An observation which suggests that 
NS5A may only transiently be in the correct conformation for drug compound interaction (481).  
 
1.2.3 RNA-binding by NS5A 
 
NS5A has been observed to possess RNA binding activity towards G/U rich RNA and binds with 
high affinity directly to the poly-U/UC region found within the 3΄-UTR of the viral genome (363-365). An 
interaction of significantly lower affinity has also been observed between NS5A and the 5´-UTR (364). 
Potential sites within the 5´-UTR for this interaction, based on presence of G/U rich sequences, include 
multiple sites within domain III of the IRES (365). However, NS5A binding to these regions remains to be 
determined. The interaction between NS5A and both the 5´- and 3´-UTRs suggests that NS5A may play a 
role in modulating the transition from translation to replication given the roles these regions play in the 
viral lifecycle (365) 
NS5A lacks similarity to any of the previously identified RNA-binding motifs including the RRM 
common to cellular proteins that preferably bind G/U rich RNA (363, 365). This suggests NS5A utilizes a 
novel mechanism for RNA binding (363, 365). In a study by Foster et al. aimed at defining the region of 
NS5A which mediates RNA binding it was found that all three of the NS5A domains are capable of 
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specifically interacting with the 3´-UTR independently (363). However, while domains I and II bound the 
3΄-UTR RNA efficiently domain III demonstrated lower, but still specific, RNA binding affinity suggesting 
RNA binding is primarily mediated thought domains I and II (363). In support of this model, expression of 
domains I and II as a single fragment displayed an additive effect on RNA binding efficiency which was not 
seen when domains II and III were expressed together as a single fragment (363). However, in the context 
of the full NS5A protein, domain III does appear to contribute to the RNA binding ability (363). While NS5A 
and the domain I/II fragment display similar RNA binding affinities, NS5A binds with greater efficiency 
(363). A separate study by Hwang et al. obtained results suggesting that NSA RNA binding activity is 
primarily mediated by the domain-LCS I region (364). In this study, the deletion of domain I negated the 
ability of NS5A to bind to rU7 RNA and domain I individually bound this RNA with much lower affinity than 
NS5A (364). However, when the LCS I region was added to the domain I fragment, RNA binding was 
restored to levels similar to NS5A indicating the importance of this region in the RNA binding ability of 
NS5A (364). Differing experimental conditions could possibly explain the different RNA binding profiles 
observed in these two studies. This study also found that both NS5A and domain I-LCS I fragments were 
able to from dimers and that the presence of U-rich RNA stimulated the formation of these dimers (364). 
This observation suggests that NS5A dimers bind to the viral RNA (364). However, a role for the LCS I in 
contributing to NS5A dimerization is unclear as all of the NS5A domain I crystallization studies lacked this 
region (479, 481, 482).  A subsequent study by the Cameron group found that four cysteine residues, Cys-
39, -57, -59 and -80, which were found to form a zinc binding motif in the domain I crystallization studies 
were critical for NS5A dimerization (489).  Mutation of any of these cysteine residues lead to a loss of 
NS5A dimerization in pull down assays (489).  These mutations were also found to result in a significant 
decrease in the RNA binding efficiency of NS5A, supporting the importance of dimerization in this activity 
(489). Furthermore, the mutation of any one of these four cysteine residues in NS5A within a subgenomic 
viral replicon inhibited viral replication (489). This study therefore identified a link between NS5A 
dimerization, NS5A RNA binding and HCV replication (489). 
 
1.2.4 NS5A domains II and III 
 
While NS5A domain I has been has been fairly well characterized, much less is known about NS5A 
domains II and III, which are significantly less conserved than domain I (26). Domain II (aa. 254-346) 
appears to be largely dispensable for viral replication. Whereas deletion of the entire domain lead to a 
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complete loss of viral replication, mutagenesis studies have identified between 12-23 amino acids within 
the C-terminal portion of domain II that was essential for viral replication (418, 454, 490). Unlike domain 
I, domain II has been found to be largely disordered and natively unfolded, and as such, no crystal 
structure has been obtained for this domain (491, 492). Potential advantages of unstructured proteins 
include a larger accessible surface for molecular interactions compared to folded proteins and the 
flexibility to bind to many different targets without sacrificing specificity (491). However, it has also been 
found that although highly unstructured, domain II is capable of adopting different transient 
conformations that may play a role in modulating domain II function and protein interactions (492, 493). 
Domain II is postulated to interact with several proteins, including PKR, phosphatidylinositol 3-kinase 
(PI3K) and CypA and CypB (458, 494-496). The interaction between domain II and CypA, a protein that 
possesses peptidyl-prolyl isomerase activity, has been fairly well characterized. This interaction was 
essential for viral replication and treatment with CypA inhibitors blocked viral replication (497, 498). The 
isomerase activity of CypA was essential for its role in modulating viral replication (498, 499). The resulting 
cis-trans peptide bond interconversion modulated by this isomerase activity is speculated to cause a 
structural shift in domain II towards a more extended form (500, 501). Mutations within domain II that 
confer resistance to CypA inhibitors lead to structural modifications that appear to mimic the effect of 
CypA isomerization, thereby reducing the dependence upon CypA to induce such structural change (500, 
501). It remains unclear how the interaction between CypA and NS5A domain II modulates HCV 
replication. However, it has been shown that CypA binding and isomerization activity enhance the RNA 
binding activity of domain II (84).  
NS5A has also been observed to function as a transcriptional trans-activator and viral replication 
was found correlates with this function (502-504). An acidic region located within Domain II was found to 
be the main driver of NS5A transcriptional activity and its role in modulating viral replication (504). This 
transcriptional trans-activation function may represent a mechanism by which the virus can alter the 
cellular environment in order to modulate the viral lifecycle.  
Domain III (aa. 360-451) is similar to domain II in that it appears to be natively unfolded as it lacks 
significant secondary structure (479). However, domain III has also been proposed to possess transient 
secondary structure (505). Domain III exhibits a tendency to form α-helices at both its N- and C-terminal 
regions and such transient structures may play a role in the interaction of NS5A domain III with viral or 
host factors (505).  Although domain III has been shown to be completely dispensable for replication, this 
region may have role in establishing early replication efficacy. Deletion of this domain leads to delayed 
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replication kinetics in the JFH-1 HCV (genotype 2a) (419). On the other hand this region plays a critical role 
in viral assembly. 
Efficiency of viral assembly correlates with the levels of NS5A-Core interaction on the lipid 
droplets associated with the membranous web (452). A number of mutagenesis studies have identified 
an important role for the C-terminal region of domain III in this interaction (418-420, 452). In particular, a 
cluster of serine residues within this region of domain III have been found to play a key role in viral 
assembly (419, 420, 452).  Mutation of these serine residues to alanine impairs basal phosphorylation and 
results in the loss of NS5A-Core co-localization on the surface of LDs, resulting in an inhibition of virion 
assembly (419, 452). Additionally, these mutations inhibited the interaction of core with viral RNA, 
supporting a role for NS5A in delivering the viral RNA to the surface of LDs during the assembly process 
(452). In contrast, mutation of these serine residues to aspartic acid, which mimics a phosphorylated 
serine, restores this interaction and viral assembly, suggesting a key role for the phosphorylation in 
modulating viral assembly (452).  Domain III has also been found to interact with multiple cellular proteins 
including CypA and SET and MYND domain containing protein 3 (SMYD3) (26, 506). SMYD3 is a lysine 
methyltransferase involved in transcriptional regulation though the methylation of histones (506). It also 
modulates the kinase activity of the vascular endothelial growth factor receptor 1 (506). SMYD3 co-
localizes with NS5A around LDs and appears to act as a negative regulator of viral assembly (506). 
Overexpression of SMYD3 reduced intracellular infectious virus titer and resulted in an accumulation of 
core protein (506).  
Domain III also contains a nuclear localization signal (NLS) that plays a role in the transcriptional 
activation properties of NS5A described above (503). Due to the presence of the amphipathic helix at the 
N-terminus, NS5A is typically associated with ER-derived membranes (460). However, N-terminal 
truncated versions of NS5A have been found during the viral lifecycle, in a caspase dependent manner 
(503). These truncated NS5A molecules are transported into the nucleus, by virtue of the NLS, where they 
can then function as transcriptional activators (504). 
One theme that emerges when looking into the roles of NS5A domains II and III in the viral lifecycle 
is the array of proposed functions and interactions ascribed to these regions despite both being natively 
unstructured. Although this may appear counterintuitive, it is a trait shared by numerous cellular proteins 
often referred to as intrinsically disordered proteins (IDP), such as p53 and BRAC1 (507, 508). IDPs are 
very abundant and often function as signalling and regulatory hubs (508). IDPs are also characterized by 
significant binding promiscuity (508). IDPs often adopt transient structured elements that are utilized to 
carry out functions (508). These are all characteristics that have been also described for domains II and III 
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of NS5A that are thought to function as a complex molecular interaction platform (362, 493). Structural 
changes within IDPs can be induced by interactions with nucleic acids, other proteins, membranes and 
post-translational modifications such as phosphorylation (508). An example of this modulation within 
NS5A has recently been identified (362). Phosphorylation of NS5A at Thr-360 in JFH-1 HCV (genotype 2a) 
by PKA leads to conformational change within a neighbouring poly-proline-II motif within LCS-II region 
resulting in a stabilized conformation adequate for binding to host proteins containing SH3 domains (362). 
NS5A has been shown to interact with multiple SH3 containing cellular proteins, such as the pro-apoptotic 
Bin1 protein, and mutation of this Thr-360 residue was lethal in JFH-1 HCV (158, 362, 509).  
 
1.2.4 NS5SA direct-acting antivirals  
 
Even though it lacks enzymatic activity, NS5A represents an attractive drug target as it has 
multiple essential roles in the viral lifecycle. As discussed previously, DAAs targeting NS5A have been 
developed and are currently utilized in the treatment of HCV infection. However, the precise mechanism 
of action of NS5A inhibitors remains unclear. A common feature of highly potent NS5A inhibitors such as 
LDV and DCV is their symmetrical nature and apparent interaction with NS5A dimers at the dimer interface 
as discussed earlier (483-486, 510). Interaction with NS5A dimers, perhaps in multimeric formation, may 
explain the incredibly potency displayed by symmetrical NS5A inhibitors (488). Furthermore, the inhibitors 
may impede the conformation or flexibility of the adjacent AH region and thus may affect NS5A membrane 
interaction (486). The phenotypes associated with NS5A inhibitors include reduced NS5A motility, 
redistribution of NS5A either from the ER to lipid droplets or into large cytoplasmic aggregates, an 
alteration in the ratio of basal to hyperphosphorylated NS5A in favour of the basal phosphorylated form 
and the inhibition of HCV induced PI4P accumulation (72, 455, 474, 486, 510-512). Furthermore, 
symmetrical NS5A inhibitors have been observed to prevent NS5A domain I binding to poly-U RNA and, 
conversely, poly-U RNA binding prevents interaction with the inhibitor (487). This supports a model in 
which these inhibitor compounds bind to an NS5A dimer that does not bind RNA, potentially preventing 
the transition to a conformation compatible for RNA binding (487).  
Modelling of HCV replication kinetics upon LDV or DCV treatment suggest that these inhibitors 
have two distinct modes of action, inhibiting both viral replication and viral assembly (72, 513, 514). This 
characteristic has been observed both in vitro and in infected patients (72, 513, 514). Independently of 
increasing compound concentration, the inhibition of viral assembly occurs almost immediately after LDV 
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treatment whereas the inhibition of RNA synthesis occurs early but it is only partial (72). This observation 
suggests that NS5A inhibitors prevent the formation of new replication complexes but do not affect RNA 
synthesis in those already formed (72, 511).  Another study found that a DCV derivative blocked NS5A-
mediated membrane rearrangements and therefore replication complex formation (486). Treatment lead 
to the collapse of the membranous web independent of RNA replication, leading to both a reduction in 
DMV diameter and number of DMVs in a concentration dependent manner (486). In disagreement with 
the kinetics studies, this study observed a rapid loss of DMVs upon NS5A inhibitor treatment (486). The 
reasons for these discrepancies remain unclear.  
Regardless of the precise mechanisms the interference with multiple functions in the viral lifecycle 
likely contributes to the high efficacy of symmetrical NS5A inhibitors. As investigation into determining 
the exact mechanisms of these inhibitors continues, it is clear that NS5A inhibitors will continue to pay a 
key role in the treatment of HCV.
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2.0 HYPOTHESES AND OBJECTIVES 
2.1 Rationale 
 
The HCV NS5A protein appears to play a role in virtually every aspect of the viral lifecycle beyond 
entry and has been found to be essential for viral replication and particle assembly.  A role for NS5A in 
modulating viral translation is strongly indicated by its ability to interact with both the 5´- and 3´ UTRs.  
The 5 ´UTR contains the HCV IRES which directly recruits the 40S ribosome to initiate HCV translation 
whereas the 3’UTR functions to stimulate translation through unknown mechanisms. However, the role 
NS5A and its association with the poly-U/UC region play in modulating viral translation remains unclear. 
Contradictory studies have been published suggesting that NS5A either stimulates, inhibits or has no 
effect on viral translation. We contend that the possible reasons for these discrepancies include reporter 
design. A number of previous studies utilized reporter constructs that lacked the HCV 3´-UTR where NS5A 
binds with high affinity to the poly-U/UC region. Other studies, however, utilized reporter systems that 
have been shown to not accurately reflect the role of the 3´-UTR in modulating HCV translation. This 
includes DNA based or bicistronic RNA reporter systems. Only when monocistronic RNA reporters 
containing the authentic 5´ and 3´UTRs are utilized is the stimulatory role of the 3´UTR in viral translation 
realized. 
 
2.2 Hypotheses 
 
(i) NS5A modulates HCV IRES-mediated translation 
 
(ii) The poly-U/UC region of the 3´UTR is required for the modulation of HCV IRES-mediated 
translation by NS5A 
 
(iii) The modulation of viral translation by NS5A plays an important role in the viral lifecycle and 
will thus have effects that extend to  viral replication 
 
2.3 Objectives 
 
i. (a)  Examine the effect of NS5A on the translation of a monocistronic HCV RNA reporter which 
contains both the 5´- and 3´-UTRs 
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(b) Determine the role of the poly-U/UC region in such an effect by utilizing the above 
described monocistronic HCV RNA reporter containing deletions in this region 
 
ii. (a)  Determine which domain of NS5A is responsible for the modulation of viral translation 
(b)  Attempt to map the residues/regions involved within the implicated domain(s)  
 
iii. Examine the effect of the implicated residues/regions on viral replication 
 
iv. Investigate the mechanism of translational modulation by NS5A domain I by examining the 
effect of the R112A mutation on domain I dimerization and RNA binding activity 
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3.1 Authors’ contribution 
 
All the experiments within this chapter were performed by Brett Hoffman with the exception of 
the RT-PCR which were performed in collaboration with Zhubing Li. The manuscript was written by Brett 
Hoffman and edited by Qiang Liu.   
 
3.2 Abstract 
 
Hepatitis C virus nonstructural protein 5A (HCV NS5A) is essential for viral replication and 
assembly, however, its effect on HCV RNA translation remains controversial. This is partially due to the 
use of reporters lacking the 3̕´untranslated region (UTR) which functions to stimulate viral translation and 
contains the poly-U/UC sequence to which NS5A binds. Various studies have also utilized plasmid based 
or bicistronic reporters, neither of which accurately reflect the role of the 3´-UTR in stimulating viral 
translation.  Thus we investigated the role of NS5A in HCV translation using monocistronic RNA containing 
the Renilla luciferase gene flanked by both HCV UTRs. We found that NS5A down-regulates viral protein 
translation in a dose-dependent manner. HCV genomic RNA translation is also down-regulated by NS5A. 
This inhibitory effect of NS5A requires the poly-U/UC sequence as NS5A does not affect translation when 
this region is deleted. In addition, we showed that three domains of NS5A can inhibit translation 
independently. These results suggest that NS5A down-regulates HCV RNA translation through a 
mechanism involving the poly-U/UC sequence in the 3´-UTR. 
 
 
3.3 Introduction 
 
Hepatitis C virus (HCV) is a serious global health issue. The World Health Organization estimates 
there are currently 170 million infected individuals worldwide, representing approximately 2% of the 
global population. HCV was first discovered in 1989 as the agent responsible for non-A, non-B post-
transfusion hepatitis and chronic HCV infection is now recognized as a major factor in the development 
of severe liver damage such as decompensated cirrhosis, hepatic steatosis and hepatocellular carcinoma 
(1, 50, 515). Chronic infection is estimated to develop in 75 to 80% of those infected (50). There is no 
vaccine available for HCV and current treatment varies as to its effectiveness against different viral 
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genotypes, although newly released direct acting antivirals are significantly improving treatment outlook 
(516-518).  
HCV is a small, enveloped, single-stranded positive-sense RNA virus and belongs to the Flaviviridae 
family as the only member in the genus Hepacivirus (519). The viral genome is 9.6 kb in size and contains 
a single open reading frame (ORF) which encodes for a polyprotein of approximately 3000 amino acids 
(515). The viral polyprotein is cleaved co- and post-translationally by both host and viral proteases into at 
least 10 viral proteins: three structural proteins, core, E1, E2,  and seven non-structural proteins, p7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B (519). The single ORF is flanked by highly conserved 5´- and 3´- 
untranslated regions (UTRs) which are involved in the control of viral translation and replication (516).   
The 5´-UTR contains an internal ribosome entry site (IRES) which initiates the cap-independent translation 
through the direct recruitment of the 40S ribosomal subunit (19). While the 3´-UTR is essential for 
replication, as it serves as the initiation site for negative strand synthesis, the exact role of the 3´-UTR in 
HCV translation remains unclear (520-522). For many years the role of the 3´-UTR in the modulation of 
HCV translation was a contentious issue with published reports suggesting that the region down-
regulates, enhances, or has no effect on IRES-mediated translation (389, 390, 520, 521, 523-529). However 
these discrepancies are thought to be at least in part due to reporter design (521). Efficient translation 
enhancement by the 3´-UTR is observed only when monocistronic RNA reporters with precise 3´ ends or 
complete RNA genomes are utilized is (521). It is now generally accepted that the 3´-UTR serves to 
stimulate translation.  
The 3´-UTR of HCV is composed of three distinct regions: the variable region, the poly-U/UC tract 
and the X-tail, a region with highly conserved secondary structure (Figure 3.1a) (521). The X-tail forms 
three stem loop structures, namely SL1, SL2 and SL3 (522).  It has been found that the variable region, the 
poly-U/UC tract and SL1 (the 3´ most terminal stem loop) of the X-region contribute significantly to the 
translation enhancement provided by the 3´-UTR while SL2 and SL3 play only minor roles (521). The 
mechanism of 3´-UTR enhancement of translation remains to be clearly defined but possible mechanisms 
include RNA-RNA interactions with HCV IRES structure and recruitment of cellular factors to the 3´-UTR 
that interact with components of the translational machinery present on the IRES in a fashion similar to 
the PABP-eIF4G interaction found on cellular mRNAs (522). A recent study by Bai et al. found that the 
3΄UTR is cabaple of binding to the 40S ribosomal subunit and enhancing not the first but subsequent 
rounds of translation (218). This led the authours to propose a model in which the 3΄UTR may function to 
recycle ribosomes from the 3´-UTR to the IRES within the 5΄UTR (218).  
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HCV NS5A is a multifunctional protein essential for viral replication and assembly (419, 456). NS5A 
has also been found to interact with multiple viral and cellular proteins (456). Despite the numerous 
functions attributed to NS5A, the protein has no known enzymatic activity (459). NS5A contains a 
conserved N-terminal amphipathic α-helix that serves as a membrane anchor for NS5A and is both 
necessary and sufficient for mediating association between the protein and cellular membranes (460, 
461). This α-helix plays an unknown but essential role in viral replication. Disruption of this region, which 
leads to a diffuse cytoplasmic localization of NS5A, prevents viral replication (460, 480). Following this N-
terminal amphipathic α-helix, NS5A is separated into three domains which are separated by two regions 
of repetitive low complexity sequences (480). Domain I is the most conserved and best characterized of 
the three domains across all HCV genotypes (480). Four distinct crystal structures have been obtained for 
domain I, all demonstrating the ability of this domain to dimerize (480, 482).  In the Tellinghuisen et al. 
study this dimerization results in the formation of a large, basic groove at the interface that is speculated 
to be involved in RNA binding activity (480). Domain I also contains an unconventional zinc binding motif 
which is composed of four conserved cysteine residues the mutation of which is lethal to virus replication 
(480).  
NS5A domains II and III are much less characterized than domain I.  Domain II was been shown to 
be required for viral replication in an early study (454). However, subsequent studies showed that only 
23-35 amino acids are essential for replication (418, 454, 530). Recent work has further narrowed this 
essential region down to 12 residues absolutely required for viral replication of JFH-1, with several of these 
residues mapping to a region involved in binding to a host factor implicated in viral replication, cyclophilin 
A (490). Domain II has also been implicated in the interaction between NS5A with the viral RNA-dependent 
RNA polymerase, NS5B, and the modulation of NS5B activity (367, 531). Other activities in which domain 
II has been implicated in are activation of the PI3K signaling pathway and the modulation of the antiviral 
response as this region contains the interferon sensitivity-determining region and binds to PKR (496, 532).  
Domain III has been found to be completely dispensable for viral replication (418). However, this domain 
has been implicated in viral particle assembly (418, 419, 454). Both domains II and III appear to be largely 
disordered and are natively unfolded which may contribute to the ability of NS5A to play a role in so many 
diverse functions as these regions are capable of adopting different transient conformations (491, 493, 
533, 534). Due to the numerous roles that NS5A appears to play in the viral lifecycle, it is a very attractive 
antiviral target and high potency drug compounds have recently been discovered to target NS5A (485). 
Additionally, NS5A has been found to bind to the poly-U/UC region of the viral 3´-UTR with high 
affinity (364). Binding was found to be a result of direct interaction between NS5A and the HCV RNA (364). 
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It was subsequently found that all three domains of NS5A were able to independently bind to the 3´-UTR 
(363). However, while domains I and II showed strong binding, domain III exhibited weaker binding affinity 
(363). This suggests that domains I and II are the major contributors in the binding of NS5A to the viral 3´-
UTR (363). A recent study has found a correlation between viral replication and the ability of NS5A to bind 
both synthetic poly-U RNA and HCV RNA in cell culture (489). Other potential binding sites for NS5A i 
include sites within each of the three domains which make up the HCV IRES (364). The fact that NS5A 
binds to regions within both the 5´- and 3´-UTRs suggests that NS5A may function in the modulation of 
HCV translation and could perhaps be involved in genome circularization or regulating the switch from 
translation to replication (363, 364, 535). Accordingly, NS5A is highly likely to be implicated in the 
modulation of viral translation, although its exact role remains uncertain. Contradictory studies have been 
published suggesting that NS5A either stimulates, inhibits, or has no effect on viral translation (527, 536-
539). The possible reasons for this discrepancy include the use of reporters that lack the 3´-UTR, where 
NS5A has been shown to bind to the poly-U/UC region, as well as the use of plasmid-based reporters 
which fail to accurately reflect the role of the 3´-UTR in HCV translation (521).   
In this study we investigated the effect of NS5A on modulating viral translation using 
monocistronic reporters by focusing on understanding the role the poly-U/UC region in the 3´-UTR in the 
modulation of viral translation by NS5A. We found that NS5A down-regulates viral translation in a dose 
dependent manner and that this modulation is dependent upon the presence of the poly-U/UC region in 
the viral 3´-UTR. Additionally, we found that each domain of NS5A is capable of modulating viral 
translation independently.  
 
3.4 Results 
3.4.1 NS5A down-regulates HCV protein translation in a dose-dependent manner in the presence of 
the poly-U/UC region of the viral 3´-UTR 
 
For this study we utilized a monocistronic RNA reporter containing the HCV 5´-UTR plus the first 
16 amino acids of the core gene, an internal Renilla luciferase gene fused to the last 5 amino acids of the 
NS5B gene, and the 3´-UTR (520).  Reporters that contained deletions of the poly-U/UC region or the 
entire 3´-UTR were also utilized.  To investigate the role of the HCV 3´-UTR in modulating viral translation, 
Huh7 cells were transfected with these RNA reporters. As shown in Fig. 1A, deletion of the poly-U/UC 
region decreased viral translation by approximately 50% whereas when the entire 3´-UTR was removed 
viral translation was decreased by approximately 90% compared to the wild-type 3´-UTR (Figure 3.1b).  
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These results showed the importance of the 3´-UTR in the modulation of viral translation and were similar 
to those obtained by others (218, 521, 522). The mechanism behind the stimulatory effect of the individual 
3´-UTR regions on viral translation remains to be clearly defined. However, it has been observed that 
differences in viral translation efficiency are not the result of differing RNA stability upon deletion of 3´-
UTR or its individual regions (218, 521, 522).  
 The effect of NS5A on HCV translation is controversial in part due to use of non-reliable reporter 
systems. As we and others have validated the monocistronic RNA reporter as a reliable system, we sought 
to investigate the role of NS5A in HCV protein translation. For this purpose, Huh7 cells were transfected 
with HCV-1b NS5A expression plasmid and followed by the transfection of the monocistronic Renilla 
luciferase HCV-1b RNA reporter. Luciferase assay was performed 4 h after RNA transfection. As shown in 
Figure 3.2a, the expression of NS5A resulted in significant decrease in luciferase activity, representing HCV 
IRES-mediated translation, compared to vector control. On the other hand, expression of green 
fluorescent protein (GFP) did not affect HCV translation suggesting this is a specific effect of NS5A 
expression (Figure 3.2f). These results suggested an inhibitory effect of NS5A on HCV translation.  
 Although it has been shown that NS5A preferentially binds to the poly-U/UC region in the 3´-UTR, the 
function of this RNA binding is not clear (363, 364). To test whether the poly-U/UC region plays a role in 
protein translation modulation by NS5A, we utilized an RNA reporter without the poly-U/UC in the 3´- 
UTR. Figure 3.2a showed that NS5A had no significant effect on the level of translation in the absence of 
the poly-U/UC region. The overall translation activity was significantly decreased in the absence of the 
poly-U/UC region as expected (Figure 3.1b). These data suggested that the poly-U/UC region of the 3´-
UTR was necessary for the down-regulation of viral translation by NS5A. These experiments were 
repeated using RNA reporters and NS5A of HCV-1a to determine if the observed effect was restricted to 
HCV-1b. In the 1a experiments the expression of NS5A led to a similar level of down-regulation of viral 
translation and again the absence of the poly-U/UC region negated the down-regulation caused by NS5A 
expression (data not shown). 
 In order to demonstrate that the down-regulation of translation observed was not due to NS5A 
expression negatively affecting the stability of the RNA translation reporters, we performed RT-PCR. We 
found that NS5A expression did not affect the RNA levels of these HCV RNA translation reporters as similar 
levels were observed in the presence or absence of NS5A (Figure 3.2b) 
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Figure 3.1 - The 3´-UTR modulates viral translation. (a) Diagram of the HCV 3´-UTR. (b) Huh7 cells were 
transfected with a monocistronic HCV RNA translation Renilla luciferase (rLuc) reporter RNA containing 
either wild-type or ∆poly-U/UC 3´-UTR. Luciferase assay was performed 4 hr after RNA transfection. The 
rLuc value after vector transfection was set to 1 and error bars indicate mean ± SD. Statistical 
differences were analyzed by Student t test and indicated as * if p ≤ 0.05 or ** if p ≤ 0.01 compared to 
wildtype unless otherwise indicated. Error bars indicate mean +SD 
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Figure 3.2 - NS5A down-regulates HCV protein translation in the presence of the poly-U/UC region in the 
3´-UTR. (a). Huh7 cells were transfected with plasmid expressing HCV NS5A or plasmid vector. At 24 hr 
later, cells were transfected with a monocistronic HCV RNA translation renilla luciferase (rLuc) reporter 
RNA containing either wild-type or ∆poly-U/UC 3´-UTR. Luciferase assay was performed 4 hr after RNA 
transfection. The rLuc value after vector transfection was set to 1. Statistical differences were analyzed 
by Student t test and indicated as * if p ≤ 0.05 compared to vector (b). The levels of rLuc RNA in cells in (a) 
were determined by real-time PCR. The RNA levels of a housekeeping gene GUSB were used for 
normalization. (c). Huh7 cells were transfected sequentially with HCV NS5A expressing plasmid or plasmid 
vector and RNA translation reporter RNAs as indicated. Luciferase assay was performed 4 hr after RNA 
transfection. (d,g). Expression of (d) NS5A or (g) GFP was demonstrated by Western blotting using either 
an (d) NS5A or (g) flag specific antibody. The levels of β-actin were also determined using a β-actin specific 
antibody, as a loading control (e) MTT assay for cell viability was performed 24 hr after transfection of 
Huh7 cells with plasmid vector or HCV NS5A expression plasmid. DMSO treatment was used as a control 
(f) Huh7 cells were transfected sequentially with Flag-GFP expressing plasmid or plasmid vector and wild-
type HCV RNA translation reporter. Luciferase assay was performed 4 hr after RNA transfection. 
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To investigate whether the effect of NS5A on translation was HCV-specific, we measured the RNA 
translation driven by EV71 5´-UTR. As shown in Figure 3.2c, HCV NS5A did not affect EV71 RNA translation. 
Furthermore, no effects were observed by NS5A on the translation of RNA with EV71 5´-UTR and HCV 3´-
UTR, or with 5´- cap and HCV 3´-UTR, or with 5´- cap and poly-A sequence (Figure 3.2c). These results 
indicate that the expression of NS5A does not result in a general decrease in global translation. This effect 
is specific to the HCV reporter. Additionally, these results demonstrate that NS5A only inhibits translation 
when both HCV 5´- and 3´-UTRs are present. This is consistent with a current model for HCV translation 
which postulates that the UTRs are adjacent to each other in a closed loop conformation during translation 
(218). A number of cellular factors such as HuR, LSm1-7 and IGF2BP1 have been identified to bind to both 
UTRs and modulate viral translation (216-218, 231). Such interactions with both UTRs could function to 
mediate an interaction between the two UTRs. Furthermore, as these cellular proteins bind to the poly-
U/UC within the viral 3´-UTR, it is conceivable that the high affinity binding of NS5A in this region could 
disrupt such interactions and in turn disrupt the interaction between the two UTRs. This possibility 
remains to be investigated. Finally, MTT assay was performed to investigate the potential effects of NS5A 
expression on cell viability. NS5A expression had no effect on cell viability (Figure 3.2e) 
Next, we performed a dose response experiment to further characterize the effect of NS5A on 
HCV protein translation. Transfection of increasing amounts of NS5A expression plasmid led to increased 
and statistically significant reductions in viral translation (Figure 3.3a). This effect was again found to be 
dependent upon the presence of the poly-U/UC region of the 3´-UTR as the increasing NS5A expression 
had no significant effect on the level of translation of the reporter lacking this region (Figure 3.3a). The 
increasing expression of NS5A protein was demonstrated by Western blotting (Figure 3.3b). The down-
regulation of HCV translation by NS5A was again specific to viral protein translation and increasing levels 
of NS5A expression did not have an effect on cap translation (Figure 3.3c). Increasing levels of NS5A did 
not induce measurable changes in cellular viability (Figure 3.3d). These results suggested that NS5A dose-
dependently down-regulates HCV RNA translation in the presence of the poly-U/UC region. 
   
3.4.2 NS5A binds to the poly-U/UC region of the HCV 3´-UTR 
 
The above results indicated a role of the poly-U/UC sequence in HCV protein translation inhibition 
by NS5A protein. As such, we hypothesized that binding of NS5A to the poly-U/UC sequence might play a  
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Figure 3.3 - NS5A down-regulates HCV protein translation in a dose dependent manner in the presence 
of the poly-U/UC region in the 3´-UTR. (a). Huh7 cells were transfected with 0, 0.25, 0.5, 1, or 2 µg of 
HCV NS5A expression plasmid for 24 hr. Total amounts of DNA transfected were kept consistent by 
adjusting the amounts of vector. Cells were then transfected with an HCV monocistronic translation 
renilla luciferase (rLuc) reporter RNA, containing either wild-type or ∆poly-U/UC 3´-UTR. Luciferase assay 
was performed 4 hr after RNA transfection. (b) The levels of NS5A and β-actin were determined by 
Western blotting. (c) Huh7 cells were transfected with increasing amounts of HCV NS5A plasmids as in 
(a), followed by a capped mRNA expressing renilla luciferase. Luciferase assay was performed 4 hr after. 
The rLuc value after vector plasmid or control mRNA transfection was set to 1. Statistical differences 
were analyzed by Student t test and indicated as * if p ≤ 0.05, ** if p ≤ 0.01 compared to 0 µg unless 
otherwise indicated (d). Cell viability was determined by MTT assay 24 hr after transfection with 
increasing amounts of HCV NS5A expressing plasmids. DMSO treatment was included as a control.  
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role. To demonstrate the binding of NS5A within this region we performed NS5A-RNA binding 
experiments. For this purpose, purified NS5A protein and Cy5-labeled HCV 3´-UTR with and without the 
poly-U/UC RNA were used in a gel shift assay. BFP protein was used as a control. As shown in Figure 3.4a, 
a shift in the RNA band was visible at 21.36 pmol NS5A and the shift became more pronounced at 37.38 
pmol NS5A relative to the RNA band when no protein was added, indicating NS5A-RNA binding. No 
significant RNA band shift was observed when the poly-U/UC was deleted (Figure 3.4b), indicating no RNA 
binding of NS5A. The control BFP protein did not cause an RNA band shift in both cases indicating the 
specific nature of the NS5A-RNA interaction. These experiments demonstrated that NS5A bound to the 
poly-U/UC sequence in the 3´-UTR, confirming the findings of other groups (84, 365). Together with our 
previous results, these results suggest that NS5A binding within the poly-U/UC region might play a role in 
HCV protein translation inhibition by NS5A. 
 
3.4.3 NS5A domains modulate HCV protein translation 
 
NS5A consists of an N-terminal amphipathic α-helix (AH), domains I, II, III with two inter-domain 
low complexity sequences (LCS) (Figure 3.5a). To map the domain(s) of NS5A responsible for this 
modulatory effect, plasmids encoding NS5A with AH deletion, or the individual domains of NS5A were 
utilized along with the monocistronic RNA reporters with or without the poly-U/UC region. Our results 
demonstrated that the AH did not play a significant role in modulating viral translation as the AH deletion 
mutant was capable of downregulating viral translation similar to Wt. NS5A (Figure 3.5b). Furthermore 
each domain of NS5A was capable of significantly down-regulating of HCV translation independently 
(Figure 3.5b). These inhibitory effects again were dependent upon the poly-U/UC sequence (Figure 3.5b). 
None of the NS5A domain proteins had an effect on cap translation or cell viability (Figures 3.5d and 3.5e). 
The expression of NS5A and mutant proteins were demonstrated in Western blotting (Figure 3.5b). The 
apparent differing levels of expression may be in part due to the use of a polyclonal antibody. The fact 
that each individual domain was capable of down-regulating viral translation may not be completely 
surprising since it has been shown that each domain is capable of binding to the 3´-UTR independently 
(363). 
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Figure 3.4 - NS5A binds to the poly-U/UC region in the HCV 3´-UTR. (a,b) Cy5-3´-UTR RNA (a) or Cy5-3´-
UTR ∆poly-U/UC RNA (b) (1.25 pmol) was incubated with the indicated amount of NS5A protein or blue 
fluorescent protein (BFP) control protein in a binding buffer (25 mM MOPS, 10 mM NaCl, pH 4) for 1 h at 
4°C. The binding reactions were then run into a 6% native polyacrylamide gel after addition of 6X loading 
buffer (50% sucrose). Cy5-RNA was visualized with a Li-Cor Odyssey scanner. Asterix indicates unbound 
RNA and arrow indicates NS5A/RNA complexes. Representative of multiple independent experiments.  
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Figure 3.5. - Individual NS5A domains down-regulate HCV RNA translation in the presence of the poly-
U/UC region in the 3´-UTR. (a). Diagram of NS5A domains and the domain fragments utilized. (b and d). 
Huh7 cells were transfected with plasmid vector, plasmids expressing HCV NS5A or mutants for 24 hr. 
Cells were then transfected with monocistronic HCV translation renilla luciferase (rLuc) reporter RNAs, 
containing either a wild-type 3´-UTR or ∆poly-U/UC 3´-UTR (b), or a capped mRNA expressing renilla 
luciferase (d). Luciferase assay was performed 4 hr after RNA transfection. The rLuc values after vector 
plasmid or control mRNA transfection was set to 1. Statistical differences were analyzed by Student t test 
and indicated as * if p ≤ 0.05, ** if p ≤ 0.01 compared to vector (c). Expression of NS5A and domains was 
demonstrated by Western blotting using a polyclonal NS5A antibody (e). Cell viability was determined by 
MTT assay 24 hr after plasmid transfection or DMSO treatment. 
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3.4.4 NS5A expression in trans down-regulates the translation of full length HCV ∆GDD viral RNA 
 
To substantiate the results obtained using the monocistronic RNA reporters, we wanted to 
measure protein translation from a full length HCV genomic RNA. For this purpose, we generated a full 
length HCV-1b genomic reporter with an insertion of Renilla luciferase gene and the foot and mouth 
disease virus 2A peptide between p7 and NS2 as described for HCV-2a genome previously (Figure 3.6a) 
(433).  The GDD sequence was deleted in the NS5B to render this viral RNA replication deficient, so the 
level of Renilla luciferase could be utilized as a measurement of viral translation only.  
When the full length HCV genomic RNA containing the wild-type 3´-UTR was utilized, additional 
NS5A expression led to decreases in viral translation compared to control at 2 hr and 4 hr post- 
electroporation, respectively (Figure 3.6b). However, when the poly-U/UC was deleted from the 3´-UTR, 
additional NS5A expression did not affect viral translation (Figure 3.6c). NS5A expression at 2 hr and 4 hr 
time points was demonstrated by Western blotting although the expression at 2h is low (Figure 3.6d). 
NS5A expression from the genomic RNA reporter was not detected in this assay, presumably due to the 
low level of expression from this reporter.  These results suggested that NS5A expression in trans could 
down-regulate viral translation from HCV genomic RNA dependent upon the presence of the poly-U/UC 
sequence in the 3´-UTR. 
 
3.5 Discussion 
 
NS5A plays key roles in the HCV lifecycle as it is essential for viral replication/assembly and has 
been found to be involved in numerous other processes such modulation of cellular signaling pathways 
and inhibition of interferon responses (419, 456). NS5A has also been found to interact with multiple viral 
and cellular proteins (456). A role for NS5A in the modulation of viral translation has however, been 
unclear as numerous contradictory studies have been published (527, 536-539). In this study, we utilized 
monocistronic RNA reporters with the precise 3´-UTR as well as HCV genomic RNAs to investigate the role 
that NS5A plays in modulating viral protein translation. 
 We first set out to determine the effect of NS5A on HCV protein translation using the 
monocistronic HCV translation reporter RNA. We found that NS5A specifically down-regulated viral 
protein translation in a dose dependent manner. The effect of NS5A on viral translation was then 
investigated using a full length viral RNA to test this effect in a situation more relevant to HCV infection. 
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Figure 3.6 - NS5A down-regulates translation of full length HCV genomic RNA in the presence of poly-
U/UC region in the 3´-UTR. (a). Diagram of HCV reporter utilized. (b and c) Huh7.5 cells were 
electroporated with HCV (p7-rLuc2A) ∆GDD full length viral RNA containing either the wild-type 3´-UTR 
(b) or ∆poly-U/UC 3´-UTR (c) together with mRNA expressing NS5A mRNA or control fLuc mRNA. Cells 
were harvested at 2 and 4 hr after electroporation for luciferase assay. The rLuc values were normalized 
to the total cell number in each sample by quantitating total protein concentration. Normalized value of 
control mRNA at 2 hr time-point was set to 1. Statistical differences were analyzed by Student t test and 
indicated as * if p ≤ 0.05. (d). Expression of NS5A was demonstrated by Western blotting using an NS5A 
antibody. The levels of β-actin were determined by a β-actin antibody as a loading control. 
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Using the full length HCV RNA, which is replication deficient, we observed that viral translation 
was again down-regulated when NS5A was expressed in trans. Importantly, in all of the above 
experiments, NS5A did not have an effect on HCV protein translation when the poly-U/UC sequence of 
the 3´-UTR was deleted, suggesting that the poly-U/UC sequence was required.  
Having established that NS5A functions to down-modulate viral translation, we then set out to 
determine which regions of NS5A were responsible for this effect. NS5A protein has an amphipathic α-
helix (AH) of approximately 30 amino acids at its N-terminus followed by three domains (480). When the 
AH sequence was deleted, NS5A could still down-regulate protein translation, indicating that the AH did 
not have an effect on viral protein translation. Interestingly, the AH region of NS5A was previously been 
found to be necessary and sufficient for membrane localization of NS5A and be required for viral 
replication (460, 461). Next, we investigated the effect of NS5A domains on viral protein translation. It 
was observed that each individual NS5A domain was able to down-modulate viral translation 
independently. This effect was again dependent upon the presence of the poly-U/UC region in the 3´-UTR.  
On one hand, the fact that each individual domain was capable of down-regulating viral translation may 
not be completely surprising since it has been shown that each domain is capable of binding to the 3´-UTR 
independently (363). On the other hand, however, since domains I and II can bind to 3´-UTR RNA to a 
stronger degree than domain III, it begs the question as to whether 3´-UTR RNA binding is the only 
mechanism for the observed translation inhibition by NS5A and its domains (363).  
The mechanisms of how NS5A down-regulates HCV RNA translation are not clear. The 
requirement of the poly-U/UC region in the 3´-UTR for this effect suggests that NS5A, potentially through 
binding to this region, may interfere with the stimulatory functions exerted by the poly-U/UC region. It 
has been shown that long range interaction between the 5´-UTR and 3´-UTR may act as molecular switches 
for different steps in HCV lifecycle (197, 198, 383). We showed that NS5A specifically down-regulates RNA 
translation when both HCV 5´-UTR and 3´-UTR are present, suggesting that NS5A may interrupt this long 
range interaction. It is also possible that the binding of NS5A to the poly-U/UC region may disrupt the 
binding of cellular factors that function to enhance viral translation or the recycling of ribosomes between 
the 3´-UTR and IRES (15, 218). A model of this theory is presented in Figure 3.7.  While the biological 
relevance and mechanism remains to be elucidated, data presented here as well as those already 
published collectively suggest that NS5A may play a role in the switch from viral translation to viral 
replication 
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In conclusion, we have shown that NS5A down-regulates viral translation though a mechanism 
that requires the poly-U/UC region in the viral 3´-UTR. Our results shed more light on the functions of 
NS5A in HCV lifecycle.   
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Figure 3.7 - NS5A down-regulates viral translation. The binding of NS5A to the poly-U/UC region of the 
3΄UTR may disrupt the binding of cellular factors and the interaction between the 5΄and 3΄UTRs that is 
thought to stimulate viral translation. This disruption may account for the down-regulation of viral 
translation observed within this study and may also be involved in the switch between viral translation 
and replication.  
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3.6 Materials and Methods 
3.6.1 RNA reporters and expression plasmids 
 
 All plasmids were constructed as per standard methods and confirmed by DNA sequencing. HCV 
monocistronic RNA translation reporter contained the HCV 5´-UTR, the sequence encoding the first 16 
amino acids of the core protein, an internal Renilla luciferase (rLuc) gene, the sequence encoding the last 
five amino acids of the NS5B and the 3´-UTR of HCV-1b N (540). This reporter was used to develop 
additional reporters with 5´-UTR, the poly-U/UC region or the entire 3´-UTR deleted. A monocistronic 
EV71 (enterovirus 71) RNA translation reporter was generated. This reporter contained the rLuc gene 
flanked by the 5´-UTR and 3´-UTR sequences of EV71 Anhui1 (541). In another construct, the EV71 3´-UTR 
was replaced by HCV 3´-UTR. A restriction enzyme recognition sequence (XbaI for HCV and XmaI for EV71) 
was engineered around the very 3´ end of the 3´-UTR sequences. Plasmid DNAs digested with XbaI or 
XmaI were treated with mung bean nuclease (New England Biolabs) to allow generation of RNA transcripts 
with authentic 3´ ends (542). The HCV-1b (p7-rLuc2A) reporter is a full length viral genome which contains 
an insertion of rLuc and the foot and mouth disease virus 2A peptide located between p7 and NS2 of the 
HCV genome as per a previously described strategy (433). The GDD sequence within the NS5B viral 
polymerase was deleted rendering this viral reporter replication deficient. We also generated an HCV-1b 
(p7-RLuc2A) GDD reporter without the poly-U/UC sequence. Translation reporter RNAs and HCV genomic 
RNAs were generated by in vitro transcription (MEGAscript T7 In Vitro Transcription kit, Ambion). These 
RNA molecules contained viral 5´-UTR at 5´- ends (no cap) and viral 3´-UTR sequences at 3´ ends.  
The coding sequences for HCV NS5A, AH deletion mutant and individual domains were amplified 
by PCR using HCV-1b N Neo C-5B (540) as template respectively and cloned into pEF/cyto/myc vector 
(Invitrogen) with a stop codon or in-frame with the myc tag sequence. These plasmids were used to 
express NS5A proteins upon transfection. The coding sequence of NS5A was also cloned into pcDNA3 
vector and used as template to generate capped mRNA by in vitro transcription after linearization 
(mMessage mMachine T7 In Vitro transcription kit, Ambion). A similar plasmid encoding firefly Luciferase 
(fLuc) was used to generate capped fLuc mRNA. These mRNAs had cap structure at 5´- ends and poly-U 
sequence at 3´ ends.  
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3.6.2 Cell lines, transfections and luciferase assay 
 
Human hepatoma cell lines HuH-7 and HuH-7.5 were kindly provided by Bartenschlager (315) and 
Rice (543) , respectively. HuH-7 and HuH-7.5 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen) supplemented with 10% fetal bovine serum and 1% gentamicin and cultured at 37°C and 5% 
CO2. In sequential transfection experiments, HuH-7 cells in 24-well plates were transfected with 1 µg of 
expression plasmid using TransIT-LT1 transfection reagent according to the manufacturer’s protocol 
(Mirus Bio). In NS5A dose experiments, cells were transfected with increasing amounts of NS5A expressing 
plasmid and the total amounts of plasmid DNA for transfection were kept to 2 µg by adjusting the amounts 
of vector. The next day the cells were transfected with 1 µg of reporter RNA using DMRIE-C (Invitrogen) 
and incubated for 4 hr. In HCV genomic RNA experiments, HuH-7.5 cells in PBS were electroporated (270 
V, 950 µF, 4 mm cuvette) with the indicated amounts of RNA using an electroporator (Bio-Rad) before 
they were harvested at the indicated time points. Following incubation, the cells were lysed with Passive 
Lysis Buffer and rLuc activity was determined according to the manufacturer’s instructions (Promega). 
Luciferase data in these electroporation experiments was normalized to protein concentration that was 
determined by Bradford assay (BCA Protein Assay kit, Thermo Scientific). For luciferase experiments 
vector control was set to 1 (100%) and error bars represent mean ± SD. All luciferase experiments are the 
average of three independent experiments performed in triplicate. 
 
3.6.3 SDS-PAGE and Western blot 
 
Western blots were performed as previously described (544). Briefly, cell lysates were subjected 
to SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were then blocked in 5% 
skimmed milk in PBS for 1 hr at room temperature before incubation with primary antibody overnight at 
4°C. Blots were then washed with PBS and incubated with the appropriate secondary antibodies (Li-Cor 
Biosciences) for 1 hr at room temperature. Blots were then washed with PBST (PBS+0.1% Tween-20) 
before a final wash with PBS. Blots were scanned using a Li-Cor Odyssey scanner at the appropriate 
wavelengths (Li-Cor Biosciences). A monoclonal anti-NS5A antibody (Virogen) and a polyclonal NS5A 
antibody (545) were used. Anti-β-actin antibody was purchased from Cell Signaling Technology.  Western 
blots shown are representative of multiple independent experiments. 
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3.6.4 MTT assays 
 
Cell viability was investigated using an MTT assay. Cells in a 96-well plate were added with 20 µL 
of MTT reagent (5 mg/mL) and the plate was placed on a shaker for 5 minutes at room temperature. The 
cells were then incubated for 4 hr to allow the MTT to be metabolized. The media were removed from 
the cells and 200 µL DMSO added to each well. After 5 minutes at room temperature on a shaker, the 
optical density was read at 560 nm and background at 670 nm was subtracted using a Spectra Max 340PC 
plate reader (Molecular Devices). Data represents average of three independent experiments performed 
in triplicate.  
 
3.6.5 Reverse transcription and real-time PCR 
 
RNA was extracted from HuH-7 cells with Trizol (Invitrogen) and reverse transcribed into cDNA by 
Superscript II (Invitrogen) as previously described (Qiao et al., 2013).  Real-time PCR experiments were 
performed with primers rLuc-FD (5´- TTGTTGAAGGTGCCAAGAAG 3´) and rLuc-rev (5´- 
TGAGAACTCGCTCAACGAAC 3´) using SYBR green based detection system. The transcript levels of β-
glucuronidase (GUSB) determined in parallel with primers GUSB-FD (5´- GGTGCTGAGGATTGGCAGTG 3´) 
and GUSB-rev (5´- CGCACTTCCAACTTGAACAGG 3´) were used for normalization.  
 
3.6.6 Protein expression and purification 
 
A poly-histidine tagged NS5A protein for RNA binding experiments was expressed in E. coli using 
the Expresso T7 SUMO cloning and expression system according to the manufacturer’s protocol (Lucigen). 
NS5A protein was purified through affinity chromatography under native conditions with the Ni-NTA 
purification system (Qiagen).  Expression and purification of His6-tagged NS5A protein was confirmed by 
both Coomassie blue staining and Western blotting. Purified proteins were aliquoted and stored at -80˚C. 
Blue fluorescent protein (BFP) was produced in a similar fashion to be used as a control in RNA binding 
experiments. 
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3.6.7 RNA binding assays 
 
Cy5 labeled HCV 3´-UTR RNA with or without the poly-U/UC region was produced using the 
MEGAscript T7 In Vitro Transcription reagent (Ambion) with Cy5 CTP (GE Healthcare). For the RNA binding 
experiments, Cy5-3´-UTR RNA or Cy5-3´-UTR∆poly-U/UC RNA was incubated with purified NS5A protein 
or BFP protein in a binding buffer (25 mM MOPS, 10 mM NaCl, pH4) for 1 h at room temperature. The 
RNA-protein mixture was loaded onto a 6% native polyacrylamide gel and the Cy5 labeled RNA was 
visualized with a Li-Cor Odyssey scanner (Li-Cor Biosciences). Data representative of multiple independent 
experiments.  
 
 
3.6.8 Statistical analysis 
 
All the experiments were performed a minimum of three times in triplicate. The experimental 
data were analyzed by Student’s t test and reported as the Mean ± SD using Microsoft Excel software.  A 
p value of  0.05 was considered statistically significant.  
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4.0 LINKER BETWEEN CHAPTERS 3 AND 5 
 
In the previous chapter, we attempted to determine which region of NS5A was responsible for 
the observed modulation of viral translation.  We observed that each domain of NS5A was capable of 
downregulating viral translation independently through a mechanism requiring the poly-U/UC region. 
Each domain has been found to bind within this region, suggesting a possible mechanism for this 
modulatory effect.  In the following chapter we set out to determine the region/residues involved in this 
modulation by domain I and investigated possible mechanisms of action.  
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5.1 Authors’ contribution 
 
All the experiments within this chapter were performed by Brett Hoffman. The manuscript was 
written by Brett Hoffman and edited by Qiang Liu.   
 
5.2 Abstract 
 
HCV NS5A is essential for viral replication but the mechanisms remain unclear. However, viral 
replication has been correlated to NS5A dimerization and RNA binding activity. We previously found that 
NS5A is able to down-regulate viral translation through a mechanism requiring the poly-U/UC region 
within the viral 3´-UTR to which NS5A binds. In this study, we have further investigated the role of domain 
I in modulating viral translation. Using a series of deletion and substitution mutants we identified a 
number of positively charged residues that played a role in this modulatory effect, most prominently 
R112. We found that mutation of R112 or E148, which form a hydrogen bond in a domain I dimer, negated 
the ability of domain I to modulate viral translation. Additionally, we found that this R112A mutation 
impeded both domain I dimer formation and binding to poly-U/UC RNA, suggesting a mechanism for the 
down-regulatory effect. Finally, when this R112A mutation was introduced into an HCV subgenomic 
replicon, the replicon was rendered replication deficient. These results collectively point to a crucial role 
for the NS5A arginine 112 residue in the modulation of HCV lifecycle by NS5A.  
 
5.3 Introduction 
 
Hepatitis C virus remains a serious global health concern with upwards of 150 million infected 
individuals worldwide (28). Furthermore, HCV results in chronic infections in approximately 75% of those 
infected and is associated with the development of significant liver diseases such as steatosis, 
decompensated liver cirrhosis and hepatocellular carcinoma (62). Accordingly, HCV infection is one of the 
major causes of end-stage liver disease and the primary indication for liver transplantation (13, 485, 546). 
Recent years have seen the development and approval of new direct-acting antivirals, such as viral 
protease inhibitors, which have substantially increased treatment efficacy (547). Although treatment 
outlook is promising, the high cost of the new antivirals, the potential for selection of resistance, limited 
efficiency in certain populations and the lack of a vaccine highlight the need for continued research. 
  
84 
 
Tremendous progress has been made in the understanding of the virus since its discovery in 1989 
as the cause of non-A non-B post-transfusion hepatitis (1, 2). HCV, as member of the Flaviviridae family, 
is a small positive sense single-stranded RNA virus (293). The 9.6 Kb viral genome contains a single open 
reading frame (ORF) which is flanked by highly conserved  5΄ and 3΄ untranslated regions (UTRs)  which 
are involved in the modulation of viral translation and replication (4, 19).  Translation of this single ORF, 
mediated by an internal ribosomal entry site (IRES) located within the 5´-UTR, results in the production of 
the viral polyprotein (4). The polyprotein is cleaved co- and post-translationally by both cellular and viral 
proteases into at least 10 viral proteins: three structural proteins (core, E1, and E2) and seven non-
structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). The IRES, located in the 5΄UTR, directly 
recruits the 40 S ribosomal subunit to initiate viral translation in a cap-independent manner (293). Viral 
polyprotein translation is also modulated by viral cis-acting factors and viral and cellular trans-acting 
factors (15, 19). One of the viral cis-acting factors that modulates translation is the viral 3΄UTR (15, 19). 
While the 3΄UTR serves as the initiation site for negative strand synthesis and as such is essential for viral 
replication, it also functions to stimulate viral translation (200, 201, 205). This is comparable to cap 
translation in which the polyA binding protein bound to the 3´polyA tail interacts with the cap binding 
complex enhancing translation by increasing initiation factor recruitment and possible circularization of 
the mRNA transcript (15). The 3´-UTR is composed of three regions: the variable region,  a poly-U/UC tract 
and an X-tail region which is composed of three stem loops; SL1, SL2 and SL3 (15). The variable region, 
poly-U/UC region and SL1 have been found to significantly contribute to the enhancement of viral 
translation mediated by the 3΄UTR (201). The mechanism of this enhancement is not clearly defined. The 
proposed mechanisms include the recruitment of viral and/or cellular factors which may mediate 5΄ and 
3΄ UTR interaction similar to the function of PABP in capped translation (293). Additionally, it has been 
observed that the 3΄UTR may function in ribosome recycling between the two UTRs, in that the 3΄UTR is 
able to bind the 40S ribosomal subunit and enhance successive rounds of translation (218).  
HCV non-structural 5A protein (NS5A) is essential for viral replication and assembly (26, 361, 418, 
419, 451-453, 455). However, although its exact role in the viral lifecycle remains unclear.  NS5A is 
composed of an N-terminal amphipathic α-helix (AH) and three domains which are separated by two 
regions of low complexity sequences (LCSs) (548). The AH is necessary and sufficient for membrane 
localization of NS5A, at the site of the viral replication complex, and is essential for replication (549-551). 
NS5A domains I and II are essential for viral replication (361, 454, 480, 490). Domain III, while largely 
dispensable for viral replication, plays an essential role in modulating viral assembly (278, 552, 553). NS5A 
is an RNA binding protein that binds with high affinity to the poly-U/UC region in the viral 3΄ UTR (214). 
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All three NS5A domains are capable of specifically interacting with the 3´-UTR independently (279). 
However, while domains I and II bound the 3΄UTR RNA efficiently, domain III demonstrated lower, albeit 
still specific, RNA binding affinity suggesting RNA binding is primarily mediated through domains I and II 
(279, 554, 555). Additional studies have suggested that domain I is the key mediator of NS5A RNA binding 
(554, 555). Due to the essential roles of NS5A in the viral lifecycle and its attractiveness as a drug target, 
a number of studies have been carried out in order to determine the structure of NS5A. Four different 
domain I structures, all in dimer formations, have been observed (479, 481, 482). Domains II and III have 
been found to be natively unfolded and largely disordered, capable of adopting different transient 
conformations (492, 493, 505, 533).  
In a previous study, we have shown that the viral NS5A protein functions to down-regulate viral 
translation through a mechanism that requires the poly-U/UC region of the 3΄UTR, where the protein has 
been shown to bind (chapter 3). We have also shown that domain I is able to modulate viral translation 
as effectively as the full NS5A protein. Given the role of domain I in modulating viral replication and NS5A 
dimerization, we further investigated the ability of domain I to modulate viral translation. Using a series 
of deletion and substitution mutants, we identified a number of positively charged residues that play a 
role in this modulatory effect, most prominently R112. We found that substitution of either R112 or E148, 
which form a hydrogen bond in one dimer structure (556), with alanine negates the ability of domain I to 
modulate viral translation. We also observed that the presence of low complexity sequence I (LCS I) can 
compensate for the E148A mutation but not the R112A mutation. Additionally we found that this R112A 
mutation impedes domain I dimer formation and reduces the ability of domain I to bind to poly-U/UC 
RNA, suggesting a mechanism for this down-regulatory effect. Finally, the R112A mutation renders an HCV 
subgenomic replicon replication deficient. These results point to a crucial role for the arginine 112 residue 
in the modulation of the viral lifecycle by NS5A.  
 
5.4 Results 
5.4.1 NS5A Domain I down-regulates viral translation in a manner dependent upon the presence of the 
poly-U/UC region in the viral 3´-UTR 
 
To substantiate our previous findings regarding domain I using a co-transfection method, we 
utilized a set of monocistronic HCV RNA reporters in combination with plasmids expressing NS5A or NS5A 
domain I (Figure 5.1a).  The monocistonic HCV RNA reporters contain the viral 5´- and 3´-UTRs, an internal  
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Figure 5.1 - NS5A domain I down-regulates HCV translation though a mechanism dependent 
upon presence of poly-U/UC region. (a) Diagram of NS5A domains with the amphipathic helic (AH), 
domains and Low complexity sequences labelled. Residues are number according to 1b N NS5A protein. 
(b,c) Huh7 cells were transfected with (b,c) plasmid vector or the indicated 1b NS5A expression plasmid 
and a monocistronic RNA 1b HCV luciferase reporter, containing either a (b) wt 3´-UTR, (b) ∆poly-U/UC 
3´-UTR or (c) a capped mRNA Luciferase reporter. Luciferase assay was performed 24 hr after transfection.  
(d) Expression of NS5A and domain I were detected by Western blot using a Myc specific antibody. (e) 
MTT assay for cellular viability 24 hr. after transfection of indicated expression plasmid. DMSO treatment 
was used as a control. Mean of vector set to 1. Error bars indicate mean +SD, **=p<0.01 relative to vector. 
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Renilla luciferase flanked by the first 16 amino acids of the HCV core gene and the last 5 amino acids of 
the HCV NS5B gene. The viral 5´-UTR contains the viral internal ribosome entry site (IRES), which drives 
the translation of the internal Renilla luciferase gene, which can be quantified as a measurement of viral 
translation. We also utilized a monocistronic HCV RNA reporter containing a deletion of the poly-U/UC 
region within the viral 3´-UTR in order to study the role of this region in modulation of viral translation by 
NS5A domain I. Monocistronic HCV RNA reporters such as the ones used in this study have been shown 
to more accurately reflect the key role of the viral 3´-UTR in modulating viral translation as compared to 
plasmid encoded or bicistronic reporters (521).  
When Huh7 cells are co-transfected with the monocistronic HCV RNA reporters and plasmids 
expressing either wt NS5A or NS5A domain I the levels of HCV IRES mediated translation are significantly 
reduced compared to vector control (Figure 5.1b). This modulatory effect on viral translation again 
required the poly-U/UC region of the viral 3´-UTR as previously reported. This effect was specific as 
translation of a capped RNA luciferase reporter was unaffected by either NS5A or domain I expression 
(Figure 5.1c). Expression of the NS5A fragments was confirmed by western blot (Figure 5.1d). Expression 
of NS5A domain I did not result in a change in cellular viability as determined by an MTT assay (Figure 
5.1e). Additionally, we have previously demonstrated that the down-regulation of viral translation by 
NS5A is not a result of RNA degradation (chapter 3). These results confirm our previous findings that 
domain I is able to down-regulate viral translation independently and that this effect requires the poly-
U/UC region of the 3΄UTR.  The mechanism of this down-regulatory effect on viral translation is unclear 
as is the mechanism behind the stimulatory function of the 3´-UTR on viral translation. One possibility is 
that through binding to the poly-U/UC region within the 3´-UTR domain I is interfering with the stimulation 
of viral translation by this region. This could be the result of interfering with such processes as the binding 
of stimulatory cellular proteins to this region, ribosome recycling or genome circularization.  
 
5.4.2 Amino acids 100-161 of domain I are sufficient for the modulation of viral translation  
 
To determine which region of this domain is involved in modulating viral translation, we 
generated a series of NS5A domain I deletion mutants (Figure 5.2a). The AH and LCS-I regions were also 
included to determine if these regions had an effect on the modulation of translation by domain I. We 
utilized four domain I fragments as shown in Figure 5.2a: aa. 1-253 (AH-domain I-LCS I), aa. 1-161, aa. 1-
99, and aa. 100-161. These truncation expression plasmids were co-transfected along with the  
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Figure 5.2 - NS5A domain I region aa. 100-161 is sufficient for the down-regulation of viral translation. 
(a) Diagram of domain I deletion fragments used. (b) HuH-7 were co-transfected with vector, plasmids 
expressing myc-tagged NS5A or the domain I deletion mutants indicated, and HCV RNA translation rLuc 
reporter RNA. Luciferase assay was performed 24 hr after transfection. Statistical differences compared 
to vector unless otherwise indicated are indicated as ** if p ≤ 0.01. (c) Expression of the NS5A and domain 
I deletion mutants in (b) was demonstrated by Western blotting using a myc-tag specific antibody. As a 
loading control, the level of β-actin was determined using a β-actin antibody.  
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monocistronic HCV RNA translation reporter RNA into HuH-7 cells. Plasmid vector and plasmid expressing 
the full-length NS5A were included as controls. As shown in Figure 5.2b expression of the AH-domain I- 
LCS I (aa. 1-253) was able to down-regulate HCV RNA translation to the same degree as full-length NS5A. 
While aa.1-161 of domain I retained the ability to down-regulate viral translation, this modulatory 
function was completely lost by the aa. 1-99 fragment (Figure 5.2b). These results indicated the 
importance of the C-terminal 62 amino acids of the aa. 1-161 fragment in down-regulating translation. To 
further investigate the significance of this 62-amino acid region, the N-terminal 99 residues of the aa. 1-
161 fragment were removed to produce the aa. 100-161 fragment. Indeed, this fragment retained the 
ability to down-regulate viral translation to similar levels as seen with both the aa. 1-161 and full AH-
domain I-LCS I fragments (Figure 5.2b). These results indicated that the aa. 100-161 of domain I is 
sufficient for the modulatory function of domain I on viral translation. The expression of these NS5A 
mutants was demonstrated by Western blot (Figure 5.2c). There were additional protein bands for NS5A 
and the aa. 1-161 truncation (Figure 5.2c), whose identities were not clear, but might result from protein 
degradation. In the case of the aa.101-162 fragment, the low signal detected was likely due to difficulties 
in transferring such small proteins rather than representative of low expression as this fragment behaved 
similar to both NS5A and aa. 1-253 (AH-domain I-LCS I) in translation assay. 
 
5.4.3 Residues K108, R112, K139, R157 and R160 are involved in the down-regulation of viral 
translation by the NS5A domain I aa. 100-161 region 
 
We previously showed that the down-regulation of viral translation by domain I required the poly-
U/UC region of the viral 3´-UTR, where domain I has been shown to bind, suggesting that RNA binding by 
domain I may be involved. Positively charged amino acids arginine and lysine residues are highly 
favourable in RNA-protein interactions as they are able to interact with the negatively charged phosphate 
backbone of RNA (557). To identify potential effector or RNA binding sites within the aa. 100-161 region 
of domain I, four arginine residues at positions 112, 123, 157 and 160 and two lysine residues at positions 
108 and 139 were substituted by alanines (Figure 5.3a). In co-transfection experiments using the HCV RNA 
translation reporter, we found that NS5A aa. 100-161 expression plasmids containing the individual amino 
acid substitutions K108A, R112A, K139A, R157A and R160A impaired the ability of NS5A aa. 100-161 to 
down-regulate viral translation (Figure 5.3b). The individual amino acid substitutions K108A, K139A, 
R157A and R160A restored viral translation to 65-70% of the vector control which is a significant increase 
over the inhibition seen with wild-type domain I aa. 100-161. The R112A substitution had the greatest  
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Figure 5.3 - Residues K108, R112, K139, R157 and R160 are involved in the down-regulation of viral 
translation by NS5A aa. 100-161. (a) Diagram of NS5A aa. 100-161 mutations. (b) HuH-7 cells were co-
transfected with vector, or plasmids expressing myc-tagged NS5A aa. 100-161, wild-type or containing the 
amino acid substitution indicated, and HCV RNA translation rLuc reporter RNA. Luciferase assay was 
performed 24 hr after transfection. Statistical differences compared to vector unless otherwise indicated 
are labelled as * if p ≤ 0.05, ** if p ≤ 0.01, or *** if p ≤ 0.001.  (c) Expression of the myc-tagged NS5A 
aa.100-161 proteins in (b) was demonstrated by Western blotting using a myc-tag specific antibody. As a 
loading control, the level of β-actin was determined by a β-actin antibody. 
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effect on this modulatory function as this mutation completely abolished the down-regulatory effect of 
the aa. 100-161 region on viral translation. Conversely, the amino acid substitution R123A did not have 
an effect on the ability of NS5A aa. 100-161 to down-regulate viral translation (Figure 5.3b). The 
expression of the domain I aa.100-161 mutants was confirmed by Western blot (Figure 5.3c). There was 
some variation in the level of expression between the NS5A aa. 100-161 mutants. The reason for the 
variation was not known. However, it was unlikely to have had an effect on the results obtained in the 
translation assay. For example, K139A and R157A exhibited different levels of expression, but both 
demonstrated a significant and similar loss in the ability to down-regulate viral translation compared to 
Wt. Taken together, these results demonstrated that a number of positively charged residues, particularly 
R112, play a role in the modulation of viral translation by the aa. 100-161 region of NS5A domain I.  
 
5.4.4 Residues R112 and E148 play a key role in the down-regulation of viral translation by NS5A 
domain I 
 
In addition to playing a key role in the modulation of viral translation by the NS5A domain I aa.100-
161 region, this R112 residue has been directly implicated in the dimerization of domain I. In the Love et 
al. study the authors determined the crystal structure of an NS5A domain I dimer and found that the dimer 
contact surfaces are formed by residues 92-99, 112-116, 139-143, 146-149 and 160-161 (556). 
Additionally, R112 was found to form an intermolecular hydrogen bond with glutamic acid 148 (E148) 
(556). We therefore set out to determine if R112 and E148 are involved in the modulation of viral 
translation within the context of the NS5A domain I (Figure 5.4a). When NS5A domain I R112A and I E148A 
substitution mutations were used in HCV translation assay, we found that the R112A mutation has a 
similar inhibitory effect when present within the context of the entire domain I as when expressed within 
domain I aa.100-161 fragment (Figures 5.4b and 5.3b). NS5A domain I E148A mutant was also no longer 
capable of down-regulating viral translation (Figure 5.4b). The expression of the NS5A domain I mutants 
was confirmed by Western blot (Figure 5.4c). These results are indicative of a significant role for both 
R112 and E148 in the modulatory ability of domain I on viral translation, perhaps through mediating 
domain I dimerization. 
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Figure 5.4 - Residues R112 and E148 are involved in the down-regulation of viral translation by NS5A 
domain I. (a) Diagram of NS5A domain I amino acid substitutions used. (b) HuH-7 cells were co-transfected 
with plasmids expressing myc-tagged NS5A domain I, wild-type, R112A, or E148A mutant, and HCV RNA 
translation rLuc reporter RNA. Luciferase assay was performed 24 hr after transfection. Statistical 
differences compared to vector unless otherwise indicated are labelled  ** if p ≤ 0.01, *** if p ≤ 0.001. (c) 
Expression of NS5A domain I proteins in (b) was demonstrated by Western blotting using a myc-tag 
specific antibody. As a loading control, the level of β-actin was determined by a β-actin antibody 
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5.4.5 Residue C39 is involved in the down-regulation of viral translation by NS5A domain I 
 
To further investigate the effect of dimerization and RNA binding on viral translation modulation 
by NS5A domain I, we used a C39A mutant, which has been reported to be unable form a dimer or bind  
RNA (479, 489). When we co-transfected the domain I C39A expression plasmid along with the HCV RNA 
translation reporter RNA, viral translation was significantly down-regulated compared to vector (Figure 
5.5a). Interestingly, viral translation after domain I C39A expression was significantly higher than that of 
wild-type domain I. Expression of the domain I C39A mutant protein was confirmed by Western blot 
(Figure 5.5b). These results suggested that domain I dimerization plays a role in modulating HCV 
translation. 
 
5.4.6 Mutations R112A and E148A impede dimer formation by domain I 
 
We next investigated the effect of the R112A and E148A mutations on NS5A domain I dimerization 
in an immunoprecipitation experiment. Cells were co-transfected with Flag-∆AH NS5A and either ∆AH 
NS5A-myc or one of the NS5A domain I-myc expression plasmids: domain I, domain I R112A E148A or 
domain I C39A. Immunoprecipitation was performed on cell lysates with an anti-Flag antibody. If the 
domain I fragments are able to form dimers with Flag-∆AH NS5A, they will be co-immunoprecipitated 
along with Flag-∆AH NS5A. In this experiment, the C39A mutation acts as a negative control as others have 
found that this mutation abolishes dimerization (554). The input and Flag-IP samples were analyzed by 
Western blot using anti-Flag and anti-myc tag antibodies, respectively. As shown in Figure 5.6, we found 
that both myc-tagged ∆AH NS5A and myc-tagged NS5A domain I were co-immunoprecipitated with Flag-
tagged ∆AH NS5A. This indicated the formation of NS5A/NS5A and NS5A/NS5A domain I dimers. The 
R112A E148A double mutation abolished the ability of domain I to interact with the Flag-tagged NS5A 
because no domain I R112A E148A could be co-immunoprecipitated with Flag-NS5A (Figure 5.6). Domain 
I C39A mutant could not be detected in the immunoprecipitates as expected. These results indicated that 
the R112A and E148A mutation impedes dimerization by NS5A domain I.  
 
5.4.7 The LCS I region can compensate for E148A, but not R112A, mutation 
 
The LCS I linker region between domains I and II may impact the function of domain I (554, 555). 
As such we investigated the effect of LCS I on viral translation modulation. As shown in Figure 5.7a, 
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Figure 5.5 - The C39A mutation reduces the ability of NS5A domain I to modulate viral translation. (a) 
HuH-7 cells were co-transfected with vector, plasmids expressing myc-tagged NS5A domain I, wild-type 
or C39A, and HCV RNA translation rLuc reporter RNA. Luciferase assay was performed 24 hr after 
transfection. Statistical differences compared to vector unless otherwise indicated are labelled * if p ≤ 
0.05 relative to vector. (b) Expression of NS5A domain I proteins in (a) was demonstrated by Western 
blotting using a myc-tag specific antibody. As a loading control, the level of β-actin was determined using 
a β-actin antibody. 
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Figure 5.6 - Mutations R112A, E148A, and C39A impede dimer formation by domain I. HuH-7 cells were 
co-transfected with a Flag-∆AH NS5A expression plasmid  and plasmids expressing myc-∆AH NS5A, NS5A 
domain I, NS5A domain I R112A E148A, or NS5A domain I C39A. Cell lysates were subjected to 
immunoprecipitation with anti-Flag antibody. The presence of myc-tagged NS5A proteins in 
immunoprecipitates was detected by Western blotting using a myc-tag specific antibody. The input Flag-
NS5A protein was demonstrated by Western blotting using a Flag specific antibody. Representative of 
multiple independent experiments. 
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Figure 5.7 - Residue R112 but not E148 is involved in the down-regulation of viral translation by NS5A 
domain I-LCS I. (a). HuH-7 cells were co-transfected with plasmids expressing NS5A domain I, domain I-
LCS I, domain I-LCS I R112A or E148A mutants, or vector, and HCV RNA translation rLuc reporter RNA. All 
NS5A proteins had a myc-tag at the C-termini. At 24 hr after transfection, luciferase assay was performed. 
Statistical differences compared to vector unless otherwise indicated are labelled  * if p ≤ 0.05, ** if p ≤ 
0.01. (b). Expression of the NS5A proteins in (a) was demonstrated by Western blot using a myc-tag 
specific antibody. As a loading control, the level of β-actin was determined using a β-actin antibody.  
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domain I-LCS I exhibited similar inhibitory effect on viral translation as domain I, suggesting that LCS I is 
not involved in regulating HCV translation. We also studied the effects of the R112A and E148A mutations 
on the ability of a domain I-LCS I fragment to modulate viral translation. We found that the R112A 
mutation negated the ability of the domain I-LCS fragment to down-regulate viral translation to a 
similar extent as when the LCS I was absent (Figure 5.7a). In contrast, the E148A mutation had no effect 
on the ability of domain I-LCS I to modulate viral translation (Figure 5.7a). This E148A mutation abolished 
this function in a domain I fragment without the LCS-I region (Figure 5.4b), suggesting that the LCS I region 
can compensate for the effect the E148A mutation has on domain I.  The expression of the NS5A domain  
I-LCS I proteins was confirmed by Western blotting (Figure 5.7b). The doublets observed in the three 
domain I-LCS I fragments were most likely due to phosphorylation because a few serine residues in LCS I 
have been shown to be modified by phosphorylation (361). 
 
5.4.8 The R112A mutation impairs the RNA binding ability of NS5A domain I  
 
We previously showed that the poly-U/UC region is required for viral translation modulation by 
domain I, suggesting domain I binding to the poly-U/UC region is involved. Mutations of numerous 
positively charged residues impaired translation modulation by this domain (Figure 5.3b). Furthermore, 
residues implicated in domain I dimerization, which has been linked to RNA binding ability, were also 
implicated in this modulatory function (Figure 5.4b). To investigate whether there is a correlation 
between translation modulation and RNA binding, we studied RNA binding activity of R112A mutant 
protein in electrophoretic mobility shift assays (EMSA). Cy5 labelled poly-U/UC RNA was utilized in 
combination with recombinant ΔAH NS5A domain I or the R112A mutant expressed and purified from 
E.coli.  The ΔAH NS5A domain I protein led to an upward shift in labelled RNA at the 6 and 20 µM protein 
concentrations, indicating the ability of this domain to bind to the poly-U/UC RNA (Figure 5.8). However, 
when the R112A mutant was utilized, this alteration of RNA mobility was not observed (Figure 5.8). These 
results suggested that the R112A mutation impairs the ability of NS5A domain I to interact with the poly-
U/UC RNA in the viral 3̕´UTR. These findings support a mechanism through which domain I down-regulates 
translation by way of a direct interaction with the viral 3΄UTR.  
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Figure 5.8 - NS5A domain I R112A does not bind to poly-U/UC RNA. The indicated amounts of purified 
NS5A domain I or NS5A domain I R112A proteins were incubated with 1 pmol of  Cy5-poly-U/UC RNA. The 
binding reactions were loaded into a 8% polyacrylamide gel. The RNA/potein  bands were visualized using 
the Odyssey scanner. Asterix indicates unbound RNA and arrow indicates NS5A/RNA complexes. 
Representative of multiple independent experiments. 
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5.4.9 The R112A mutation is lethal for HCV replication  
 
Since NS5A is essential for viral replication and a correlation between NS5A RNA binding and viral 
replication has been previously identified, we investigated the effect of the R112A mutation on viral 
replication. To this end, the R112A mutation was introduced into an HCV subgenomic replicon (Figure 
5.9a). A SgR reporter containing a deletion of the GDD motif within the NS5B polymerase was utilized as 
a negative control as this deletion renders the SgR replication deficient. As another control, a SgR 
containing the C39A mutation within NS5A domain I was created as this mutation abolishes the replicative 
capacity of HCV (554). These SgR reporters were electroporated into HuH-7.5 cells and replicative capacity 
was determined by luciferase assays at 4, 24, 48, 72 and 96 hr post electroporation. The luciferase activity 
was normalized against the 4 hr time-point to account for any differences in transfection efficiency. As 
shown in Figure 5.9b, all of the SgR reporters exhibited a similar level of luciferase activity between 24 
and 48 hr post-electroporation. A stabilization in the luciferase activity of the wild type HCV SgR was 
observed from the 48 hr time-point on which was indicative of viral replication. However, the luciferase 
activity of the R112A mutant continued to decrease at all time-points beyond the 48 hr time-point to a 
similar extent as the replication deficient C39A and ΔGDD SgR reporters. These results indicated that the 
R112A mutation renders the SgR replication deficient.  
 
5.5 Discussion 
 
In this study, we further characterized the effect of HCV NS5A domain I on viral translation. 
Through the use of a series of deletion mutants, we showed that the aa. 100-161 region within this domain 
was sufficient for down-regulating viral translation (Figure 5.2). Furthermore, this function was found to 
dependent upon a number of positively charged residues within this region (Figure 5.3). Of these residues, 
mutation of the highly conserved R112 had the greatest effect on this down-modulatory function, 
completely nullifying this activity (Figure 5.3). The aa. 100-161 region identified here contained the 
majority of the domain I dimer contact interfaces identified in both the Love et al. dimer and Lambert et 
al. AB dimer (481, 482). The Love et al. dimer contains an intramolecular hydrogen bond between R112 
and E148 (556). We found that when either R112 or E148 were replaced with alanines within the context 
of a full domain I fragment, the ability of domain I to down-regulate viral translation was completely lost 
(Figure 5.4). These results suggest that the intramolecular hydrogen bond formed by R112 and E148 is 
important for down-regulating viral translation.  
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Figure 5.9 - The R112A mutation within NS5A Domain I renders HCV subgenomic replicon replication 
deficient. (a). Diagram of the HCV subgenomic replicon (SgR) with a luciferase reporter. (b). HuH-7.5 cells 
were electroporated with the indicated HCV SgR RNAs. Cells were harvested at the indicated time points 
and luciferase assay performed. Values were normalized to 4 hr time point and protein concentration. * 
indicates statistical difference of p ≤ 0.001 of the three mutant replicons compared to wildtype. Error bars 
in panel (b) are not visible at this scale. 
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Based on our findings and this crystal structure, we investigated the effect of the R112A and 
E148A mutations on the ability of domain I to dimerize. Our results indicated that the R112A and E148A 
mutations impede the formation of NS5A domain I dimers (Figure 5.6). These results suggest that domain 
I dimerization may have an impact on the ability of this domain to modulate viral translation. Interestingly, 
another domain I mutant, C39A, which can disrupt domain I dimerization, as shown by the Gallay group 
(554) and by our own data (Figure 5.6), did not completely impede the ability to modulate viral translation 
by domain I (Figure 5.5). C39, along with other three cysteine residues, was proposed to promote NS5A 
dimerization through disulfide bonds (554). While these results support a role of dimerization in 
modulating viral translation by NS5A domain I, the differences in the degree of translation down-
regulation conferred by C39A and R112A or E148A mutations suggest that the R112A and E148A 
mutations may interrupt other mechanisms required for viral translation in addition to dimerization.  
We next studied the role of LCS I in viral protein modulation by domain I. Our results indicated that LCS I 
did not have an effect on this function (Figure 5.7). However, we obtained interesting data when 
investigating the R112A and E148A mutations in a domain I fragment containing the LCS I region (Figure 
5.7). The domain I-LCS I fragment containing the E148A mutation was capable of modulating viral 
translation to a similar extent as observed for the wild type domain I. The mechanism behind this apparent 
compensatory function of the LCS I is not clear. The LCS I has been observed by the Cameron group to 
enhance domain I dimerization (555). Therefore, it is possible that the LCS I enhances domain I 
dimerization even in the presence of the E148A mutation. Unfortunately, none of the domain I fragments 
used in crystallization studies completed thus far contained the LCS-I region, so it is unclear how this 
region could affect the proposed interaction between R112/E148. Alternatively, we have not eliminated 
the possibility that the R112A and E148A mutations lead to significant structural alterations within domain 
I. As such, the LCS I region may support the retention of functional structure in a manner that compensates 
for the effects of E148A mutation. Finally, LCS I is modified by phosphorylation when expressed in 
mammalian cells (361). It is possible that phosphorylation of LCS I can compensate for the original function 
of E148 due to its charge which is lost in the E148A mutation.  
In an effort to determine the mechanism of the down-regulation of viral translation by domain I, 
we investigated the effect of the R112A mutation on the ability of domain I to bind to poly-U/UC RNA. 
Using recombinant domain I and domain I R112A proteins in combination with Cy5-poly-U/UC RNA, we 
found that the R112A mutation results in a loss of RNA binding ability for domain I (Figure 5.8). These 
findings point to a possible mechanism through which domain I down-regulates viral translation. As the 
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mechanisms behind the stimulatory effect of the 3´-UTR on viral translation remain inconclusive, it is 
unclear how NS5A domain I binding within this region interferes with this function. However, this 
interaction could impede genome circularization, ribosome recycling or the binding of proteins, which are 
proposed as potential mechanisms to stimulate viral translation by the 3´-UTR (19, 218).  
 Finally, we found that the R112A mutation was lethal to HCV replication (Figure 5.9). This 
mutation behaved in a similar fashion to the C39A mutation identified by the Gallay group, which 
identified a link between domain I dimerization, RNA binding and viral replication (554). Therefore our 
study reaffirms this link but through mutation to R112 rather than mutations within the zinc binding motif 
in the N-terminal region of domain I.  
In summary, we found that the mutation of a single residue within domain I, R112, resulted in the 
loss of the modulatory function on viral translation exhibited by domain I. Furthermore, this mutation 
lead to the disruption of domain I dimerization and RNA binding and was lethal to HCV replication. These 
findings lend support for the previously observed correlation between NS5A dimerization, RNA binding 
and viral replication (554). NS5A is proving to be an extremely complex protein with a seemingly endless 
array of functions attributed to it despite the lack of enzymatic activity. Understanding the mechanisms 
behind such activities will facilitate the development of direct acting antivirals with increasing efficacy. 
 
5.6 Materials and Methods 
5.6.1 Plasmid construction and RNA synthesis  
 
The monocistronic HCV RNA translation reporter plasmid T7 HCV 5´-UTR-Coreaa1-16-rLuc-NS5B5-3´-
UTR of genotype 1b was described previously (chapter 3). This reporter contains T7 promoter, HCV 5´-
UTR, sequence encoding the first 16 amino acids of the core protein, an internal Renilla luciferase (rLuc) 
gene, sequence encoding the last five amino acids of the NS5B protein and the 3´-UTR. The 5´-UTR 
contains the viral IRES which drives the expression of the internal Renilla luciferase gene. In other two 
constructs, the poly-U/UC region in the 3´-UTR or the entire 3´-UTR with the coding sequence for the last 
five amino acids of the NS5B were cloned downstream of the T7 promoter sequence. HCV subgenomic 
replicon (SgR) is composed of the HCV 5´-UTR, which directs translation of a luciferase reporter gene, 
followed by the IRES of the encephalomyocarditis virus (EMCV), which directs translation of the HCV 
replicase genes NS3-NS5B, and the 3´-UTR (Fig. 8a) (558). The SgR reporter allows for transient replication 
assay as the amount of luciferase produced can be measured as an indicator of viral replication (559). As 
a negative control, the GDD sequence within the NS5B viral polymerase was deleted which rendered 
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replication deficient. Plasmids expressing HCV NS5A with or without the amphipathic α-helix (AH) were 
reported previously (BH, submitted for publication). Coding sequences for NS5A domain I with or without 
LCS I were amplified by PCR using HCV-1b N Neo C-5B (540) as template and cloned into pEF/cyto/myc 
vector (Invitrogen/Life Technologies). NS5A domain I truncations were constructed by a PCR-based 
approach. Amino acid substitution mutants in the expression plasmid or SgR were generated by site-
directed mutagenesis. In additional constructs, a Flag or a myc tag was added to the N- or C-termini of 
various NS5A expressing constructs, respectively. All plasmids were confirmed by DNA sequencing. HCV 
RNA translation reporter and SgR RNAs were produced from linearized plasmids by in vitro transcription 
using the MEGAscript T7 In Vitro Transcription kit (Ambion).  
 
5.6.2 Cell lines, transfections, HCV transient replication and luciferase assay  
 
Human hepatoma cell lines HuH-7 and HuH-7.5 were kindly provided by Bartenschlager (315) and 
Rice (543) , respectively. HuH-7 and HuH-7.5 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen/Life Technologies) supplemented with 10% fetal bovine serum and 1% gentamicin and 
cultured at 37°C and 5% CO2. In co-transfection experiments, HuH-7 cells in 24-well plates were co-
transfected with 1 µg or the indicated amount of expression plasmid and 1 µg of the indicated RNA 
reporter using Jet-PEI transfection reagent according to the manufacturer’s protocol (Polyplus-
Transfection). Luciferase assay was performed at 24 hr after transfection. For these luciferase experiments 
vector control was set to 1 (100%) and error bars represent mean ± SD. In SgR experiments, HuH-7.5 cells 
were electroporated (270 V, 950 µF, 4 mm cuvette) with the indicated amounts of RNA using an 
electroporator (Bio-Rad) before they were harvested at the indicated time points. Following incubation, 
the cells were lysed with Passive Lysis Buffer and luciferase assay was performed according to the 
manufacturer’s instructions (Promega). Luciferase data in these electroporation experiments was 
normalized to protein concentration which was determined with a BCA protein assay kit (Thermo 
Scientific). All luciferase experiments are the average of three independent experiments performed in 
triplicate. 
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5.6.3 SDS-PAGE and Western blot 
 
SDS-PAGE and Western blots were performed as previously described (560). Briefly, cells were 
lysed in SDS lysis buffer (1% SDS, 10 mM Tris-HCl, pH 8.0). After SDS-PAGE, proteins were transferred onto 
nitrocellulose membranes. The membranes were then blocked in 5% skimmed milk in PBS for 1 hr at room 
temperature before incubation with a primary antibody overnight at 4°C. Blots were then washed with 
PBS and incubated with the appropriate secondary antibodies (Li-Cor Biosciences) for 1 hr at room 
temperature. Blots were then washed with PBST (0.1% Tween-20) before a final wash with PBS. Blots were 
scanned using an Odyssey scanner at the appropriate wavelengths (Li-Cor Biosciences). A monoclonal anti-
NS5A antibody was purchased from Virogen and a polyclonal NS5A antibody was kindly provided by Dr. 
Cameron (561). The myc tag and β-actin antibodies were purchased from Cell Signaling Technology. 
Western blots shown are representative of multiple independent experiments. 
 
 
5.6.4 Immunoprecipitation 
 
HuH-7 cells were co-transfected with a Flag-∆AH NS5A expression plasmid or vector, together 
with plasmids expressing myc-tagged ∆AH NS5A, domain I, domain I with R112A and E148A mutations, or 
domain I with C39A mutation. Cells were then incubated at 37°C for 24 hr. Cell lysates were subjected to 
immunoprecipitation with an anti-Flag antibody (Sigma-Aldrich). The presence of myc-tagged NS5A 
proteins in the immunoprecipitates was analyzed in Western blotting using a myc-tag specific antibody. 
Results representative of multiple independent experiments.  
 
5.6.5 Recombinant NS5A domain I protein expression and purification from E. coli 
     
Poly-histidine tagged NS5A domain I proteins, wild-type or R112A mutant, were expressed in E. 
coli with the Expresso T7 SUMO Cloning and Expression system (Lucigen). NS5A domain I proteins were 
then purified through affinity chromatography under native conditions with the Ni-NTA purification 
system according to the manufacturer’s instructions (Qiagen). Expression and purification of His6-tagged 
NS5A domain I proteins were confirmed by both Coomassie blue staining and Western blotting. Purified 
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proteins were aliquoted and stored at -80˚C. Blue fluorescent protein (BFP) was produced in a similar 
fashion to be used as a control in RNA binding experiments. 
 
5.6.6 RNA binding electrophoretic mobility shift assays (EMSA) assays  
 
Cy5 labeled poly-U/UC RNA was produced using the MEGAscript T7 In Vitro Transcription reagent 
(Ambion) with Cy5 CTP (GE Healthcare). Prior to binding, the Cy5-poly-U/UC RNA (in 50 mM Tris and 100 
mM NaCl) was denatured at 96 °C for 1 min and then placed in boiling water and allowed to cool to room 
tempearture. The indicated amounts of purified NS5A domain I or NS5A domain I R112A proteins were 
incubated with 1 pmol of Cy5-poly-U/UC RNA in a binding buffer (20 mM HEPES, 5 mM MgCl2, 5 mM DTT) 
and 4% glycerol for 5 min at 25 °C.  The binding reactions were then loaded into an 8% non-denaturing 
polyacrylamide gel. The RNA/protein bands were visualized using a Odyssey scanner (Li-Cor Biosciences). 
Results representative of multiple independent experiments. 
 
5.6.7 MTT assay 
 
See methods described in section 3.6.4 
 
5.6.8 Statistical analysis 
 
All the experiments represent three independent experiments performed in triplicates. The 
experimental data were analyzed by Student’s t test. A p value of  0.05 was considered statistically 
significant. Results reported as Mean ± SD. 
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6.0 LINKER BETWEEN CHAPTERS 5 AND 7 
 
Given the success of the strategy followed in the previous chapter at identifying individual 
residues involved in the modulation of translation by NS5A domain I we chose to extend this to domains 
II and III. Therefore, we utilized a similar approach as the previous chapter using a combination of deletion 
and amino acid substitution mutants. Despite being less characterized than domain I residues within these 
domains have been found to be essential in both replication and assembly.  
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7.1 Authors’ contribution 
 
All the experiments within this chapter were performed by Brett Hoffman. The Manuscript was 
written by Brett Hoffman and edited by Qiang Liu.   
 
7.2 Abstract 
 
NS5A is a multifunctional protein that plays a critical role in the HCV lifecycle. Although NS5A has 
essential roles in viral replication and virus production, its potential role in modulating viral translation 
has remained questionable. We have previously demonstrated that NS5A down-regulates viral translation 
through a mechanism requiring the poly-U/UC region of the viral 3´-UTR and that each of NS5As three 
domains are capable of this function individually. For domain I, we determined that one residue in 
particular, R112, plays a key role in modulating viral translation and is also involved in the dimerization 
and RNA binding ability. Additionally, the R112A mutation also proved lethal in an HCV sub-genomic 
replicon.  In this study, we set out to map the regions and amino acids within domain II and domain III 
involved in the modulation of viral translation. Using a series of deletion and amino acid substitution 
mutants we found that K312 and E446 play important roles in the modulation of viral translation by NS5A 
domains II and III, respectively. When these residues are substituted with alanine in full length domain II 
and domain III fragments they result in a complete loss of this downregulatory affect. Mutation of K312 
again leads to a loss of this modulatory effect in a domain II-LCS II-domain III fragment, whereas mutation 
of residues E446 and S447 in domain III are required for this loss of function. 
 
7.3 Introduction 
 
Hepatitis C virus (HCV), discovered in 1989 as the agent responsible for infectious non-A, non-B 
hepatitis, currently infects approximately 130-150 million people worldwide, representing approximately 
2% of the world’s population (1, 2, 562). Up to 75% of those infected develop a chronic infection (31). 
Many of those infected can remain unaware for decades of their status, as the initial infection tends to be 
asymptomatic (31). Clinical manifestations of chronic HCV infection include liver steatosis cirrhosis and 
hepatocellular carcinoma (13, 31). The standard of care for many years consisted of a treatment regimen 
that included ribavirin and pegylated-interferon, treatment which produced multiple adverse side effects 
that hindered treatment uptake and adherence (62) . While effective in up to 80% of those infected with 
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genotype 2 or 3 HCV, this treatment was only effective at best in 50% of those infected with genotype 1, 
the most common genotype in North America (62). However, tremendous progress has been made in the 
development of direct acting antivirals (62, 68). Recently, the field has seen the development and 
regulatory approval of numerous direct acting antivirals such as viral protease and polymerase inhibitors 
(62, 68).  New treatment regimens which combine direct acting antivirals targeting different aspects of 
the viral lifecycle are effective in up to 90-99% of genotype 1 patients in clinical trials (62, 70, 74). Although 
major advancements in treating HCV have significantly improved treatment outcome, a vaccine that offers 
protection against infection has yet to be developed. Additionally, many aspects of the viral lifecycle 
remain unclear, particularly the role that NS5A, an essential viral protein and attractive drug target, plays 
in the various aspects of viral infection.  
HCV is an enveloped, single stranded positive sense RNA virus and classified within  the 
Flaviviridae family as the only member of genus Hepacivirus (4). The viral RNA contains a single ORF 
flanked by two highly conserved untranslated regions (UTRs) (15). The 5´-UTR contains an internal 
ribosomal entry site (IRES) which can directly recruit the 40S ribosomal subunit to initiate translation of 
the viral polyprotein (19). The 3´-UTR serves as the initiation site for negative stand synthesis during 
genome replication (19). It is composed of three regions; the variable region, a long poly-U/UC tract and 
an x-tail region which consists of three stem-loops (19). The 3´-UTR also functions to stimulate viral 
translation through an unknown mechanism which may involve long range RNA-RNA interactions with the 
5´-UTR, binding of cellular proteins or the retention and recycling of ribosomes during subsequent rounds 
of translation (19, 218). The viral polyprotein is cleaved co- and post translationally by both cellular and 
viral proteases into at least ten viral proteins (19). This includes three structural proteins (core, E1, E2) 
and seven non-structural proteins (p7, NS2, NS3, NS4A/B, NS5A and NS5B ) (19).  Following viral 
polyprotein processing, genome replication occurs in replication complexes found at an ER-derived 
membranous web (4). HCV virions are then assembled in close proximity to ER-associated lipid droplets 
and are exported through the secretory pathway in association with lipoproteins (11).  
Numerous cellular and viral proteins have been implicated in the modulation of viral translation 
but this process remains unclear (15, 19). Particularly unclear is the role that the essential viral protein 
NS5A may play in this process (19). NS5A, which lacks any enzymatic activity, is a multifunctional 
phosphoprotein essential for viral replication and assembly, although through unknown mechanisms. 
NS5A exists within infected cells as basally phosphorylated and hyperphosphorylated forms, with 
apparent molecular weights of 56 kDa and 58 kDa, respectively. (361). The sites of phosphorylation and 
kinases responsible remain ambiguous, but cellular kinases PI4KIIIα and CKII have been implicated in 
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hyper- and basal phosphorylation respectively (453, 478). Phosphorylation has been implicated in 
regulating various functions of NS5A, possibly though modulating the conformation of NS5A and protein 
interactions (361, 362). NS5A has been found to interact with numerous viral and host proteins and is an 
essential component of the viral replication complex. A recent study identified 132 host proteins with 
which NS5A is proposed to interact (27). NS5A preferentially interacts with proteins central to cell 
signalling networks, suggesting that NS5A plays a key role in modulating the cellular environment in favour 
of viral pathogenesis (27). The pathways within the NS5A interactome include cell growth/death, cellular 
signalling, cell adhesion and transport and the immune response (27).   
NS5A is made up of an N-terminal amphipathic helix followed by three domains separated by 
regions consisting of low complexity sequences (LCS) (480). The amphipathic helix is essential for viral 
replication and mediates NS5A localization to the replication complex at ER derived membranes (460, 
479). The three domains of NS5A have been implicated in numerous functions in the HCV lifecycle and 
each possess RNA binding ability towards the poly-U/UC tract within the viral 3´-UTR, although with 
different affinities (363, 364). Domain III binds to this region weakly when compared to domain I and II 
(363). NS5A has also been observed to bind to sites within the IRES found within the 5´-UTR (364). As NS5A 
interacts with both ends of the genome, it may play a role in modulating viral translation and the switch 
from translation to replication which must occur during the lifecycle of a positive sense RNA virus. 
 Domain I (aa. 33-213) is highly structured, possesses an essential zinc-binding motif and is 
proposed to mediate NS5A dimerization within infected cells (479). Currently, domain I is the only domain 
of NS5A which has been crystalized. However, four different domain I structures have been crystalized, 
all as dimers with differing structures (479, 482, 563). The physiological relevance of these different 
dimers is unclear. One possibility is that they serve different functions during the viral lifecycle and that 
their formation is regulated though phosphorylation, protein interactions or by binding the viral RNA (361, 
563). Another possibility is that different domain I dimers with different dimer interfaces form an 
extended multimeric network during infection (482, 563).  Based on the selection for resistance 
mutations, models of NS5A structure and the symmetrical nature of some of the most potent NS5A 
inhibitors, it is likely that these compounds interact with domain I dimer interfaces (483-486). 
Furthermore, a correlation between NS5A dimerization, RNA binding and viral replication has been 
observed, supporting the biological relevance of domain I dimerization (489).  
While Domain I has been has been fairly well characterized, much less is known about NS5A 
domains II and III. Domain II (aa. 254-346), like domain I, is essential for viral replication (418, 454, 490). 
However, large regions of this domain are dispensable. Various mutagenesis studies have found that only 
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between 12 and 23 amino acids within the C-terminal portion of domain II are essential for viral replication 
(418, 454, 490). No crystal structure has been obtained for domain II. It appears to be largely disordered 
and natively unfolded (491, 492). Despite this disordered state, domain II is capable of adopting different 
transient conformations which may play a role in modulating domain II function and protein interactions 
(492, 493). The overall unstructured nature of domain II may provide a larger accessible surface for 
molecular interactions and the flexibility to bind to many different targets without sacrificing specificity 
compared to folded proteins (491). Accordingly, domain II has been found to interact with numerous 
cellular proteins including PKR, PI3K and cyclophilin A and B (458, 494-496). The interaction between 
domain II and Cyclophilin A (CypA), a protein which possesses peptidyl-prolyl isomerase activity, is 
essential for viral replication (497, 498) . As such, a number of CypA inhibitors are currently in clinical trials 
as treatment against HCV infection. The mechanism of action of these inhibitors remains to be clearly 
defined, but the isomerase activity of CypA is essential for its role in modulating viral replication (498, 
499). The resulting cis-trans peptide bond interconversion modulated by this isomerase activity is 
speculated to cause a structural shift in domain II towards a more extended form (500, 501). This 
structural alteration is mimicked by CypA inhibitor-resistance mutations which therefore reduce the 
dependence upon CypA to induce such modifications (500, 501). How this structural shift within NS5A 
domain II modulates HCV replication remains unclear. It could potentially involve modulating protein 
interactions and/or the RNA binding ability of domain II (84).  
Domain III (aa. 360-451) is similar to domain II in that no crystal structure for this domain has been 
resolved. It also appears to lack significant secondary structure and to be natively unfolded (479). 
However, domain III, much like domain II, has been proposed to possess regions of transient secondary 
structure (505). Domain III exhibits a tendency to form intrinsic α-helices at both its N- and C-terminal 
regions (505). Such transient structures may play a role in the interaction of NS5A domain III with viral or 
host factors (505).  Domain III appears to be dispensable for viral replication in that deletion of this region 
is tolerated in viral replicons (419). However, this region may have a role in establishing early replication 
efficacy in that deletion of this domain leads to delayed replication kinetics in the JFH-1 cell culture system 
(419). On the other hand, this region plays a critical role in viral assembly (452). The C-terminal region of 
domain III has been implicated in the localization of NS5A to lipid droplets (LDs) and the efficacy of virus 
production correlates with the levels of NS5A-core interaction on the surface of LDs (418-420, 452).  In 
particular, a cluster of serine residues within the domain III C-terminal region have been found to play a 
key role in modulating this interaction and viral assembly (419, 420, 452).  Mutation of these residues to 
alanine impairs NS5A basal phosphorylation and results in the loss of NS5A: Core co-localization on the 
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surface of LDs, resulting in an inhibition of virion production (419, 452). These mutations also inhibited 
the interaction of core with viral RNA, supporting a role for NS5A in delivering the viral RNA to the surface 
of LD’s during the assembly process (452).  However, these interactions and virus assembly are restored 
upon mutation of these serines to glutamic acid, which mimics a phosphorylated state (452). These finding 
suggesting a key role for the phosphorylation in modulating viral assembly (452). 
We have previously found that NS5A down-regulates viral translation through a mechanism 
requiring the poly-U/UC region of the 3´-UTR to which we and others have shown NS5A binds (363, 365). 
Furthermore, we determined that each of the three NS5A domains is capable of this modulation 
independently. Upon investigation into domain I, we found that a number of positively charged residues, 
most notably arginine 122 (R112), play key roles in this effect. Upon mutation of R112 or glutamic acid 
148 (E148), with which R112 forms a hydrogen bond within a domain I dimer crystal structure, the ability 
of domain I to modulate viral translation is abrogated. Furthermore, we found that this R112A mutation 
appears to impede both the dimerization and RNA binding ability of NS5A domain I.  Adding to these 
results it was found that this R112A mutation was lethal when introduced into a 1b HCV subgenomic 
replicon (SgR). These results suggested a key role for NS5A domain I R112 in potentially modulating viral 
translation and also to an essential role in viral replication, perhaps by modulating a switch between the 
two processes. In this current study we have taken a similar approach to determine the regions and 
residues of domains II and III of NS5A that are involved in the modulation of viral translation by these 
domains. We investigated this first through use of a series of deletion mutants to identify effector regions. 
Amino acid substitutions were then produced within these regions in an effort to map the effect of 
individual residues. Amino acid substitutions that were found to participate in modulating viral translation 
were then cloned back into the full domains to determine their importance in the modulation of viral 
translation by domains II and III. Finally the implicated residues were mutated within a HCV subgenomic 
replicon to determine if viral replication is affected as well.  
 We found that K312 and E446 play important roles in the modulation of viral translation by NS5A 
domains II and III, respectively. When these residues are substituted with alanine in full length domain II 
and domain III fragments they result in a complete loss of this down-regulatory affect. In a domain II-LCS 
II-domain III fragment mutation of K312 again leads to a loss of this modulatory effect whereas the 
concurrent mutation of two residues, E446 and S447, in domain III are required for this affect. However, 
neither the identified domain II or domain III mutations had a significant effect on the replication of a 1b 
SgR either alone or in combination.  
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7.4 Results 
7.4.1 Domain II and III downregulate viral translation though a mechanism requiring the poly-U/UC 
region of the viral 3´-UTR 
 
We first confirmed our previous findings that NS5A domains II and III were capable of modulating 
viral translation independently through a process requiring the poly-U/UC region within the 3´-UTR. Huh7 
cells were co-transfected with a monocistronic RNA HCV reporter and expression plasmids encoding for 
either domain II or domain III (Figure 7.1a). The monocistronic reporter utilized in this study contains the 
viral 5´-UTR, an internal Renilla Luciferase gene and the viral 3´-UTR. Small portions of the core and NS5B 
coding sequences are also included to avoid interfering with the secondary structure found within the 
untranslated regions. A reporter lacking the poly-U/UC region was also utilized to determine the role this 
region plays. As shown in Figure 7.1b the expression of either domain II or domain III independently leads 
to the down-regulation of translation, relative to vector, of the HCV reporter containing the Wt. 3´-UTR. 
Translation of the HCV reporter lacking the poly-U/UC region was unaffected by expression of either NS5A 
domain II or III, confirming the importance of this region in such modulation. These findings are in 
agreement with our previous results. We found that this is effect is specific to IRES-dependent translation. 
Domain II or III had little to no effect on the translation of a cap-dependent translation reporter (Figure 
7.1c). Expression of the domain fragments was confirmed by western blot (Figure 7.1d). The migration of 
domain III was significantly slower than expected from the predicted molecular weight of this fragment. 
However, this observation is consistent with previous observations and attributed to the abundance of 
acidic and proline residues (505, 545) . We also determined that the expression of these NS5A domains 
did not affect cellular viability through use of an MTT assay (Figure 7.1e). We have previously 
demonstrated that both the HCV 5´- and 3´-UTRs are required for modulation by NS5A and that the down-
regulation observed is not a result of changes in RNA levels caused NS5A expression.   
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Figure 7.1 - NS5A domains II and III downregulate HCV translation through a mechanism requiring the 
poly-U/UC region of the 3´-UTR. (a) Diagram of NS5A domain composition. Amphipathic helix (AH), 
individual domains and Low-complexity sequences (LCS) are labelled. Corresponding amino acid residues 
are numbered according to NS5A protein sequence of HCV 1b. (b,c) Huh7 cells were co-transfected with 
either vector, 1b NS5A domain II or domain III expression plasmid and a (b) monocistronic 1b HCV RNA 
luciferase reporter with either the full length 3´-UTR or the Δpoly-U/UC 3´-UTR or a (C) capped luciferase 
RNA reporter. At 24 hr after transfection, luciferase assay was performed. (d) Expression of the domain II 
and domain III fragments was confirmed by western blot using a Myc specific antibody, with β-actin as a 
loading control. (e) Cell viability was determined by MTT assay 24hr. After transfection of either vector, 
domain II or domain III expression plasmids. DMSO treatment was included as a control. Mean of vector 
set to 1. Error bars indicate mean +SD. Statistical differences were indicated as * if p ≤ 0.05, ** if p ≤ 0.01 
relative to vector. 
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7.4.2 NS5A Domain II region aa. 299-346 is sufficient for the down-regulation of viral translation 
 
 To map the region of NS5A domain II required for the translation modulation we constructed an 
initial set of domain II deletion mutants in which the LCSII region was removed along with deletion of 60aa 
from the N-terminus in 30aa segments. Using these domain II deletion mutants in combination with the 
monocistronic HCV RNA reporter described earlier we found that the LCS-II region did not appear to play 
an essential role in modulation of translation and that the  domain II aa. 284-346 fragment lacking first 30 
residues of domain II was still capable of modulating viral translation. However upon deletion of 60 
residues (aa. 314-346 fragment) from the domain II N-terminus this regulatory effect was lost (Figure 
7.2a). Expression of the fragments was confirmed by western blot except for the aa. 314-346 fragment 
which was undetectable despite numerous attempts and varying experimental conditions (Figure 7.2b). 
This was likely due to the difficulties in transferring such small proteins. Despite this issue we moved on 
to delete a further 15 amino acids from the N-terminus of the aa. 284-346 fragment to produce the 
domain II aa. 299-346 fragment. We found that this region was still able to down-regulate viral translation 
of our monocistronic HCV RNA reporter (Figure 7.2c). Expression of this fragment was confirmed by 
western blot (Figure 7.2d). It is interesting to note that this aa. 299-346 region contains the aa. 299-315 
region previously identified to make contact with poly-U RNA (365). When this region is disrupted, as is 
the case with the aa. 314-346 deletion mutant, the effect on HCV translation is lost.  Additionally, this aa. 
299-346 region contains a highly conserved CypA binding site and the interaction between CypA and 
domain II has been shown to enhance the RNA binding ability of domain II (84, 495, 497).  As the poly-
U/UC region is required for the effect of domain II on viral translation this suggest that RNA binding by 
domain II may play a role in this effect. 
 
7.4.3 Residue K312 is involved in the down-regulation of viral translation by NS5A domain II region aa. 
299-346 
 
 To identify residues within this domain II aa. 299-346 that were potentially involved in the 
modulation of viral translation by this region a number of positively charged amino acids within this 
fragment were mutated. These residues are favoured in protein/RNA interactions as they can interact 
with the negatively charged phosphate backbone of RNA. This aa. 299-346 region contained 4 positively 
charged amino acids. These residues, arginine 308, lysine 309, lysine 311 and lysine 312 were substituted  
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Figure 7.2 - NS5A Domain II region aa. 299-346 is sufficient for the down-regulation of viral translation. 
(a, c) Huh7 cells were co-transfected with either vector, 1b NS5A domain II or the indicated domain II 
deletion expression plasmid and a monocistronic 1b HCV RNA luciferase reporter. At 24 hr after 
transfection, luciferase assay was performed. (b, d) Expression of the domain II fragments in (a,c) was 
confirmed by western blot using a Myc specific antibody, with β-actin as a loading control. Approximate 
location of 15 kDa marker band shown. Mean of vector set to 1. Statistical differences were indicated as 
* if p ≤ 0.05, ** if p ≤ 0.01 relative to vector unless otherwise indicated 
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with alanine individually through site directed mutagenesis. The effect of these amino acid substitutions 
on the ability domain II aa. 299-346 to modulate viral translation was then investigated using the 
monocistronic HCV RNA reporter. The domain II aa. 299-346 fragments that contained substitutions of 
residues arginine 308, lysine 309, and lysine 311 with alanines maintained the ability to modulate viral 
translation (Figure 7.3a). However, mutation of lysine 312 (K312) essentially abolished the ability of this 
domain II region to modulate viral translation. The fragment which contained substitutions of all four 
residues behaved in a similar fashion to the K312A mutant.  The expression of the domain II aa. 299-346 
mutant fragments utilized in this experiment were confirmed by western blot (Figure 7.3b). These results 
point to an essential role of K312 in the ability of aa. 299-346 to modulate viral translation. Furthermore, 
all of these positively charged residues are found within the 299-315 region that was found to contact 
poly-U RNA (365). In the same study it was found that when NS5A is bound and cross-linked to poly-U 
RNA the expected trypsin cleavage is blocked at all four of these residues suggesting they interact directly 
with the RNA (365). If the modulation of viral translation observed is in fact due in part to RNA binding 
activity, then these results suggest K312 may play a predominate role in such as interaction.   
 
7.4.4 The K312A mutation negates the ability of NS5A domain II to modulate viral translation but does 
not affect viral replication. 
 
 To confirm the importance of K312 in the modulation of viral translation by NS5A domain II the 
K312A mutation was introduced into the full length domain II fragment. The ability of this fragment to 
modulate viral translation was then compared to that of wild-type domain II. Upon co-transfection with a 
monocistronic HCV RNA reporter we observed that the K312A mutation negates the ability of domain II 
to modulate viral translation (Figure 7.4a). This suggests that this residue is critical for the down-
regulatory effect of domain II on HCV translation. Expression of this K312A domain II mutant was 
confirmed by western blot (Figure 7.4b).  
To investigate possible additional effects of this mutation in the viral lifecycle, the K312A mutation 
was cloned into a HCV sub genomic replicon (SgR). These SgR reporters are composed of the HCV 5´-UTR, 
which directs translation of a Luciferase reporter gene, followed by the IRES of the encephalomyocarditis 
virus, which directs translation of the HCV replicase genes NS3-NS5B, and the 3´-UTR (Figure 7.4c). These 
reporters allow for transient replication assay and the amount of luciferase produced can be measured as 
an indicator of viral replication.  A SgR reporter containing a deletion of the GDD motif within the NS5B 
polymerase was utilized as a negative control as this deletion renders the SgR replication deficient. Upon  
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Figure 7.3 - Residue K312 is involved in the down-regulation of viral translation by NS5A domain II region 
aa. 299-346. (a) Huh7 cells were co-transfected with either vector or a domain II aa. 299-346 expression 
plasmid containing the indicated amino acid substitution and a monocistronic 1b HCV RNA luciferase 
reporter. At 24 hr after transfection, luciferase assay was performed. (b) Expression of the domain II aa. 
299-346 fragments in (a) was confirmed by western blot using a Myc specific antibody, with β-actin as a 
loading control. Mean of vector set to 1. Statistical differences were indicated as * if p ≤ 0.05, ** if p ≤ 
0.01, *** if p≤ 0.001 relative to vector unless otherwise indicated.  
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Figure 7.4 - The K312A mutation negates the ability of NS5A domain II to modulate viral translation but 
does not affect viral replication. (a) Huh7 cells were co-transfected with either vector, wt. NS5A domain 
II or NS5A domain II K312A expression plasmid and a monocistronic 1b HCV RNA luciferase reporter. At 
24 hr after transfection, luciferase assay was performed. (b) Expression of the domain II fragments in (a) 
was confirmed by western blot using a Myc specific antibody, with β-actin as a loading control. (c) Diagram 
of the 1b HCV subgenomic replicon (SgR) utilized, see text for details. (d) Huh 7.5 cells were electroporated 
with the indicated 1b HCV SgR and a capped Luciferase mRNA. The ΔGDD mutation within the viral NS5B 
polymerase renderers the SgR replication deficient. Cells were harvested at the indicated time points and 
luciferase assay performed. Values were normalized to 4hr time point and protein concentration as 
determined by BCA assay. Statistical differences were indicated as * if p ≤ 0.05, ** if p ≤ 0.01 relative to 
vector/wildtype unless otherwise indicated. Error bars in panel (d) are not visible at this scale. 
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electroporation into Huh 7.5 cells we found that the K312A mutation within NS5A domain II had no 
significant effect on viral replication throughout the 96h time course (Figure 7.4d). So while K312 appears 
to play an essential role in the modulation of viral translation by NS5A domain II, possibly by mediating 
interaction with the poly-U/UC region within the viral 3´-UTR, it does not have an effect on viral replication 
in the context of full length NS5A within a subgenomic replicon. 
 
7.4.5 Residues G445A, E446A and S447A are involved in the down-regulation of viral translation by NS5A 
domain III region aa. 420-451 
 
 Using the same approach used to identify K312 within domain II, we attempted to identify 
potential regions and residues involved in the modulation of viral translation by NS5A domain III.  An initial 
set of domain III deletion mutants were produced in which 60 amino acids were removed from the N-
terminus of domain III in 30 aa segments. Using these deletion mutants in combination with the 
monocistronic HCV RNA reporter we found that domain III aa. 420-451 was sufficient for modulating viral 
translation (Figure 7.5a). Oddly, the aa. 390-451 fragment was unable to modulate viral translation, 
suggesting that the region aa.390-420 may somehow interfere with the function of the aa. 420-451 region. 
Expression of the domain III deletion mutants was confirmed by Western blot (Figure 7.5b). The band 
observed for the aa. 420-451 deletion mutant was significantly less intense than for domain III and the aa. 
390-451 deletion mutant. Although this could be due to lower expression this fragment behaved in a 
similar fashion to domain III in the translation assay.  
Utilizing this domain III aa. 420-451 fragment, we cloned a series of alanine scanning mutants in 
which we progressively mutated three amino acids at a time within this region to alanine. This approach 
was taken as this region contained no positively charged amino acids that could potentially be involved in 
the RNA binding activity of domain III. Domain III was found to bind to the 3´-UTR relatively weakly 
compared to domains I and II and regions involved in such an interaction remain to be defined (363). The 
ability of this set of domain III aa. 410-451 alanine scanning mutants to modulate HCV translation was 
examined in co-transfection experiments with the monocistronic HCV RNA reporter (Figure 7.5c). In this 
experiment one fragment, domain II aa. 420-451 containing alanine substitutions at glycine 445 (G445A), 
glutamic acid 446 (E446A), serine 447 (S447A), lost the ability to modulate viral translation. Expression of 
the alanine scanning mutants was confirmed by western blot (Figure 7.5d). Next, these amino acid 
substitutions were cloned into the domain III aa. 420-451 fragment individually to determine the role of 
each residue in the modulation of viral translation by this region. In a co-transfection experiment the  
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Figure 7.5 - Residues G445A, E446A and S447A play a role in the down-regulation of viral translation by 
NS5A domain III region aa. 420-451. (A, C, E) Huh7 cells were co-transfected with either plasmid vector 
or the indicated domain III deletion and/or amino acid substitution mutant expression plasmid and a 
monocistronic 1b HCV RNA luciferase reporter. At 24 hr after transfection, luciferase assay was 
performed. (b,d,f) Expression of the domain III deletion mutant fragments in (a, c, e) was confirmed by 
western blot using a Myc specific antibody. Mean of vector set to 1. Statistical differences were indicated 
as * if p ≤ 0.05, ** if p ≤ 0.01 relative to vector unless otherwise indicated. 
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E446A mutation was found to have the greatest effect, leading to a loss of a significant down-regulatory 
effect on viral translation (Figure 7.5e). Both the G445A and S447A mutants still lead to a significant 
decreases in translation levels compared to vector but to a statistically significant lower degree than the 
wild-type domain III aa 420-451 fragment suggesting this residues may play a smaller role in this effect 
than E446A. Expression of these domain III aa. 420-451 fragments was confirmed by Western blot (Figure 
7.5f). 
 
7.4.6 The E446A mutation negates the ability of NS5A domain III to modulate viral translation 
 
To investigate the role of the E446 and S447 residues within the context of domain III, the E446A 
and S447A mutations were introduced into a full domain III fragment. When these domain IIII mutants 
were co-transfected with a monocistronic HCV RNA reporter, we found that double domain III E446A 
S447A mutant leads to a loss of the translational regulatory effect (Figure 7.6a). When mutated 
individually, the E446A mutation also resulted in the loss of this modulatory effect (Figure 7.6c). The 
S447A mutation, on the other hand, appeared to have no effect on this function. (Figure 7.6c). These 
results confirm the importance of the E446 residue in the modulation of translation by domain III. 
Expression of the domain III mutants was confirmed by western blot (Figures 7.6b and 7.6d). The fact that 
the modulation of translation by domain III is dependent upon E446, a negatively charged amino acid, 
suggests that this effect may not be the result of domain III binding to the viral RNA. However, due to the 
ability of this region to adopt transient structure this possibility cannot be completely excluded.   
To determine if this E446A mutation had an effect on viral replication, this mutation was cloned into a 1b 
N SgR, as was done for domain II. The S447A mutation was investigated as well since it was identified as 
playing a role in the modulation of viral translation within the domain III aa. 420-451 deletion mutant. We 
did not expect these mutations to have a dramatic effect on viral replication since others have shown that 
NS5A domain III is largely dispensable for RNA replication. However, deletion of portions of NS5A domain 
III have been found to lead to a delay in viral replication in the JFH-1 genotype suggesting domain III may 
play a small role in establishment of the RNA replication at early time-points (419).  As expected, within 
the context of full length NS5A in the SgR, neither the E446A nor S447A mutations alone or in combination 
had a significant effect on viral replication at any of the time-points (Figure 7.6e). How the E446A mutation 
affects the ability of domain III to modulate viral translation is unclear at this point but potential 
mechanisms include reduced RNA binding ability, an effect on an interaction between cellular proteins 
and domain III required for this effect, a shift in potentially required transient structure in this region or a  
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Figure 7.6 - The E446A mutation negates the ability of NS5A domain III to modulate viral translation. (a, 
c) Huh7 cells were co-transfected with either vector, wt. NS5A domain III or the indicated NS5A domain 
III amino acid substitution expression plasmid and a monocistronic 1b HCV RNA luciferase reporter. At 24 
hr after transfection, luciferase assay was performed. (b, d) Expression of the domain II fragments in (a, 
c) were confirmed by western blot using a Myc specific antibody, with β-actin as a loading control. (e) Huh 
7.5 cells were electroporated with the indicated 1b HCV SgR and a capped Luciferase mRNA. The ΔGDD 
mutation within the viral NS5B polymerase renderers the SgR replication deficient. Cells were harvested 
at the indicated time points and luciferase assay performed. Values were normalized to 4hr time point 
and protein concentration as determined by BCA assay. Mean of vector set to 1. Statistical differences 
were indicated as * if p ≤ 0.05, ** if p ≤ 0.01 relative to vector unless otherwise indicated. Some error bars 
in panel (e) not visible at this scale.  
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combination of any of these possibilities.  
 
7.4.7  Mutation of K312 alone or E446 and S447 together abrogates the ability of the NS5A domain II-
LCS II-Domain III fragment to modulate viral translation 
 
 To further investigate residues implicated in the modulation of viral translation by NS5A domains 
II and III, these mutations were introduced into a domain II-LCS II-domain III fragment. In addition to the 
K312A and E446A mutations, within domains II and III respectively, we also included S447A, even though 
it appeared not to play a role in the effect of domain III, given the importance of other nearby serine 
residues in modulating viral assembly. The effect of these mutations on the ability of this domain II/IIII 
fragment to modulate viral translation was determined in co-transfection experiments using the 
monocistronic HCV RNA reporter. As shown in Figure 7.7a the K312A mutation within domain II leads to 
a complete loss of modulatory effect on translation by this domain II-LCS II-domain III fragment whereas 
the E446A and S447A mutations within domain III do not have an effect. These results suggest that domain 
II is more dominant in modulation of viral translation by this domain II-LCS II-domain III fragment. The 
fragment that contains the K312A S447A double mutation also leads to a significant loss of this modulatory 
effect compared to Wt. but not to the same extent as the K312A mutant. The reasons for this are unclear 
at this time.  It was also observed that the K312A E446A double mutant leads to a significant reduction in 
the modulatory effect on viral translation compared to Wt. domain II-LCS II-domain III fragment but still 
displays a slight, but statistically significant, down-regulatory effect (Figure 7.7c). The E446A S447A double 
mutant leads to a complete loss of modulatory effect by this fragment, which is interesting and 
unexpected as the S447A mutation did not have an effect on the modulation of viral translation by domain 
III individually.  Finally, expression of the triple domain II-LCS II-domain III K312A, E446A, S447A mutant 
also had no effect on viral translation which is not surprising given the above results. Expression of the 
domain II-LCS II-domain III fragments was confirmed by western blot (Figures 7.7b and 7.7d). As done for 
domains II and III we investigated a combination of these mutations within both domains on the 
replication of the 1b SgR.  Neither the double, K312A/E446A, nor triple, K312A/E446A/S447A, mutations 
had an adverse effect on the replicative capacity of the HCV SGR (Figure 7.7e). In fact a relatively small 
but statistically significant enhancement of viral replication, compared to the wild type SgR, was observed 
for the triple mutant at the 72 hour time-point and for both the double and triple mutant at the 96 hour 
time-point.  The mechanisms behind this and the possible biological relevance are unknown.  
 
  
126 
 
 
 
Figure 7.7 - Mutation of K312 alone or E446 and S447 together abrogates the ability of the NS5A domain 
II-LCS II-Domain III fragment to modulate viral translation. (a, c) Huh7 cells were co-transfected with 
either vector, wt. NS5A domain II-LCS II-domain III or the indicated NS5A domain II-LCS II-domain III amino 
acid substitution mutant expression plasmid and a monocistronic 1b HCV RNA luciferase reporter. At 24 
hr after transfection, luciferase assay was performed.  (b, d) Expression of the NS5A domain II-LCS II-
domain III in (a, c) were confirmed by western blot using a Myc specific antibody, with β-actin as a loading 
control. (e) Huh 7.5 cells were electroporated with the indicated 1b HCV SgR and a capped Luciferase 
mRNA. The ΔGDD mutation within the viral NS5B polymerase renderers the SgR replication deficient. Cells 
were harvested at the indicated time points and luciferase assay performed. Values were normalized to 
4hr time point and protein concentration as determined by BCA assay. Mean of vector set to 1. Statistical 
differences were indicated as * if p ≤ 0.05, ** if p ≤ 0.01 relative to vector unless otherwise indicated. 
Error bars in panel (e) are not visible at this scale 
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7.5 Discussion 
 
We have previously demonstrated that NS5A down-regulates viral translation in a dose-
dependent manner through a mechanism requiring the poly-U/UC region within the viral 3´-UTR. We have 
also demonstrated that NS5A binds to this poly-U/UC region (chapter 3). Furthermore, each of the three 
NS5A domains retained this modulatory function individually. While this redundancy is somewhat 
surprising, it is not completely unexpected. Each domain maintains RNA binding capability (363). How 
NS5A interaction with the 3´-UTR may function to down-regulate translation is unclear at this point as is 
the mechanism behind 3´-UTR stimulation of IRES mediated translation.  Potential mechanisms include 
binding to viral or host factors involved in circularization of the genome, long range interactions between 
the IRES and 3´-UTR, or the retention and recycling of ribosomes between the 3´-UTR and IRES (19, 218). 
It is conceivable that NS5A binding to the poly-U/UC region may interfere with such functions, thereby 
downregulating viral translation and possibly mediating the switch between translation and replication. 
In a study focusing the on the mechanism of this down-regulatory effect by domain I, we identified R112 
as residue critical in this effect (chapter 5). Substitution of this R112 residue with alanine was found to 
negate the effect of domain I on viral translation, impair the dimerization of domain I and reduce the RNA 
binding ability of this domain. Additionally, viral replication was inhibited when this R112A mutation was 
introduced into a 1b HCV SgR. These findings suggested an essential role for R112 in key functions of 
domain I in the viral lifecycle and lend credence to the biological relevance of the domain I dimer 
crystalized by Love et al. (482). In this study we sought to extend our initial findings and further investigate 
the modulation of viral translation by NS5A domains II and III. 
Through the use of a set of domain II deletion mutants we first identified domain II aa. 299-346 
as sufficient for the modulation of viral translation by domain II. This region contains the aa. 299-315 
region that was previously found, along with a second region aa. 267-275 to make contact with poly-U 
RNA (365). Furthermore, this aa. 299-346 region contains a highly conserved CypA binding site, an 
interaction essential for viral replication. Binding of CypA to domain II results in structural change within 
this domain and also stimulate domain II RNA binding (84, 501).  As we determined that the poly-U/UC 
region within the 3´-UTR is required for the modulation of viral translation by domain II, we considered 
that the mechanism might involve RNA binding. To investigate this possibility positively charged amino 
acids, which are favorable in protein/RNA interactions, were mutated within this aa. 299-346 region. We 
observed that the substitution of a lysine residue at position 312 (K312) with alanine negated the ability 
of this region to modulate viral translation. When this K312A mutation was introduced into a full length 
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domain II fragment, the ability to modulate viral translation was lost. This finding suggests that K312 
participates in some function required for the modulation of translation by domain II. K312 is found within 
the aa. 299-315 region that makes contact with poly-U RNA (365). RNA cross-linking studies show that the 
expected trypsin cleavage is blocked at this residue suggesting a direct interaction with the RNA (365). 
Other residues corresponding to those at which trypsin cleavage is blocked, R308, K309 and K311A were 
also mutated in this study but had little to no effect on the modulation of translation by this region 
suggesting that K312 may play a predominant role in potential RNA binding (365).  
This K312 residue also corresponds to the very N-terminal residue of the region thought to 
interact with CypA (495). However, the K312A mutation does not affect viral replication when introduced 
into the 1b HCV SgR whereas the interaction between NS5A and CypA is essential for viral replication. It 
is therefore unlikely that the K312A mutation has a negative impact on the interaction of CypA with 
domain II. CypA binding has been shown to enhance the RNA binding ability of this domain (84). However, 
the cyclosporine A (CsA) resistance mutation that exhibits CypA independence for viral replication does 
not exhibit enhanced RNA binding (84). This observation raises the question as to whether the enhanced 
RNA binding is essential to the role of CypA in modulating viral replication. Therefore this enhanced RNA 
binding activity of domain II stimulated by CypA may possibly play a role in the modulation of viral 
translation by domain II and the K312A mutation may interfere with this function. The effect of this K312 
mutation on the RNA binding ability of domain II and interaction with CypA and subsequent enhanced 
binding currently remain unanswered. 
 In addition to CypA, NS5A has been found to interact with a vast array of host proteins, many 
involving domain II. Furthermore, domain II has been found to contain two regions, aa. 255-270 and aa. 
301-310 (1b N protein numbering), which transiently adopt α-helical structures (493). Such transient 
structures may play a role in the recognition of binding partners, accordingly, an interaction between the 
cellular tumour suppressor Bin1 with a region including the aa.301-310 α-helix has been observed (493). 
The effect of this interaction on the viral lifecycle is unclear but regions affected by Bin1 binding extend 
significantly outside the boundaries of this transient helix, which is suggestive of changes to the local 
structure or additional contacts with Bin1 (493). This aa.301-310 transient α-helical structure is found with 
the domain II aa. 299-346 fragment and is directly N –terminal to the K312A mutation. It is thus plausible 
that this K312A mutation may affect protein interactions that function to modulate viral translation.  
In regards to domain III, which has an essential role in viral assembly, we found that a relatively 
small region, aa.420-451, was sufficient for its modulation of viral translation. Translation modulation by 
NS5A domain III requires the poly-U/UC region within the viral 3´-UTR. Domain III has also been observed 
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to possess RNA binding affinity towards this poly-U/UC region, although relatively weak compared to 
domain I and II (363). Therefore, we speculated that RNA binding may represent a mechanism for the 
observed effect (363). However, this aa.420-451 region contained no positively charged RNA residues 
suggesting an alternative mechanism may be responsible. Through alanine scanning within this aa. 420-
451 region we identified two mutations, E446A and S447A which significantly affected its ability to 
modulate viral translation. A third mutation G445A was also identified, but had a less predominant effect. 
Upon insertion into a full domain III fragment, the E446A mutation resulted in a complete loss of this 
domains modulatory function on viral translation whereas the S447A had no observable effect. Although 
this E446 residue appears to play an essential role in the modulation of viral translation the E446A 
mutation did not have any effect upon viral replication when inserted into NS5A within the 1b HCV SgR.  
This result is not surprising. Previous studies have shown that NS5A domain III is dispensable for viral 
replication (419, 454). The mechanism of the modulatory effect and the role that E446 may play in it 
remain unclear. The regions of NS5A domain III that are involved in its binding the poly-U/UC region of 
the viral 3´-UTR remain undefined. Despite the reasons discussed above, this aa. 420-451 may perhaps 
contains novel RNA binding activity and E446A may play a role in such an interaction.  
 Domain III, which is globally unfolded, has been found to adopt regions of transient secondary 
structure. Two regions within domain III, aa. 364-379 and aa.446-449, have been observed to transiently 
form α-helical structure within Con1 (also genotype 1b) (505).  Notably this second helical region is found 
within the domain III aa.420-451 fragment that is sufficient for modulation of viral translation and contains 
the E446A residue that is essential for this function. The S447A mutation, which did not affect translation 
modulation by domain III, is the only residue not conserved between Con 1 and N subtypes within this 
transient helical region. Transient structures such as these α-helices may be essential for interaction with 
cellular proteins involved in the HCV lifecycle. CypA, which has an essential interaction with domain II, has 
also been found to interact with domain III in a region just N-terminal to this transient α-helical structure 
(505). A CsA resistance mutation, corresponding to V449A (1b N numbering), has been observed in this 
region (505). CypA has also been found to possess in vitro isomerase activity towards this C-terminal 
region of domain III, resulting in structural modifications with potential functional consequences (505). 
Therefore, the E446A mutation identified in this study could potentially interfere with the formation or 
function of this region of transient structure resulting in a disruption of protein interactions that modulate 
viral translation.   
In a final set of experiments, we investigated the effects of the mutations identified within domain 
II and III in the context of a domain II-LCS II-domain III fragment. This fragment retained the ability to 
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down-regulate viral translation. The single mutation K312A within domain II resulted in the loss of this 
modulatory function. On the other hand, the E446A mutation within domain III had no effect on the 
modulatory ability of this fragment. These results suggest that domain II may play a predominate role in 
this modulation of translation and can compensate for any loss of function caused by the E446A mutation 
in domain III.  However, the domain II-LCS II-domain III mutant containing the double mutation 
E446A/S447A within domain III also nullified the effect of this fragment on viral translation. The 
involvement of S447A mutation was surprising. Whereas this mutation was implicated in this function of 
domain II aa. 420-451, it did not have a significant effect when cloned into the full domain III. Furthermore, 
when this S447A mutation was cloned into the domain II-LCS II-domain III fragment in combination with 
the K312A mutation, the ability of this fragment to modulate viral translation is significantly reduced, but 
to a lower extent than seen with the K312A mutation alone. The reasons for these conflicting finding are 
unknown but could include alterations of transient structures or interactions between domains II and III 
within this fragment that affect either the RNA binding ability of this fragment or protein interactions 
required for the observed effect on viral translation. A number of other serine residues within C-terminal 
region of domain III have been implicated in NS5A basal phosphorylation and viral assembly. It would be 
interesting to examine the phosphorylation status of serine 447 and determine if this plays a role in these 
observations (419, 420, 452).  
At first, it seems unusual that such a wide array of functions and protein interactions have been 
attributed to NS5A domains II and III. Both of these regions are natively unstructured. However this is a 
trait shared by numerous cellular proteins often referred to as intrinsically disordered proteins (IDPs), 
such as p53 and BRAC1 (507, 508). Such IDPs are very abundant within the cell and often function as 
signalling and regulatory hubs as they exhibit extraordinary binding promiscuity (508). IDPs often adopt 
transient structured elements that are utilized to carry out functions (508). These characteristics have 
been also described for domains II and III of NS5A, which are thought to function as complex molecular 
interaction platforms (362, 493). Structural changes within IDPs can be induced by interactions with 
nucleic acids, other proteins, membranes, or post-translational modifications such as phosphorylation 
(508). As discussed, the mutations identified within this study are found within or adjacent to regions of 
transient structure and thus might result in structural changes or the shifting of isomer populations to 
favour one confirmation over the other thereby interfering with function. 
In this study, we have identified residues, K312 in domain II and E446 in domain III, which are 
essential for the downregulatory effect of these domains on viral translation. It will be interesting to 
determine if these mutations affect RNA binding or protein interactions of these domains and if the 
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alteration of transient functional structure is involved in this effect. Efforts to answer some of these 
intriguing questions are currently on going in our lab.  
 
7.6 Materials and Methods 
7.6.1 Plasmid construction and RNA synthesis 
 
The monocistronic HCV RNA translation reporter plasmid T7 HCV 5´-UTR-Coreaa1-16-rLuc-NS5B5-3´-
UTR of genotype 1b was described previously (BH et al., submitted for publication). This reporter contains 
T7 promoter, HCV 5´-UTR, sequence encoding the first 16 amino acids of the Core protein, an internal 
Renilla luciferase (rLuc) gene, sequence encoding the last five amino acids of the NS5B protein and the 3´-
UTR. The 5´-UTR contains the viral IRES which drives the expression of the internal Renilla luciferase gene. 
In other two constructs, the poly-U/UC region in the 3´-UTR or the entire 3´-UTR with the coding sequence 
for the last five amino acids of the NS5B were cloned downstream of the T7 promoter sequence. HCV 
subgenomic replicon (SgR) is composed of the HCV 5´-UTR, which directs translation of a luciferase 
reporter gene, followed by the IRES of the encephalomyocarditis virus (EMCV), which directs translation 
of the HCV replicase genes NS3-NS5B, and the 3´-UTR (Fig. 8a) (558). The SgR reporter allows for transient 
replication assay as the amount of luciferase produced can be measured as an indicator of viral replication 
(559). As a negative control, the GDD sequence within the NS5B viral polymerase was deleted which 
rendered replication deficient. Plasmids expressing HCV NS5A with or without the amphipathic α-helix 
(AH) were reported previously (chapter 3). Coding sequences for NS5A domain II with or without LCS II 
and NS5A domain III were amplified by PCR using HCV-1b N Neo C-5B (540) as template and cloned into 
pEF/cyto/myc vector (Invitrogen/Life Technologies). NS5A domain II and domain III truncations were 
constructed by a PCR-based approach. Amino acid substitution mutants in the expression plasmid or SgR 
were generated by site-directed mutagenesis. For all constructs a myc tag was added to the C-termini. All 
plasmids were confirmed by DNA sequencing. HCV RNA translation reporter and SgR RNAs were produced 
from linearized plasmids by in vitro transcription using the MEGAscript T7 In Vitro Transcription kit 
(Ambion). 
 
7.6.2 Cell lines, transfections, HCV transient replication and luciferase assay 
 
See methods described in section 5.6.2 
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7.6.3 SDS-PAGE and Western blot 
 
See methods described in section 5.6.3 
 
7.6.4 MTT assay 
 
See methods described in section 3.6.4 
 
7.6.5 Statistical analysis 
 
See methods described in section 5.6.7 
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8.0 GENERAL DISCUSSION AND CONCLUSION 
8.1 General Discussion 
 
NS5A appears to be involved in nearly every aspect of the viral lifecycle and performs essential 
functions in both viral replication and assembly. We thus set out to determine how this protein is involved 
in the regulation of viral translation. We hypothesized that NS5A would modulate viral translation due to 
its interactions with both the 5´- and 3´-UTRs (363-365). In addition, we aimed at mapping the regions of 
NS5A responsible for translation modulation in an effort to elucidate the potential mechanism.  NS5A is 
an important antiviral drug target and the further characterization of its roles in the viral lifecycle could 
facilitate the design of future treatments targeting the multiple functions of NS5A. 
In chapter 3, we determined that NS5A down-regulates HCV IRES-mediated translation in a dose-
dependent manner through a mechanism that requires the presence of the poly-U/UC region of the 3´-
UTR. In addition to our monocistronic HCV RNA reporter, this down-regulatory effect was also observed 
in the full-length viral genome upon expression of additional NS5A in trans and was again dependent upon 
the presence of the poly-U/UC region. The effect was specific to HCV translation and required the 
presence of both the HCV 5´- and 3´-UTRs. We and others have shown that NS5A binds to the poly-U/UC 
region, our results thus suggest that such binding may modulate viral translation. How the interaction 
between NS5A and the poly-U/UC region could modulate HCV translation remains unclear. The poly-U/UC 
region is proposed to act as a molecular interaction platform for the recruitment of host and viral proteins 
that modulate both viral translation and replication (212-215). As the amount of NS5A produced increases 
after multiple rounds of translation, binding within the poly-U/UC region could potentially interfere with 
the enhancement of viral translation by the 3´-UTR. 
In Classical Swine Fever virus (CSFV), which also belongs to the Flaviviridae family but within a 
different genus (Pestivirus), NS5A has also been found to downregulate IRES mediated translation in a 
dose dependent manner (564, 565). However, this effect was proposed to be dependent upon a potential 
interaction with the 5´-UTR rather than the 3´-UTR, as we have observed for HCV NS5A (564, 565). 
Nonetheless, this finding suggests that the down-regulation of viral translation by NS5A may be a 
conserved mechanism. Despite sharing only approximately 17% amino acid identity, a number of 
additional functions have been found to be conserved between the CSFV and HCV NS5A proteins. Both 
perform essential functions within the viral replication complex and during virion assembly (26, 566, 567). 
A number of serine residues within the C-terminal region of CSFV NS5A play an essential role in viral 
assembly, very similar to what has been observed for HCV (452, 565). Furthermore, NS5A from both 
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viruses interacts with numerous host proteins. Both interact with heat shock protein 70 and annexin A2 
(425, 568-570). The interaction between NS5A and heat shock protein 70 is proposed to function during 
viral replication whereas the interaction with annexin A2 is involved in modulating viral assembly in both 
CSFV and HCV (425, 568-570). Other similarities include that both interact with and stimulate the viral 
polymerase, both localize to the ER membrane, and both are extensively phosphorylated (366, 571-574).  
One question that arises when considering our observations is why a virus would encode a protein 
that functions to downregulate its own translation? HCV, like all viruses, which poses a positive sense RNA 
genome, utilizes its genome for both translation and replication (575-577). After successive rounds of viral 
translation and polyprotein processing, the increasing accumulation of viral proteins involved in viral 
replication leads to massive rearrangements of intracellular membranes and the formation of the 
replication complex (576). However, viral RNA templates being actively translated cannot undergo 
replication due to the opposing direction in which these processes occur (576, 577). Translation begins at 
the start codon at the 5´- end of the viral genome and the ribosome proceeds down the genome in the 
5´- to 3´ direction. Replication is initiated at the 3´ end of the genome and the viral polymerase proceeds 
down the genome in the 3´to 5´- direction. Therefore, there must be a mechanism in place to switch from 
translation to replication once the necessary quantity of viral proteins has been produced. Such a 
transition would also serve prevent the continued accumulation of viral proteins which could potentially 
be cytotoxic to the infected cell (234). How this switch between stages in the viral lifecycle occurs remains 
unclear for many viruses. However, for poliovirus one mechanism involved in this switch has been well 
characterized.  
Poliovirus (PV), like HCV, is a single stranded positive sense RNA virus that translates it genome 
through use of an IRES to produce a polyprotein (576). Although structurally different than that of HCV, 
the PV 5´-UTR is similarly highly structured and contains six stem loops with stem-loops II to VI comprising 
the IRES (576).  Much like HCV, both canonical and non-canonical cellular translation factors aid in the 
initiation of translation. One of the cellular factors which plays a key role in this process is the poly(rC) 
binding protein 2 (PCBP2) (576). PCBP2 binds to stem-loop IV of the poliovirus IRES and forms a 
ribonucleoprotein complex which stimulates translation, possibly through recruitment of ribosomes (576, 
578-580). Furthermore, PCBP2 also binds to stem-loop I of the 5´-UTR from where it can interact with 
poly(A) binding protein (PABP) which is bound to the PV 3´-poly-A tail (576, 579, 581). This interaction also 
functions to stimulate viral translation, potentially by circularizing the genome to facilitate ribosome 
recycling (576, 581). However, the interaction between PCBP2 and stem-loop I of the 5´-UTR is also 
required for viral replication where it functions in the initiation of negative strand synthesis (576, 580). 
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PCBP2 contains three hnRNP K homologous (KH) domains, which are common in RNA binding proteins 
(582). KH3 is necessary for binding to stem-loop IV within the IRES (582). Following PV translation and 
processing of the viral polyprotein, the viral 3CD proteinase cleaves PCBP2, removing the KH3 domain 
(576, 580). This cleaved PCBP2 can no longer bind to stem-loop IV of IRES (576, 580, 582). As a result PV 
translation is inhibited by the loss PCBP2 binding, potentially due to the disruption of ribosome 
recruitment (576, 580). Furthermore, the viral proteinase has also been found to cleave PABP, disrupting 
the interaction between the two UTRs and contributing to the inhibition of PV translation and the 
clearance of ribosomes from the viral genome (581). However, cleaved PCBP2 retains the ability to bind 
to stem-loop I and perform an essential function in RNA replication (576, 580). It was additionally found 
that Inhibition of PCBP2 and PABP cleavage impairs viral replication (576, 581). Therefore these findings 
strongly suggest that the viral protease cleaves cellular ITAFs altering their interaction with the 5´- and 3´-
UTRs in order to promote the switch from translation to replication. 
For HCV, the molecular mechanisms that may mediate the transition from viral translation to 
genome replication remain unclear. One study has implicated viral NS3 protease mediated cleavage of La 
autoantigen in this process (234). Multiple cellular factors which are implicated in both viral translation 
and replication have been proposed to be involved, including miR-122 and hnRNP L and D (225-228, 234). 
It is also highly likely that the 3´-UTR of HCV is involved in this process in that it is involved in regulating 
both translation and replication (577). The mechanism whereby the 3´-UTR modulates viral translation 
remains unclear but may involve long-range RNA-RNA interactions between the 5´- and 3´-UTRs, the 
binding of cellular factors which function to enhance translation and/or ribosome recycling (19, 218). 
Conceivably, the binding of NS5A within the poly-U/UC region could disrupt the stimulation of viral 
translation by the 3´-UTR by interfering with these mechanisms. Therefore the switch between viral 
translation and replication could result from the combined efforts of multiple viral factors such as NS3 
functioning at the IRES to remove La autoantigen while NS5A functions at the 3´-UTR. This process would 
be similar to the situation in PV where the viral 3CD proteinase cleaves translation enhancing factors at 
both end of the viral genome.  
The cellular factors shown to bind within the poly-U/UC and stimulate viral translation include 
HuR, LSm1-7 and IGF2BP1 (216, 217, 231). Interestingly, LSm1-7 and IGF2BP1 also bind within the 5´-UTR 
to IRES stem-loops II and IV, respectively (216, 227). These proteins also interact with other factors such 
as hnRNP D and La autoantigen, which bind within the 5´-UTR and function to stimulate viral translation 
(15). IGFBP2 is also capable of self-interaction (231). This interaction network suggests that these factors 
are involved in an interaction between the 5´- and 3´-UTRs that functions to stimulate viral translation 
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possibly through recruitment of additional translation factors or the recycling of ribosomes. It is therefore 
possible that as concentrations of NS5A increase after successive rounds of translation, factors favouring 
viral translation are displaced from the poly-U/UC region by NS5A. Preliminary results obtained in our lab, 
which are not presented in this thesis, are consistent with such a model. We observed that the expression 
of IGF2BP1 stimulates viral translation, dependent on presence of the poly-U/UC region. When NS5A and 
IGF2BP1 are co-expressed, however, the down-regulatory effect of NS5A dominants. Experiments such as 
these will be continued in our lab in an effort to investigate this potential mechanism. 
NS5A has also been found to interact with a number of host proteins that bind to the viral genome 
and function to stimulate viral replication, including the FUSE binding protein (FBP), NF90, PCBP2 and the 
dual functioning hnRNP L (227, 382, 583). The mechanisms behind the stimulation of viral replication by 
these factors remains to be determined. FBP was found to interact with NS5A and bind to the poly-U/UC 
region (382). Overexpression of FBP results in stimulation of replication and inhibition of viral translation 
suggesting a role in the switch between the two (382). PCBP2 binds to both the stem-loop I in the 5´-UTR, 
similar to its role in PV replication, and the poly-U/UC region within the 3´-UTR (227, 583). It is also 
involved in stimulating viral replication (227, 583). PCBP2 is implicated in modulating viral translation. It 
can interact within domain IV of the IRES but its role in modulating viral translation remains unclear (15, 
583). Stem-loop I within the 5´-UTR is essential for viral replication, through unknown functions, and NS5A 
is also speculated to interact with this stem-loop (364). Both hnRNP L and NF 90 bind both the 3´-UTR and 
within the 5´-UTR upstream of the IRES (227). NS5A also interacts with the NS5B polymerase and 
stimulates its polymerase activity (366, 573, 584). Furthermore, this interaction has been implicated in 
recruitment of NS5B to the viral 3´-UTR in in vitro replication experiments (366, 573, 584). Therefore, 
NS5A interacts with a set of proteins which function to promote viral replication and bind to both the 5´- 
and 3´-UTRs and could potentially be involved in the circularization of the genome in a fashion that favours 
replication similar to other positive sense RNA viruses (585, 586).  
Given the number of host proteins that bind to the poly-U/UC region and participate in either viral 
translation or replication, one function of NS5A binding to the poly-U/UC region may be to coordinate 
these interactions. As the concentration of NS5A increases, it may function to displace a set of cellular 
factors which function in stimulating viral translation and recruit a different set of host proteins involved 
in modulating viral replication. To investigate this potential mechanism, a number of different 
experimental approaches could be followed, for example, RNA binding competitions and RNA pull-down 
experiments similar to those performed by Li et al. and Nag et al. in the presence and absence of NS5A 
(227, 587). Additionally, iCLIP (individual-nucleotide resolution UV crosslinking and immunoprecipitation) 
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could be utilized to investigate how different levels of NS5A expression affect the binding patterns of host 
proteins which function to enhance viral translation, similar to the approach used by Flynn et al. to study 
the binding of PCBP2 and HCV RNA (588). The results from experiments such as these could provide an 
insight into the mechanism of the modulation of viral translation by NS5A and how it affects the RNA 
binding activity of cellular proteins.  
Additionally, the effect NS5A on ribosome recycling, one potential mechanism of translational 
enhancement by the 3´-UTR, should also be investigated in future studies. The effect of NS5A on the ability 
of the 3´-UTR to bind the 40S ribosome could be accomplished using an RNA binding competition assay.  
In a study by Bai et al., a system in which luciferase activity was measured in situ over the course of an in 
vitro translation reaction was utilized to demonstrate that the 3´-UTR does not affect the rate of a single 
round translation but does function to enhance subsequent rounds of translation (218). In vitro produced 
and purified NS5A could be added to this system to determine the effect on ribosome recycling. 
Furthermore, the effect of NS5A on the formation of polysomes in in vitro translation reactions could be 
investigated as ribosome recycling by the 3´-UTR has been shown to significantly enhance polysome 
formation (218).  
The 3´-UTR has also been found to influence the folding of the IRES through direct RNA-RNA 
interactions and likewise the 5´-UTR influences the structure of the 3´-UTR (197, 198). Such modulation 
may regulate viral translation and replication and may perhaps play a role in the transition between the 
two processes (197, 198).  However, this structural modification has only been shown in the absence of 
proteins. It would be interesting to evaluate the effect of NS5A’s interaction with the poly-U/UC region 
on such interactions. This could be accomplished by utilizing SHAPE (selective 2′-hydroxyl acylation 
analyzed by primer extension) assays in the presence of NS5A. 
Having established that NS5A functions to downregulate viral translation we then set out to figure 
out which region(s) were responsible for this effect. We found that each of the three NS5A domains were 
able to carry out this effect individually, again requiring the poly-U/UC region. Although surprising, this 
result was not completely unexpected as each domain has been shown to possess RNA binding activity 
towards the poly-U/UC region (363). Based on these results, we aimed to map the regions within each of 
the three NS5A domains responsible for this modulatory effect using a series of deletion mutants and 
amino acid substitutions.  
In chapter 4 we focused on NS5A domain I that performs multiple essential functions in viral 
replication and is proposed to be the main driver of NS5As RNA binding activity. Domain I also mediates 
the dimerization of NS5A which is thought to be involved in both RNA binding activity and viral replication. 
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However, the functions of a domain I dimer remain unclear due to the isolation of 4 different crystal 
structures (479, 481, 482). It is possible that all of the dimer structures are physiologically relevant and 
perform different functions within the viral lifecycle. Alternatively, NS5A may form a large multimeric 
complex.  In this chapter we determined that the domain I region aa. 101-161 was sufficient for the down-
regulation of viral translation by NS5A domain I. Interestingly, this region contained the majority of the 
contact interfaces of the domain I dimers identified by both Lambert et al. and Love et al. A number of 
positively charged amino acids within this aa. 101-161 region were implicated in the modulatory effect. 
The mutation of K108, K139, R157 or R160, to alanine partially disrupted the ability of domain I to 
modulate viral translation. However, mutation of R112 to alanine led to a complete loss of this regulatory 
function.  This R112 residue is within the contact interface of the Love et al. dimer. Moreover, it is 
proposed to form an intermolecular hydrogen bond with E148, suggesting it plays a key role in the 
structure of this dimer. Upon mutation of this E148 residue to alanine, we again observed a complete loss 
of the ability of domain I to modulate viral translation, suggesting the importance of the hydrogen bond 
between the two residues in dimer formation. In further support of this model, we found that a domain I 
fragment containing both R112A/E148A mutations fails to dimerize. Given the proposed role of NS5A 
dimerization in mediating NS5A domain I RNA binding, we tested the effect of this R112A mutation on the 
ability of NS5A domain I to bind to poly-U/UC RNA. We observed that this mutation impaired the ability 
of domain to interact with the RNA. Furthermore, when this R112A mutation was inserted into an HCV 
replicon, a loss of replicative capacity was observed. Therefore, these results indicated that the R112 
residue is critical for the downregulatory effect of NS5A domain I on viral translation and performs an 
essential function in viral replication. It also suggests that dimerization and RNA-binding activity of domain 
I is involved in modulating these effects. Our results also suggest a biological relevance of the domain I 
dimer observed in the Love et al. study.  These results were also similar to those obtained by Lim et al. 
who identified a correlation between domain I dimerization, RNA-binding activity and viral replication 
through mutation of a number of cysteine residues in the N-terminal zinc binding motif (489).  
It is somewhat surprising that R112, which appears to play a prominent role in the Love et al. 
dimer, was found to play a key role the RNA binding ability of domain I.  The Love et al. dimer model lacks 
the large positively charged groove proposed to act as an RNA binding site found in the Tellinghuisen et 
al. dimer (479, 482). The highly conserved contact interface of Love et al. dimer, including R112, is fully 
exposed in Tellinghuisen et al. dimer and may function as a site of molecular interaction when in this 
conformation (482).  Alternatively, the R112A mutation identified in this study may affect the transition 
between different dimer conformations during the viral lifecycle or the formation of larger multimeric 
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NS5A complexes that conceivably consist of NS5A dimers in different conformations via interactions with 
alternating exposed surfaces (481, 482, 488). However, a number of results obtained in this chapter 
questioned the role of dimerization in the ability of domain I to modulate viral translation. Firstly, we 
found that through the addition of the LCS-I region to domain I, the effect of the E148A mutation on 
translation modulation could be compensated for. This suggests that the LCS-I can either make up for 
structural defects caused by E148A mutation or perhaps phosphorylation, which occurs extensively within 
the LCS-I, produces negatively charged residues that can interact with R112A. Although not expressed in 
cis, which is thought to be required for full hyperphosphorylation, our results suggest that our domain I-
LCS-I fragment undergoes phosphorylation due to presence of a doublet on Western blot. Studies by the 
Cameron group have suggested that this LCS-I region contributes to domain I dimerization. To clarify the 
role of the LCS-I, immunoprecipitation experiments utilizing the domain I R112A/E148A-LCS I fragment 
could be performed. In addition, phosphatase treatment could be added to determine the role that 
phosphorylation within the LCS-I region may play in this effect.   
Secondly, we found that a domain I C39A mutant partially retains the ability to modulate viral 
translation. We and others have found that this domain I mutant also impairs viral dimerization and it has 
been found to inhibit RNA binding by domain I and is lethal to viral replication in the study by Lim et al. 
(489). These findings suggest that NS5A domain I dimerization may play a role in the observed effect of 
domain I on viral translation but not be absolutely required for this effect. Perhaps the domain I monomer 
retains low efficiency binding to the poly-U/UC region, binding which is dependent upon R112. 
Alternatively, It remains possible that domain I fragments containing the C39A mutation are still able to 
dimerize to a degree necessary for the modulation of viral translation but to a weaker extent that is 
undetectable by the assays used. The presence of the viral reporter in the translation studies could 
stimulate this activity as U-rich RNA has been found to enhance dimerization (365). An inefficient ability 
to dimerize could explain the reduced modulatory ability of this C39A mutant relative to Wt. domain I. An 
approach which could be utilized to clarify the role of domain I dimerization and RNA binding in the 
modulation of viral translation would be through the use of symmetrical NS5A inhibitors such as DCV. DCV 
is thought to target the NS5A dimer and has been observed to impair the ability of domain I to bind to U-
rich RNA (487). This is proposed to be the result of trapping the dimer in a conformation that does not 
bind RNA (487). Assessing the ability of domain I to modulate viral translation in the presence of DCV 
could provide insights into the importance of dimerization and RNA binding in the mechanism of 
modulation. 
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The importance of this R112 residue in multiple functions of NS5A involved in both translation 
and replication suggests that it mediates functions conserved among the different HCV genotypes. This 
model is supported by the conservation of this residue across all six circulating HCV genotypes (Figure 
8.1). The conservation of this residue and its essential roles in the viral lifecycle suggest that R112 could 
be targeted in the development of novel direct acting antivirals. The identification of new drug targets is 
important in attempts to increase treatment efficacy and to combine with existing antivirals in order to 
decrease the potential of resistance.  
In chapter 5, we shifted our focus onto NS5A domains II and III and used an approach similar to 
that utilized for domain I in an effort to map the regions and residues that mediate the ability of these 
domains to modulate viral translation. For domain II, we determined that the aa. 299-346 region is 
sufficient for the down-regulation of viral translation.  Through the mutation of positively charged  amino 
acids within this region, we were able to identify K312 as the main mediator of this effect. As mutation of 
this residue lead to a complete loss of the modulation of viral translation by domain II. However, mutation 
of this residue within a HCV replicon had no observable effect on viral replication indicating that the 
function mediated by this residue is limited to viral translation. 
The mechanism behind the modulation of viral translation remains unclear. However, the 
requirement for the poly-U/UC region and the disruption that mutation of a positively charged residue 
produces leads us to speculate that RNA binding may be a potential mechanism. In support of this model, 
the K312 residue has previously been observed to contact poly-U RNA, resulting in a block of trypsin 
mediated cleavage in RNA binding studies (365). This aa. 299-346 region also contains the CypA binding 
site (495). K312 is located just N-terminal to this site, within a region whose structure is altered by the 
isomerase activity of CypA (495). The binding of CypA to domain II enhances the RNA binding activity of 
this domain towards poly-U RNA (84). This enhanced binding, however, is not thought to mediate the 
essential function of CypA in viral replication (84). Mutations which facilitate CypA independent 
replication do not demonstrate this enhanced binding (84). Therefore, it is possible that this CypA binding 
alters the structure of the region containing the K312 residue resulting in enhanced RNA binding and the 
down-regulation of viral translation. This possibility could be investigated through mutation of the CypA 
binding site to determine if this interaction has an effect on the ability of domain II to modulate viral 
translation.  
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Figure 8.1 – Sequence alignment of residue implicated in the modulation of viral translation by NS5A 
domains I, II and III. Alignment performed using Clustal Omega software. Sequences of prototypical HCV 
strains retrieved from HCV database (http://hcv.lanl.gov/content/index). Conserved residues are bold and 
highlighted whereas residue with similar characteristics to the implicated residues are in bold.       
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In addition to RNA binding, the interaction between domain II and host proteins may be involved 
in the modulation of viral translation observed. The domain II aa. 299-346 region sufficient for modulating 
viral translation has been found to contain a region (aa. 301-310) capable of transiently adopting α-helical 
structures and bind host proteins such as Bin1 (493). Therefore the K312 mutation proximal to this region 
could potentially alter the structure of this region, interfering with interactions with host proteins. The 
effects of this mutation on the structure within this region could be investigated though the use of NMR 
analysis and the binding of cellular proteins could be investigated through a pull-down assay. NS5A has 
also been found to act as a transcriptional activator and domain II plays an essential role in this function. 
Domain II contains an acidic region that is responsible for the majority of the trans-activation activity (502-
504). The K312A mutation which negated domain II effect on viral translation is located just N-terminal to 
this region. Perhaps through alterations of transient domain structure, this K312A mutation may affect 
the transcriptional activation properties of this region. Even though this fragment lacks an NLS, NS5A 
lacking an NLS are still transported into the nucleus, although to a lower extent, likely due to passive 
migration (504). As the transcriptional activation properties of NS5A have been observed to correlate with 
viral replication, it is possible that the up-regulation of factors that favour viral replication play a role in 
the switch between translation and replication and could result in the down-regulation of viral translation 
observed (504). However, this possibility remains to be investigated. 
In terms of sequence conservation this K312 residue is conserved across genotypes 1, 3, 4 and 6 
(Figure 8.1). However, in genotype 2 this residue corresponds to an arginine residue that like lysine is 
positively charged, suggesting it could function similar to K312. In genotype 5, whereas K312 corresponds 
to a neutral alanine residue, there are two arginine residues at positions 308 and 309 that could function 
in a similar manner. 
Within domain III, we identified the aa. 420-451 region as sufficient for the down-regulatory effect 
on viral translation. We subsequently found that mutation of E446 to alanine resulted in a loss of the 
modulatory ability of domain III on viral translation. Similar to K312 identified within domain II, this 
domain III mutation was found not to affect viral replication.  How this domain modulates viral translation 
and the role of E148 remains unclear. Even though this residue is negatively charged, it is possible that it 
is involved in the RNA binding activity of domain III through function in a novel RNA binding fold. The 
effect of the E148 mutation on the RNA binding ability of domain III remains to be investigated. However, 
given the small size of the aa. 420-451 region and the relatively weak binding affinity domain III possess 
towards the poly-U/UC region it is possible that this region mediates other functions. Similar to the K312 
mutation in domain II, this E446 residue may play a role in transient structure adopted by domain III. E446 
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falls within the aa. 446-449 region of domain III found to transiently form an α-helical structure which may 
be important for the interaction with host proteins (505). Interestingly, CypA has been found to bind 
within this C-terminal region and a CsA resistance mutation is observed at position V449A (505). The 
function of CypA binding within domain III is unknown (505). It would be interesting to determine if CypA 
binding enhances the RNA binding activity of this region in a fashion similar as domain II and if this is 
involved in the modulation of viral translation by domain III.  Furthermore, given the essential role domain 
III plays in viral assembly, the effect of the E446A mutation on this processes should also be determined. 
In regards to the sequence conservation of this E446 residue, it is only conserved between 
genotypes 1 and 4 (Figure 8.1). However, there is an aspartic acid residue, which is very similar to glutamic 
acid in its negative charge, at this position in genotypes 2, 5 and 6. Genotype 3 possesses a glutamic acid 
one position away at position 445. Therefore, it appears that a negatively charged acid in this region of 
NS5A domain III performs a conserved function in the viral lifecycle.  
To further investigate the effects of the R112A, K312A and E446A mutations on the viral lifecycle 
the cellular localization and motility of NS5A containing these mutations should be assessed. Within 
infected cells, NS5A localizes to the ER associated membranous web in addition to the surface of lipid 
droplets where it performs functions essential to genome replication or viral assembly, respectively (511). 
Furthermore, two populations of NS5A-positive foci, likely representing distinct replication complex 
populations, are observed in infected cells (589, 590). One population is composed of large structures 
demonstrating restricted mobility whereas the second population is characterized by small, fast-moving 
structures (589, 590). These distinct NS5A containing replication complex populations may have distinct 
functional roles during the viral lifecycle, however, this remains to be determined.   
From the results obtained in this work, we have determined that NS5A functions to 
downregulate viral translation in addition to its already demonstrated essential roles in viral replication 
and assembly. Furthermore, we have mapped this effect to individual residues within each domain of 
NS5A and proposed potential mechanisms. It is clear that NS5A is capable of carrying out a remarkable 
number of pro-viral functions within the cell, especially for a protein that lacks enzymatic activity. The 
continued characterization of NS5A and the processes that modulate its functions may aid in the 
development of future treatments against this complex and enigmatic protein. 
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8.2 Conclusions 
  
 NS5A down-regulates viral translation in a dose dependent manner though a mechanism 
requiring the poly-U/UC region within the viral 3´-UTR 
 Each domain of NS5A is capable of modulating viral translation independently, also through a 
mechanism requiring the poly-U/UC region within the viral 3´-UTR 
 Residue R112 is essential for the effect of NS5A domain I on viral translation 
 Mutation of R112 and E148 impairs NS5A domain I dimerization 
 The R112 residue is involved in RNA binding by NS5A domain I as the R112A mutation impairs this 
activity 
 The R112A inhibits viral replication when inserted into an HCV subgenomic replicon 
 The K312 residues is essential for the down-regulation of viral translation by NS5A domain II but 
has no effect on replication of an HCV subgenomic replicon 
 Mutation of E446 negates the translation modulatory activity of NS5A domain III but has no effect 
on replication of an HCV subgenomic replicon 
 Mutation of K312 within domain II negates the ability of an NS5A domain II-LCS II-domain III 
fragment to modulate viral translation while mutation of two residues, E446/S447, is required 
within domain III for this effect 
 No combination of these mutations within domains II and III has a significant effect on replication 
of an HCV subgenomic replicon 
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